OMB APPROVAL
                                                      --------------------------
                                                      OMB Number:      3235-0059
                                                      Expires: February 28, 2006
                                                      Estimated average burden
                                                      hours per response...12.75

                                 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION WASHINGTON,

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) [ ] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material Pursuant to Section 240.14a-12 Akorn, Inc. - -------------------------------------------------------------------------------- (Name

☒  Filed by the Registrant☐  Filed by a Party other than the Registrant

Check the appropriate box:
Preliminary Proxy Statement
CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to Section 240.14a-12

AKORN, INC.

 (AKORN LOGO)

(Name of Registrant as Specified In Its Charter) - -------------------------------------------------------------------------------- (Name

(Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies: - -------------------------------------------------------------------------------- 2) Aggregate number of securities to which transaction applies: - -------------------------------------------------------------------------------- 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): - -------------------------------------------------------------------------------- 4) Proposed maximum aggregate value of transaction: - -------------------------------------------------------------------------------- 5) Total fee paid: - -------------------------------------------------------------------------------- [ ] Fee paid previously with preliminary materials. [ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. 1) Amount Previously Paid: - -------------------------------------------------------------------------------- 2) Form, Schedule or Registration Statement No.: - -------------------------------------------------------------------------------- 3) Filing Party: - -------------------------------------------------------------------------------- 4) Date Filed: - -------------------------------------------------------------------------------- PERSONS WHO POTENTIALLY ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER. SEC 1913 (02-02) PRELIMINARY PROXY MATERIALS AKORN, INC. 2500 MILLBROOK DRIVE BUFFALO GROVE, ILLINOIS 60089 - -------------------------------------------------------------------------------- NOTICE OF 2004 ANNUAL MEETING OF SHAREHOLDERS TO BE HELD [JUNE 10, 2004] - -------------------------------------------------------------------------------- TO THE SHAREHOLDERS OF AKORN, INC.:

Payment of Filing Fee (Check the appropriate box):
No fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11
(set forth the amount on which the filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form. Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:

(AKORN LOGO)

1925 West Field Court, Suite 300
Lake Forest, Illinois 60045

Dear Shareholder:

You are cordially invited to attend a special meeting of the 2004 annualshareholders of Akorn, Inc. to be held at 10:00 a.m., local time (Central Daylight Time) on December 16, 2016, at the Company’s corporate headquarters at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045 for the following purposes, as more fully described in the proxy statement:

1.To approve the Akorn, Inc. 2016 Employee Stock Purchase Plan;

2.To approve the amendment and restatement of the Akorn, Inc. 2014 Stock Option Plan; and

3.To transact such other matters as may properly come before the meeting.

You may attend the 2016 special meeting in person or by proxy. Only shareholders or their legal proxy holders will be allowed to attend the 2016 special meeting. To be admitted to the 2016 special meeting, you must present a form of government-issued photo identification and valid proof of ownership of the Company’s common stock as of October 28, 2016 or a valid legal proxy.

Your vote is important. We strongly urge you to cast your vote as soon as possible, even if you currently plan to attend the meeting in person. You may vote your shares by Internet or telephone, or by following the instructions on the proxy card or the voting instruction form you receive with your paper copy of the print materials.

We appreciate your investment in the Company.

By Order of the Board of Directors

/S/ Raj Rai

Raj Rai

Chief Executive Officer 

November [●], 2016

(COVER PAGE)

A special meeting of shareholders of Akorn, Inc. ("Akorn" or the "Company") to, a Louisiana corporation, will be held at [ a.m.], localthe time on [JUNE 10, 2004] at [ ]and place and for the following proposals, as more fully described in the accompanying proxy statement: 1. To elect six directors to the Board of Directors. 2. To approve an amendment to Akorn's Articles of Incorporation to increase the authorized number of shares of common stock from 40,000,000 to 150,000,000. 3. To approve the adoption of the Akorn, Inc. 2003 Stock Option Plan. 4. To ratify the selection by the Audit Committee of the Board of Directors of BDO Seidman, LLP as independent auditors of Akorn for its fiscal year ending purposes indicated below.

December 31, 2004. 5. To transact such other business as may properly come before the meeting or any adjournments thereof. The record date for the determination of the shareholders entitled to vote at the meeting or at any adjournment thereof is the close of business on [ ], 2004. A list of shareholders entitled to vote at the meeting will be open to the examination of any shareholder, for any purpose germane to the meeting, at the location of the meeting on [ ], 2004, and during ordinary business hours for ten days prior to the meeting at our principal offices located at 2500 Millbrook Drive, Buffalo Grove,16, 2016

10:00 a.m., Local Time

1925 West Field Court, Suite 300, Lake Forest, Illinois 60089. YOUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE IN FAVOR OF THE FOUR PROPOSALS OUTLINED IN THE PROXY STATEMENT. Please refer to the proxy statement for detailed information on each of the proposals. 60045

Items ofbusiness:

· To approve the Akorn, Inc. 2016 Employee Stock Purchase Plan (Proposal 1);

· To approve the amendment and restatement of the Akorn, Inc. 2014 Stock Option Plan
(Proposal 2); and

· To transact such other matters as may properly come before the special meeting and any adjournment or postponement thereof.
recommendations of theboard:The Board of Directors unanimously recommends that you vote “FOR” Proposal 1 and Proposal 2.
recorddate:Shareholders of record as of the close of business October 28, 2016, are entitled notice of and to vote at the special meeting.
voting:Your vote is very important.  To ensure your representation at the meeting, please vote your shares as soon as possible, by Internet, telephone, or proxy card or voter instruction form.

By Order of the Board of Directors Arthur S. Przybyl President and

/S/ Raj Rai

Raj Rai 

Chief Executive Officer Buffalo Grove,

Important Notice Regarding the Availability of Proxy Materials for the
Special Meeting of Shareholders to Be Held on December 16, 2016. 

The proxy statement, the form of proxy card, and the annual report to shareholders for the
fiscal year ending December 31, 2015 are availableat http://www.proxyvote.com.

Table of Contents

PROXY STATEMENT6
I. PROPOSALS7
Proposal 1 Approval of the Akorn, Inc. 2016 Employee Stock Purchase Plan7
Proposal 2  Approval of the amendment and restatement of the Akorn, Inc. 2014 Stock Option Plan10
II. EXECUTIVE COMPENSATION AND OTHER INFORMATION16
Executive Summary16
Compensation Discussion and Analysis17
Executive Compensation Tables27
Director Compensation35
Compensation Committee Interlocks and Insider Participation37
Equity Compensation Plans37
III. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT38
IV. QUESTIONS AND ANSWERS40

AKORN, INC. 2016 Special Meeting Proxy Statement5

(AKORN LOGO)

AKORN, INC.

1925 West Field Court, Suite 300

Lake Forest, Illinois [ 60045

November [●], 2004] It2016

Proxy Statement

For the Special Meeting of Shareholders to be held December 16, 2016

The Board of Directors (the “Board”) of Akorn, Inc. (the “Company”) is importantfurnishing you this proxy statement to solicit proxies on its behalf to be voted at the 2016 special meeting of shareholders of Akorn, Inc. The special meeting will be held at the Company’s headquarters, at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045, on December 16, 2016, at 10:00 a.m., local time.

This proxy statement contains information on matters to be voted upon at the 2016 special meeting or any adjournments of that your shares be representedmeeting. As of the date of this proxy statement, management is unaware of any other matter for action by shareholders at the meeting regardlessother than those described in the accompanying Notice of the 2016 Special Meeting. All properly executed written proxies and all properly completed proxies submitted by telephone or Internet that are delivered pursuant to this solicitation will be voted at the meeting in accordance with the directions given in the proxy, unless the proxy is revoked prior to completion of voting at the meeting.

The proxy materials for our 2016 special meeting include: (1) the Notice of 2016 Special Meeting of Shareholders; (2) this Proxy Statement for the Special Meeting, including the forms of the Akorn, Inc. 2016 Employee Stock Purchase Plan and Amended and Restated Akorn Inc., 2014 Stock Option Plan; (3) Akorn’s Annual Report for the year ended December 31, 2015; and (4) the proxy card or voting instruction form for the 2016 special meeting that you received with your paper copy of the proxy materials.

Please see the section “Questions and Answers” at the back of this proxy statement for more information regarding the proxy materials, the special meeting, voting, and other related matters.

This proxy statement is dated November [●], 2016 and we are first furnishing the proxy materials to shareholders on or about November [●], 2016.

Important Notice Regarding the Availability of Proxy Materials for the Special Meeting of
Shareholders to Be Held on December 16, 2016:

The Notice of 2016 Special Meeting, proxy statement, form of proxy card, and 2015 annual report to
shareholders are available at http://www.proxyvote.com.

AKORN, INC. 2016 Special Meeting Proxy Statement6

I. PROPOSALS

PROPOSAL 1APPROVAL OF THE AKORN, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN

On October 26, 2016, our Board adopted, subject to shareholder approval, the Akorn, Inc. 2016 Employee Stock Purchase Plan (the “2016 ESPP”). The 2016 ESPP is intended to replace the Amended and Restated Akorn, Inc. Employee Stock Purchase Plan (the “Prior ESPP”), which was terminated in 2015 in connection with our restatement process. The purposes of the 2016 ESPP are to provide eligible employees with a convenient means of acquiring an equity interest in the Company through payroll deductions with no brokerage fees at a discounted rate, and to provide an incentive for continued employment. Under the 2016 ESPP, during a six-month or one-year offering period, eligible employees will be able to acquire shares of our common stock at a 15% discount from the lower of the market price on the date the offering period begins or on the purchase date, contributing funds through payroll deductions not exceeding 15% of base wages.

If the 2016 ESPP is approved,2,000,000shares of common stock will be available for issuance thereunder, which represents approximately 1.6% of our shares of common stock outstanding on October 28, 2016. The 2016 ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code of 1986, as amended (the “Code”).

The following is a brief description of the 2016 ESPP. This summary is qualified in its entirety by reference to the full text of the 2016 ESPP, a copy of which is attached asAppendix A. You are urged to read the actual text of the 2016 ESPP in its entirety.

If approved by our shareholders, the 2016 ESPP will allow eligible employees to acquire shares of our common stock at a 15% discount. The 2016 ESPP will be effective upon approval by our shareholders, and will continue until terminated by the Board or all shares authorized to be purchased under the 2016 ESPP have been purchased.

Authorized Shares, Administration and Offering Period

If approved, the total amount of shares of our common stock acquired by participants in the 2016 ESPP will not exceed 2,000,000 shares. In the event of any recapitalization, stock dividend, stock split, combination of shares or other change in our common stock, the number of shares of common stock permitted to be purchased under the 2016 ESPP will be adjusted in proportion to the change in outstanding shares of common stock. This 2016 ESPP will be administered under the direction of the Board or a committee designated by the Board in accordance with applicable laws and regulations (the “Committee”). The Company will pay all expenses incurred in connection with the administration of the plan.

There will be two offering periods (the “Offering Periods”) each calendar year during the 2016 Plan: (i) the period from January 1 through December 31; and (ii) the period from July 1 through December 31, provided, however, for the initial year of the plan only, 2017, the first Offering Period will begin January 9 and run through December 31. The Committee may also designate other offering periods from time to time. A participant may participate in only one Offering Period at a time.

Eligible Participants and Payroll Deductions

Employees eligible to participate in the 2016 ESPP are those employed by the Company or a designated subsidiary on the day before the first day of the Offering Period, and customarily employed for more than 20 hours per week and 5 months in a calendar year. However, no employee will be eligible to participate in the 2016 ESPP who owns stock or holds options to purchase stock possessing 5% or more of the total combined voting power or value of all classes of stock of the Company or a subsidiary, or as a result of being granted an option under the 2016 ESPP with respect to such Offering Period, would own stock or hold options to purchase stock possessing 5% or more of the total combined voting power or value of all classes of stock of the Company or any subsidiary. As of October 26, 2016, approximately 1,600 permanent employees, including seven executive officers, would be eligible to participate in the 2016 ESPP.

To participate in the 2016 ESPP, an eligible employee must authorize payroll deductions from his or her current compensation in whole percentages from 1% to 15%, or such lower limit as may be set by the Company from time to time.

Purchase of Shares

At the end of each Offering Period, the Company will automatically apply the funds then in the participant’s payroll deduction account to purchase the applicable number of whole shares of common stock. The purchase price of such shares will be the lower of (i) 85% of the fair market value of a share of common stock on the first day of the Offering Period or (ii) 85% of the fair market value of a share of common stock on the date of purchase, which would be the last trading day of the Offering Period.

AKORN, INC. 2016 Special Meeting Proxy Statement7

As promptly as practicable after the end of each Offering Period, the Company will electronically issue shares of common stock purchased for a participant into the participant’s brokerage account. No fractional shares will be issued to a participant. Any cash remaining in a participant’s payroll deduction account following the purchase of such shares of our common stock will be returned to the participant as soon as administratively feasible without interest. A participant will have no interest in any shares of common stock, including any voting rights, until the Company has purchased shares of common stock for such participant.

Limitations on Purchase and Transfer of Shares

No participant will be entitled to purchase shares of common stock under the 2016 ESPP with a fair market value that exceeds $25,000, as determined as of the first day of the Offering Period, in any calendar year in which such participant participates in the 2016 ESPP (or such other limit as may be imposed by the Code). The Company will automatically suspend the payroll deductions of any participant as necessary to enforce this limit. Except as otherwise determined by the Company prior to the first day of an Offering Period, the aggregate number of shares that may be purchased by an individual participant in an Offering Period will not exceed 15,000 shares.

If the number of shares of common stock to be purchased by all participants for an Offering Period exceeds the number of shares then available for issuance under the 2016 ESPP, then the Company will make apro rata allocation of the remaining shares of common stock in as uniform manner as will be reasonably practicable and equitable. In such event, the Company will give written notice of such reduction of the number of shares of our common stock to be purchased to each participant affected.

Any funds in a participant’s payroll deduction account which are not used to purchase shares of common stock due to the above limitations will be returned to the participant as soon as practicable after the Offering Period without interest.

The right to receive shares of our common stock is non-transferable (except in the case of a participant’s death following the purchase, but prior to delivery, of shares of our common stock) and no shares of our common stock acquired under the 2016 ESPP may be transferred or sold (other than by gift or inheritance) until 90 days following the date shares are issued to a participant, without prior written approval from the Company.

Changes to Deductions, Withdrawal from Plan, Termination of Employment

A participant may elect to increase or decrease his or her rate of payroll deductions for a subsequent Offering Period by delivering written notice prior to the commencement of the Offering Period. A participant may not effect an increase or decrease in the rate of payroll deductions during an Offering Period, but may elect to withdraw from the plan.

A participant may at any time cease making any further payroll deductions by delivering a timely written notice of withdrawal from the 2016 ESPP. Upon withdrawal, the balance of the participant’s payroll deduction account will be returned as soon as practicable, without interest, and participation in the 2016 ESPP will automatically and immediately terminate. In the event of a withdrawal, the participant may not resume participation in the 2016 ESPP during the calendar year of withdrawal but may elect to participate in any subsequent calendar year.

A participant will be immediately and automatically terminated from the plan upon the occurrence of any of the following events: (i) termination of the participant’s employment for any reason (including retirement or death), (ii) the placement of the participant on a leave of absence exceeding 3 calendar months with no right to reemployment by the Company provided by statute or contract or (iii) the failure of a participant to remain an eligible employee. In such event, the payroll deductions credited to such participant’s payroll deduction account will be returned to the participant or, in the case of death, to the participant’s designated beneficiary, in either case, without interest.

If a participant is enrolled in an Offering Period in one year and takes no further action regarding his or her election related to the following year, the Company will assume that the participant desires to continue making purchases and will automatically enroll the participant in the next annual Offering Period (January 1 to December 31) with the same level of payroll deduction as in the preceding year.

Amendment, Termination or Suspension of the Plan by the Company

The 2016 ESPP may be amended by the Board, but any amendment which (a) materially increases the number of shares of our common stock which may be acquired through the 2016 ESPP, (b) changes the definition of “common stock” as defined in the 2016 ESPP, (c) materially increases the benefits accruing to participants in the 2016 ESPP or (d) materially modifies the requirements for eligibility for participation in the 2016 ESPP must be approved by the shareholders.

The 2016 ESPP will be effective upon approval by the shareholders of the Company. Unless terminated earlier by the Company, the plan will terminate on the date all of the shares of common stock authorized for issuance under the 2016 ESPP are purchased. The Company reserves the right to terminate or suspend the 2016 ESPP at any time. If the 2016 ESPP is terminated or suspended, the Company may elect in its sole discretion to either (i) complete the purchase of shares of common stock at the end of the current Offering Period or (ii) deliver to each participant the then balance of such participant’s payroll deduction account, if any, as soon as reasonably practicable following the date of termination or suspension of the 2016 ESPP. In either case, no participant will have any right to acquire shares of common stock (other than the as described under clause (i) of the immediately preceding sentence) under the 2016 ESPP. In the event the 2016 ESPP is terminated, the participation of all participants will terminate immediately.

In the event of the proposed dissolution or liquidation of the Company, the Offering Period then in progress shall be shortened by setting a new purchase date, and the 2016 ESPP will terminate immediately prior to the consummation of the proposed dissolution or liquidation, unless provided otherwise by the Committee.

AKORN, INC. 2016 Special Meeting Proxy Statement8

If the Board or the Company’s shareholders approve a sale of all or substantially all of the assets of the Company, or the merger, consolidation or similar transaction involving the Company with or into another corporation in which the Company is not the surviving, controlling corporation, the 2016 ESPP provides that each outstanding right to purchase shares of our common stock under the 2016 ESPP will be assumed, or an equivalent right to purchase shares of our common stock will be substituted by the successor corporation or a parent or subsidiary of the successor corporation. In the event that the successor corporation chooses not to assume or substitute for the right to purchase shares of our common stock, the Offering Period then in progress shall be shortened by setting a new purchase date, which will be at least 15 days prior to the date of the transaction.

Federal Income Tax Consequences

The following is a brief description of the Company’s understanding of the U.S. federal income tax consequences to the Company and participants subject to U.S. taxation with respect to participation in the 2016 ESPP. This description may be inapplicable if such laws and regulations are changed. This summary is not intended to be exhaustive or constitute tax advice and does not address any state, local or foreign tax consequences.

The 2016 ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Code. Under such an arrangement, no taxable income would be recognized by a participant, and no deductions would be allowable to the Company, upon either the grant or the exercise of the options. Taxable income would not be recognized until either there is a sale or other disposition of the shares of our common stock acquired under the 2016 ESPP or in the event the participant dies while still owning the purchased shares of our common stock. The amounts withheld from a participant’s pay under the 2016 ESPP will be taxable income to that participant and must be included in gross income for federal income tax purposes in the year in which the amounts otherwise would have been received.

The federal income tax consequences of a sale or disposition of shares of our common stock acquired under the 2016 ESPP depend in part on the length of time the shares are held by a participant before any sale or disposition. If a participant sells or otherwise disposes of shares of our common stock acquired under the 2016 ESPP (other than any transfer resulting from the participant’s death) within two years after the date on which the option is granted to such participant or within one year after the date on which the option is exercised and the shares purchased (such period, the “Holding Period”), the participant will recognize ordinary income in the year of such sale or disposition in an amount equal to the excess of (1) the fair market value of the shares on the date such shares were acquired by him or her over (2) his or her purchase price. The tax law requires a participant to recognize this amount of ordinary income even if the fair market value of the shares of our common stock has decreased since the date the shares were purchased, and the ordinary income recognized is added to his or her basis in such shares. Any gain realized on the sale or disposition in excess of the purchase price will be taxed as short-term capital gains and any loss realized will be a short-term capital loss.

If a participant sells or otherwise disposes of shares of our common stock acquired under the 2016 ESPP after the Holding Period, or the participant dies, he or she must recognize as ordinary income in the year of sale (or his or her taxable year ending with his or her death) an amount equal to the lesser of (1) the excess of the fair market value of the shares of our common stock on the date such shares were acquired over the purchase price, or (2) the excess of the fair market value of the shares on the date he or she sells or otherwise disposes of the shares or on the date of his or her death over the purchase price. Except in the case of a transfer as a result of death, this amount of ordinary income recognized by the participant is added to his or her basis in the shares. The basis of shares transferred as a result of the death of a participant will not be increased as a result of the ordinary income recognized by the deceased participant. Any gain realized on the sale or disposition in excess of the participant’s basis (after increasing the basis in such shares of our common stock by the ordinary income recognized) will be taxed as a long-term capital gain. Any loss realized will be treated as long-term capital loss.

The Company will not receive any income tax deduction as a result of issuing shares of our common stock pursuant to the 2016 ESPP, except upon sale or disposition of shares by a participant prior to the end of the Holding Period. In that event, the Company ordinarily will be entitled to a deduction equal to the amount included as ordinary income to the participant with respect to the sale or disposition of the shares.

New Plan Benefits

Our executive officers, including our named executive officers who are current employees of the Company, will be eligible to participate in the 2016 ESPP, provided they meet the detailed eligibility requirements. Non-employee directors are not eligible to participate in the 2016 ESPP. Because benefits under the 2016 ESPP will depend upon employees’ elections to participate, the restrictions of Section 423 of the Code and the fair market value of the common stock at various future dates, it is not possible to determine the benefits that will be received by executive officers and other employees if the 2016 ESPP is approved by the shareholders. No options have been granted and no shares of our common stock have been issued under the 2016 ESPP prior to, or pending, shareholder approval of the 2016 ESPP.

The Board of Directors unanimously recommends that you hold. WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING IN PERSON, PLEASE COMPLETE, DATE, SIGN AND RETURN THE ACCOMPANYING PROXY IN THE ENCLOSED ENVELOPE TO ENSURE THE PRESENCEvote “FOR” the approval of the Akorn, Inc. 2016 Employee Stock Purchase Plan.

AKORN, INC. 2016 Special Meeting Proxy Statement9

PROPOSAL 2APPROVAL OF THE AMENDMENT AND RESTATEMENT OF THE AKORN, INC. 2014 STOCK OPTION PLAN

(GRAPHIC)Summary of proposed amendments

On October 26, 2016, the Board adopted, subject to shareholder approval, the Amended and Restated Akorn, Inc. 2014 Stock Option Plan (the “Amended 2014 Option Plan”), which contains certain material changes to the Akorn, Inc. 2014 Stock Option Plan (the “2014 Option Plan”). As described more fully below, the changes are based upon current best practices, and include (i) adding sub-limits to our plan, in order to provide us with added flexibility to grant performance-based awards that are tax deductible to the Company under Section 162(m) of the Code, (ii) adding a sub-limit for our director awards and (iii) clarifying the terms and conditions that generally apply to restricted stock units granted under our plan.We are not requesting approval of additional shares under the Amended 2014 Option Plan.

If approved, the Amended 2014 Option Plan will impose the following sub-limits:

·the maximum aggregate number of shares that may be issuable or deliverable under options or stock appreciation rights granted in any calendar year to any one participant will be 2,000,000 shares of our common stock;

·with respect to awards (as defined below) intended to qualify as “performance-based compensation” within the meaning of Section 162(m) of the Code (other than options or stock appreciation rights), the maximum aggregate number of shares of our common stock that may be issuable or deliverable under such awards granted in any calendar year to any one participant will be 2,000,000 shares of our common stock or, with respect to awards denominated in cash, $3,000,000 (measured as of the date of grant);

·the maximum aggregate number of shares of our common stock that may be issuable or deliverable under awards granted in any calendar year to any one director shall be 200,000 shares of our common stock plus cash in an amount not to exceed $250,000.

In addition, the Amended 2014 Option Plan clarifies the terms and conditions that generally apply to grants of restricted stock units (or “RSUs”) under our plan, as described more fully below.

(GRAPHIC)Background

The Amended 2014 Option Plan is intended to attract and retain exceptional directors, employees and consultants and to enable such individuals to participate in our long-term growth and financial success.

Set forth below is the number of shares available for issuance pursuant to outstanding equity awards under the 2003 Option Plan and the 2014 Option Plan as of October 26, 2016:

 Number of Shares As a Percentage
of Stock
Outstanding (1)
    
Shares reserved for issuance pursuant to outstanding stock options (2)4,639,355 3.70%
Shares reserved for issuance pursuant to unvested restricted stock unit awards420,720 0.34%
Shares available for issuance pursuant to future equity awards (3)2,911,046 2.32%
    
    
Total shares reserved for issuance pursuant to outstanding equity awards under the 2003 Option Plan and the 2014 Option Plan7,971,121 6.36%

(1)The percentages are based on outstanding shares of our common stock on October 28, 2016.

(2)As of October 26, 2016, 747,624 options remained outstanding under the 2003 Option Plan and had a weighted average exercise price of $13.68 per share and a weighted average term remaining term of 0.93 years. As of October 26, 2016, 3,891,731 options remained outstanding under the 2014 Option Plan and had a weighted average exercise price of $29.95 per share and a weighted average term remaining term of 5.85 years. As of October 26, 2016, the aggregate 4,639,355 options outstanding under the 2003 Option Plan and the 2014 Option Plan had a weighted average exercise price of $27.33 per share and a weighted average term remaining term of 5.06 years.

(3)The 2003 Option Plan expired November 6, 2013 and no further awards may be granted under that plan.

AKORN, INC. 2016 Special Meeting Proxy Statement10

Following is a summary of the Amended 2014 Option Plan. This summary is qualified in its entirety by reference to the complete text of the Amended 2014 Option Plan, a copy of which is attached asAppendix B. You are urged to read the actual text of the Amended 2014 Option Plan in its entirety.

Eligible Participants

Any director, employee, consultant or advisor (including any prospective director, employee, consultant or advisor) of Akorn or any affiliate of Akorn shall be eligible to be designated a participant in the Amended 2014 Option Plan for purposes of receiving awards. As of October 26, 2016, approximately 1,620 employees and non-employee directors would be eligible to participate in the Amended 2014 Option Plan, plus consultants. However, only employees are eligible to receive incentive stock options (“ISOs”).

Plan Administration

Our Board, or one or more committees appointed by our Board, will administer the Amended 2014 Option Plan (in either case, the “administrator”). In the case of awards intended to qualify as “performance-based compensation” within the meaning of Section 162(m) of the Code, the administrator will consist of two or more “outside directors” within the meaning of Section 162(m). The administrator will have the authority to construe and interpret the terms of the Amended 2014 Option Plan and awards, to prescribe, amend and rescind rules and regulations relating to the Amended 2014 Option Plan, and to modify or amend an award (subject to limitations). In addition, the administrator will have the authority to determine the terms of the awards, including the exercise price (which may be changed by the administrator after the date of grant), the number of shares subject to each award, the exercisability of the awards, any vesting acceleration or waiver or repurchase restrictions, and the form of consideration payable upon exercise. Subject to shareholder approval, the administrator also will have the authority to reduce the exercise price of an award to the then current fair market value or implement an award exchange program (whereby awards may be exchanged or cancelled for awards with lower exercise prices or different terms), or a program through which participants may reduce cash compensation payable in exchange for awards. The administrator may also create other stock based awards that are valued in whole or in part by reference to (or are otherwise based on) shares of our common stock.

Shares Available For Awards

Subject to adjustment as provided below, the aggregate number of shares of our common stock that may be issued pursuant to awards granted under the Amended 2014 Option Plan is 7,500,000. The maximum number of shares of our common stock that may be delivered pursuant to ISOs granted under the Amended 2014 Option Plan will be 1,500,000. The maximum aggregate number of shares of our common stock that may be issuable or deliverable under options or stock appreciation rights granted in any calendar year to any one participant will be 2,000,000 shares. With respect to awards intended to qualify as “performance-based compensation” within the meaning of Section 162(m) of the Code (other than options or stock appreciation rights), the maximum aggregate number of shares of our common stock that may be issuable or deliverable under such awards granted in any calendar year to any one participant will be 2,000,000 shares or, with respect to awards denominated in cash, $3,000,000 (measured as of the date of grant).

In addition, the maximum aggregate number of shares of our common stock that may be issuable or deliverable under awards granted in any calendar year to any one director will be 200,000 shares of our common stock plus cash in an amount not to exceed $250,000.

If an award expires or is terminated or canceled without having been exercised or settled in full, it is forfeited back to us and the terminated portion of the award (or forfeited or repurchased shares subject to the award) will become available for future grant or sale under the Amended 2014 Option Plan (unless it has terminated). Shares are not deemed to be issued under the Amended 2014 Option Plan with respect to any portion of an award that is settled in cash. If the exercise or purchase price of an award is paid for through the tender of shares, or tax withholding obligations are met through the tender or withholding of shares, those shares tendered or withheld will again be available for issuance under the Amended 2014 Option Plan.

In the event a change, such as a stock split, is made in our capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested awards in the number of shares subject to each outstanding option or other awards in order to prevent dilution or enlargement of the benefits or potential benefits intended to be provided under the Amended 2014 Option Plan. Under such circumstances, the administrator also may deem it appropriate to cancel awards in consideration for a cash payment. The administrator also may make provisions for adjusting the number of awards in the event we effect one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of our outstanding common stock. Awards may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the award on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the administrator may provide that each award granted under the Amended 2014 Option Plan shall terminate as of a date fixed by the administrator.

Awards

The Amended 2014 Option Plan provides for the grant of options intended to qualify as ISOs under Section 422 of the Code to our and our affiliates’ employees and non-qualified stock options (“NQSOs”), stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, performance unit awards, performance share awards and other stock based award (each, an “Award”) to our and our affiliates’ directors, employees, consultants and advisors.

AKORN, INC. 2016 Special Meeting Proxy Statement11

Stock Options

An option is the right to purchase shares of our common stock at a fixed exercise price for a fixed period of time. The administrator may grant both ISOs and NQSOs under the Amended 2014 Option Plan. Except as otherwise determined by the administrator in an award agreement, the exercise price for options cannot be less than the fair market value (as defined in the Amended 2014 Option Plan) of our common stock on the date of grant. The term of each option will be determined by the administrator; provided that no ISO will be exercisable after the tenth anniversary of the date the option is granted. In the case of ISOs granted to an employee who, at the time of the grant of an option, owns stock representing more than 10% of the voting power of all classes of our stock or the stock of any of our affiliates, the exercise price cannot be less than 110% of the fair market value of a share of our common stock on the date of grant and its term will be five years or less from the date of grant. As of October 26, 2016, the fair market value of our common stock was $24.61 per share, which represents the closing market price of our stock that day as reported on the NASDAQ Global Select Market. All options granted under the Amended 2014 Option Plan will be NQSOs unless the applicable award agreement expressly states that the option is intended to be an ISO.

Options shall vest and become exercisable as determined by the administrator. The exercise price will be payable with cash (or its equivalent) or by other methods as permitted by the administrator to the extent permitted by applicable law.

If a participant’s employment or relationship with the Company is terminated, the participant (or his or her designated beneficiary or estate representative in the case of death) may exercise his or her option within such period of time as is specified in the award agreement to the extent that the option is vested on the date of termination. In the absence of a specified time in the award agreement, the option will remain exercisable for 3 months following the date of termination, except in the case where termination is as a result of disability or death, in which case the option will remain exercisable for 12 months following the date of termination.

The administrator may at any time offer to buy out an option previously granted for a payment in cash or shares of our common stock based on such terms and conditions as the administrator shall establish in compliance with Section 409A of the Code and communicate to the participant at the time that such offer is made.

Restricted Stock

Restricted stock awards are awards of shares of our common stock that vest in accordance with terms and conditions established by the administrator. The administrator may impose whatever conditions to vesting it determines to be appropriate. The administrator will determine the number of shares of restricted stock granted to any participant, and if applicable, any purchase price. Unless the administrator determines otherwise, restricted shares that fail to vest will revert to the company and again will be available for grant under the plan. Holders of restricted stock will not have voting rights with respect to such stock until the restrictions lapse, unless the administrator determines otherwise. During the period of restriction, holders of restricted stock will be entitled to receive all dividends and other distributions paid with respect to such stock while unvested, unless otherwise provided in the applicable award agreement. If any such dividends or distributions are paid in shares of our common stock, such shares will be subject to the same restrictions on transferability and forfeitability as the restricted stock with respect to which they were paid.

Restricted Stock Units

The Amended 2014 Option Plan clarifies the terms and conditions that generally apply to grants of RSUs under our plan. RSUs are awards of an unfunded and unsecured promise to deliver shares, cash, other securities or other property, subject to certain specified restrictions. Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the administrator. RSUs are forfeitable until they vest or are no longer subject to restrictions. Upon vesting, RSUs may be settled as a lump sum, in installments or on a deferred basis, as determined by the administrator (subject to applicable tax laws). RSUs generally cannot be transferred. In addition, RSUs do not provide voting rights unless and until the shares covered by such units are issued and delivered without restriction. RSUs do not entitle the holder to dividend equivalents unless otherwise specified in the award agreement or as determined by the administrator. If provided for in the award agreement, RSUs may be credited with dividend equivalent payments either in cash or shares of common stock, and any accumulated dividend equivalents (and any interest thereon) will be payable at the time the underlying RSU is settled.

Unrestricted Stock

Subject to the terms of an award agreement, a participant may be awarded (or sold at a discount) shares of our common stock that are not subject to restrictions on transfer, in consideration for past services rendered to us, our affiliates or for other valid consideration.

Stock Appreciation Rights

A QUORUM AT THE MEETING. Evenstock appreciation right is the right to receive an amount equal to the appreciation in the fair market value of our common stock between the exercise date and the date of grant, for that number of shares of our common stock with respect to which the stock appreciation right is exercised. We may either pay the appreciation in cash, in shares of our common stock with equivalent value, or in some combination of cash and shares, as determined by the administrator and in conformance with Section 409A of the Code. The administrator determines the exercise price of stock appreciation rights, the vesting schedule and other terms and conditions of stock appreciation rights; however, stock appreciation rights expire under the same rules that apply to stock options. The administrator may at any time offer to buy out for a payment in cash or shares of our common stock a stock appreciation right previously granted based on such terms and conditions as the administrator shall establish and communicate to the participant at the time that such offer is made.

AKORN, INC. 2016 Special Meeting Proxy Statement12

Performance Units and Performance Shares

Performance units and performance shares are awards that will result in a payment to a participant only if youperformance goals established by the administrator are achieved or the awards otherwise vest. The administrator will establish performance goals in its discretion, which, depending on the extent to which they are met, will determine the number and/or value of performance units and performance shares to be paid to the participant. The performance goals may be based upon the achievement of company-wide, divisional or individual goals or objectives, or any other basis that the administrator determines. Payment for performance units and performance shares may be made in cash or in shares of our common stock with equivalent value, or in some combination, as determined by the administrator. Performance units will have votedan initial dollar value established by proxy,the administrator prior to the grant date. Performance shares will have an initial value equal to the fair market value of our common stock on the grant date.

Other Stock Based Awards

The administrator has the authority to create awards under the Amended 2014 Option Plan in addition to those specifically described in the Amended 2014 Option Plan. These awards must be valued in whole or in part by reference to, or must otherwise be based on, the shares of our common stock. As described above, other stock-based awards may include, without limitation, awards that represent an unfunded and you attendunsecured promise to deliver shares, cash, other securities or other property following a specified passage of time or period of service, the satisfaction of predetermined individual or Company performance goals or objectives, or otherwise in accordance with the terms of the applicable award agreement.

Performance Goals

The administrator may designate any award as a qualified performance-based award for the purpose of allowing the award to be deductible without regard to the $1,000,000 deduction limit imposed by Section 162(m) of the Code. If an award is so designated, the administrator must establish objectively determinable performance goals for the award. Performance periods for such awards must be at least 12 months and may be any longer period. Performance goals for such awards shall be based on one or more of the following criteria, which may be expressed in terms of company-wide objectives or in terms of objectives that relate to the performance of a subsidiary or a division, region, department or function within the Company or a subsidiary: earnings (e.g., earnings before interest and taxes; earnings before interest, taxes, depreciation and amortization; or earnings per share); financial return ratios (e.g., return on investment; return on invested capital; return on equity; or return on assets); increase in revenue, operating or net cash flows; cash flow return on investment; total shareholder return; market share; net operating income, operating income or net income; debt load reduction; expense management; economic value added; stock price; and strategic business objectives, consisting of one or more objectives based on meeting specific cost targets, business expansion goals and goals relating to acquisitions or divestitures.

Transferability of Awards

Generally, unless the administrator determines otherwise, the Amended 2014 Option Plan does not allow for the transfer of awards other than by will or by the laws of descent and distribution, and only the participant may exercise an award during his or her lifetime.

Amendment and Termination of the Amended 2014 Option Plan

The Board may at any time amend, alter, suspend or terminate the Amended 2014 Option Plan, subject to applicable shareholder approval requirements under federal or state law or NASDAQ rules. Unless sooner terminated, the Amended 2014 Option Plan shall terminate on December 30, 2023, the date that is 10 years from the date the Amended 2014 Option Plan was adopted by the Board.

Amendment Effectiveness

The Amended 2014 Option Plan was approved by the Board on October 26, 2016. The Board’s approval of the Amended 2014 Option Plan is contingent upon the shareholders’ approval of the amendments.

Liquidation or Dissolution of Akorn

In the event of the proposed dissolution or liquidation of Akorn, the administrator will notify each participant as soon as practicable prior to the effective date of such proposed transaction. The administrator in its discretion may provide for a participant to have the right to exercise his or her award, to the extent applicable, until 10 days prior to such transaction as to all of the stock covered thereby, including shares of our common stock as to which such award would not otherwise be exercisable. In addition, the administrator may provide that any Akorn repurchase option or forfeiture rights applicable to any award shall lapse 100%, and that any award vesting shall accelerate 100%, provided the proposed dissolution or liquidation takes place at the time and in the manner contemplated. To the extent it has not been previously exercised or vested, an award will terminate immediately prior to the consummation of such proposed action.

AKORN, INC. 2016 Special Meeting Proxy Statement13

Change in Control

Generally, in the event Akorn experiences a “change in control” (as described below), awards may be assumed by the successor corporation, or the successor corporation may substitute an equivalent award in its place. However, if the successor corporation cannot or will not assume or substitute the outstanding award, then the administrator may provide that the vesting of any award shall accelerate 100%. Upon, or in anticipation of, a change in control, the administrator may cause any outstanding awards to terminate at a specific time in the future, including the date of such change in control, and will give each participant the right to exercise such awards during a period of time as the administrator, in its sole and absolute discretion, shall determine, but in no event shorter than 10 trading days.

Under the Amended 2014 Option Plan, a “change in control” is generally defined as (i) a merger or consolidation of the Company with another entity which thereby becomes the beneficial owner of more than 50% of the outstanding voting securities of the surviving entity, (ii) a meeting involving a contest for election of at least one directorship, if Directors who were members of the Board immediately prior to the meeting youdo not constitute at least a majority of the Directors following the meeting or election, (iii) an acquisition, directly or indirectly, of more than 50% of the outstanding shares of any class of voting securities or (iv) a sale of all or substantially all of the Company’s assets. A change in control also occurs if, during any period of 2 consecutive years or less, a majority of the Board is replaced by directors not approved by 2/3 of the Board. A change in control is not deemed to have occurred if the Company forms a holding company and holders of voting securities continue to hold approximately the same relative proportions.

Federal Income Tax Consequences

The following is a brief description of the Company’s understanding of the U.S. federal income tax consequences to the Company and participants subject to U.S. taxation with respect to participation in the Amended 2014 Option Plan. This description may be inapplicable if such laws and regulations are changed. This summary is not intended to be exhaustive or constitute tax advice and does not address any state, local or foreign tax consequences.

NQSOs. A non-qualified stock option results in no taxable income to the participant or deduction to the Company at the time it is granted. A participant exercising a non-qualified stock option will, at that time, realize taxable income (subject to withholding and employment taxes) in the amount equal to the excess, if any, of the then fair market value of the shares over the option exercise price. Subject to the applicable provisions of the Code, the Company will be entitled to a deduction for federal income tax purposes in the year of exercise in an amount equal to the taxable income realized by the participant. The participant’s tax basis in shares received upon exercise is equal to the sum of the option exercise price plus the taxable income recognized by him or her upon exercise.

Any gain (or loss) upon subsequent disposition of the shares will be a long- or short-term capital gain (or loss) to the participant, depending upon the holding period of the shares. If a non-qualified option is exercised by tendering previously owned shares in payment of the option price, then, instead of the treatment described above, the following will apply: a number of new shares equal to the number of previously owned shares tendered will be considered to have been received in a tax-free exchange; the participant’s basis and holding period for such number of new shares will be equal to the basis and holding period of the previously owned shares exchanged. The participant will have taxable income equal to the fair market value on the date of exercise of the number of new shares received in excess of such number of exchanged shares; the participant’s basis in such excess shares will be equal to the amount of such taxable income, and the holding period in such shares will begin on the date of exercise.

ISOs. An incentive stock option results in no taxable income to the participant or a deduction to the Company at the time it is granted or exercised. However, upon exercise, the excess of the fair market value of the shares acquired over the option exercise price is an item of adjustment in computing the alternative minimum taxable income of the participant, if applicable. If the participant holds the stock received as a result of an exercise of an incentive stock option until the later of two years from the date of the grant and one year from the date of exercise, then the gain realized on disposition of the shares is treated as a long-term capital gain. If the shares are disposed of during this period, however (i.e., a “disqualifying disposition”), then the participant will realize taxable income for the year of the disposition in an amount equal to the excess, if any, of the fair market value of the shares upon exercise of the option over the option exercise price (or, if less, the excess of the amount realized upon disposition of the shares over the option exercise price). Any additional gain or loss recognized upon the disposition will be recognized as a capital gain or loss by the participant. In the event of a disqualifying disposition, the Company will generally be entitled to a deduction, in the year of such a disposition, in an amount equal to the taxable income realized by the participant. The participant’s tax basis in the shares acquired upon exercise of an incentive stock option is equal to the option exercise price paid, plus any amount includible in his or her income as a result of a disqualifying disposition.

Stock Awards.Generally, if a participant receives a stock award under the Amended 2014 Option Plan, the participant will recognize ordinary compensation income at the time the stock is received equal to the excess, if any, of the fair market value of the stock received over any amount the participant paid in exchange for the stock. If, however, the stock is not vested when it is received under the Amended 2014 Option Plan (for example, if the participant is required to work for a period of time in order to have the right to sell the stock), the participant generally will not recognize income until the stock becomes vested, at which time the participant will recognize ordinary compensation income equal to the excess, if any, of the fair market value of the stock on the date it becomes vested over any amount the participant paid in exchange for the stock. The participant may, however, file an election with the Internal Revenue Service, within 30 days of the participant’s receipt of the stock award, to recognize ordinary compensation income, as of the date the participant received the stock award, equal to the excess, if any, of the fair market value of the stock on the date the other stock award is granted over any amount the participant paid in exchange for the stock. If the participant is an employee of the Company, the ordinary compensation income the participant recognizes will be subject to federal and state income and employment tax withholding.

AKORN, INC. 2016 Special Meeting Proxy Statement14

RSUs. A participant who is granted restricted stock units does not recognize income at the time of grant. When the award vests or is paid, participants generally recognize ordinary income in an amount equal to the fair market value of the units at such time, and the Company will receive a corresponding deduction.

Stock Appreciation Rights.Generally, a participant who is granted a stand-alone SAR will not recognize taxable income at the time the stand-alone SAR is granted. The value received by a participant (in cash or stock) from the exercise or settlement of a SAR will be taxed as ordinary income to the participant in the year of exercise or settlement. In general, there will be no federal income tax deduction allowed to the Company upon the grant or termination of SARs. However, upon the exercise or settlement of a SAR, the Company will be entitled to a deduction equal to the amount of ordinary income the participant is required to recognize as a result of the exercise or settlement.

Performance Units and Performance Shares. A participant who is granted a performance unit or performance share generally recognizes no income until the performance objectives are satisfied and the award is vested. When the award vests or is paid, participants generally recognize ordinary income in an amount equal to the fair market value of the unit or share at such time, and the Company will receive a corresponding deduction.

Deductions Generally. The Company will be entitled to a deduction for federal income tax purposes equal to the amount of ordinary income taxable to the participant, provided (i) the amount constitutes an ordinary and necessary business expense for the Company, (ii) it is reasonable in amount, (iii) either the participant includes that amount in income or the Company timely satisfies its reporting requirements with respect to that amount and (iv) the deduction is not otherwise disallowed under the Code.

Section 162(m) Limitations.Section 162(m) of the Code generally disallows a public company’s tax deduction for compensation to covered employees in excess of $1 million. Compensation that qualifies as “performance-based compensation” is excluded from the $1 million deductibility cap, and therefore remains fully deductible by the company that pays it. Awards granted to employees under the Amended 2014 Option Plan whom the Committee expects to be covered employees at the time a deduction arises, may, if and to the extent that the Committee determines to do so, be granted in a manner that will qualify as such “performance-based compensation,” so that such awards will not be subject to the Section 162(m) deductibility cap of $1 million. Future changes in Section 162(m) or the regulations thereunder may adversely affect the Company’s ability to ensure that options under the Amended 2014 Option Plan will qualify as “performance-based compensation” that are fully deductible by us under Section 162(m).

New Plan Benefits

The number of awards that an employee, director, consultant or advisor may receive under the Amended 2014 Option Plan is in the discretion of the administrator. Upon approval of the Amended 2014 Option Plan, the following benefits or amounts will be allocated to the following individuals: Raj Rai, Chief Executive Officer, dollar target value of $824,000 (maximum value of $1,648,000).

The Board of Directors unanimously recommends that you prefer, revoke your proxyvote “FOR” the approval of an amendment and vote your sharesrestatement of the 2014 Stock Option Plan

AKORN, INC. 2016 Special Meeting Proxy Statement15

II.Executive Compensation and Other Information

Executive Summary

(GRAPHIC)2015 Performance Highlights

Despite facing challenges, our financial performance in person. PLEASE NOTE, HOWEVER, THAT IF YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR OTHER NOMINEE AND YOU WISH TO VOTE AT THE MEETING, YOU WILL NOT BE PERMITTED TO VOTE IN PERSON AT THE MEETING UNLESS YOU FIRST OBTAIN A LEGAL PROXY ISSUED IN YOUR NAME FROM THE RECORD HOLDER. AKORN, INC. 2500 MILLBROOK DRIVE BUFFALO GROVE, ILLINOIS 60089 PROXY STATEMENT FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD [JUNE 10, 2004] QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING WHY HAVE I RECEIVED THESE MATERIALS? 2015 was solid and included the following highlights:

·     We generated net revenue of $985.1 million and maintained a consolidated gross margin of 60.5%.

·     We generated operating income of $294.6 million (or 29.9% of net revenues).

·     We received 15 product approvals and 2 tentative approvals from the FDA, including 11 ANDA approvals, 2 ANADA approvals, 1 NDA approval, 1 significant supplemental ANDA new product approval and 2 tentative ANDA approvals.

·     Our R&D organization submitted 18 ANDA filings and 1 NDA filing to the FDA for approval during 2015.

·     We launched 12 new products.

·     We completed the operational integrations of Hi-Tech Pharmacal Co., Inc. and VersaPharm, Inc.

·     We closed the acquisition of a sterile ophthalmic manufacturing facility in Hettlingen, Switzerland.

·     We invested in our organizational capital, significantly expanding our accounting and finance organization, manufacturing and operations leadership and commercial infrastructure.

(GRAPHIC)Changes in Our Executive Team in 2015

In 2015, we made several changes and additions to our executive team, and we believe these changes have better situated our Company for growth and success. Among our Named Executive Officers (as defined below) these changes involved the addition of our new Chief Financial Officer and our Corporate Controller as well as the addition of our Executive Vice President, Sales and Marketing, and our Executive Vice President, Pharmaceutical Operations.

(GRAPHIC)2015 Named Executive Officers

We refer to the following individuals as our 2015 “Named Executive Officers” or “NEOs”:

NEOPrincipal Position
Raj RaiChief Executive Officer
Duane A. PortwoodExecutive Vice President and Chief Financial Officer effective October 30, 2015
Randall E. PollardSenior Vice President, Corporate Controller and Chief Accounting Officer, also served as Interim Chief Financial Officer from August 3, 2015 to October 30, 2015
Timothy A. DickFormer Chief Financial Officer, resigned August 3, 2015
Joseph BonaccorsiSenior Vice President, General Counsel and Secretary
Bruce KutinskyChief Operating Officer
Steven LichterExecutive Vice President, Pharmaceutical Operations
Jonathan KaferExecutive Vice President, Sales and Marketing

AKORN, INC. 2016 Special Meeting Proxy Statement16

Compensation Discussion and Analysis

In this Compensation Discussion and Analysis section we present an overview of our compensation program, focusing on the elements of compensation awarded or paid to our Named Executive Officers. Below is a roadmap of the discussion that follows.

Table of Contents

How We Determine Pay17
Compensation Philosophy and Objectives and Role of the Compensation Committee17
Role of the CEO18
Role of the Compensation Consultants19
Role of Peer Group19
Role of the Shareholders19
Elements of our Compensation Program20
Base Salary20
Performance-Based Annual Incentive Plan20
Long-Term Equity Incentive Plan20
Stock Options20
Restricted Stock Units21
Timing of Equity Grants and Equity Grant Practices21
Analysis of What We Paid21
2015 Base Salaries21
2015 Performance-Based Annual Incentive Awards22
2015 Performance-Based Annual Incentive Award for our Chief Executive Officer23
2015 Performance-Based Annual Incentive Award for our Other Named Executive Officers23
2015 Long-Term Incentive Grants24
2016 Performance Objectives24
Other Elements of Compensation24
Company-Wide Benefits24
Perquisites24
ESPP25
Executive Share Retention and Ownership Guidelines25
Hedging Policy25
Clawback Policy25
Recovery of Bonuses in Connection with the Restatement25
Tax Considerations26
Accounting Treatment Considerations26

(GRAPHIC)How We Determine Pay

Compensation Philosophy and Objectives and Role of the Compensation Committee

The accompanying proxy statementCompensation Committee leads the development of our compensation philosophies and practices to assure that the total compensation paid to our executive officers is fair and reasonable relative to the extremely competitive nature of the specialty pharmaceutical industry of which we are a part. For several years, our Company experienced major business and financial challenges, and has more recently experienced a significant turn-around that is largely attributable to the success of our current management team. During the challenging downturn years, the Compensation Committee focused intently on attracting and rewarding executives with the unique intersection of industry and turnaround skills and made compensation decisions based on our objective of aligning the Company’s key executives’ goals and incentive pay with the goals of our shareholders in order to enable and encourage the turn-around effort. Consistent with our ongoing goal to keep the Company’s key executives’ objectives and incentive pay aligned with the goals of our shareholders, we continue to pursue a compensation philosophy that is intended to provide total compensation opportunities, which include base salary, performance-based cash bonus, long term equity compensation, and a health and welfare benefits package. These are intended to incentivize the uniquely skilled employees who will continue to carry out our strategic plan, mission and goals, while maintaining our required high quality standards and growth.

In 2012, we refined our compensation philosophy to reflect the Company’s current posture in the industry in order to align it with the achievement of the Company’s business strategies. Accordingly, we developed and adopted a philosophy that is intended to serve the foundation upon which the executive compensation program is structured and administered and to serve as a basis for guiding the continued development and evolution of the program.

Our compensation philosophy is based on the following goals and principles:

·Attract and retain results-oriented executives with proven track records of success to ensure the Company has the caliber of executives needed to perform at the highest levels of the industry,

·Support Company growth, alignment with shareholder interests and the achievement of other key corporate goals and objectives,

·Design packages to achieve external competitiveness, internal equity, and be cost-effective,

·Focus attention on and appropriately balance current priorities and the longer-term strategy of the Company through short- and long-term incentives,

·Encourage teamwork and cooperation while recognizing individual contributions by linking variable compensation to Company and individual performance based on position responsibilities and ability to influence financial and organizational results,

·Promote ownership of Company stock by executives to enhance the alignment of interests with shareholders,

AKORN, INC. 2016 Special Meeting Proxy Statement17

·Motivate and reward a prudent level of risk and decision making in an effort to drive reasonable performance,

·Provide flexibility and some discretion in applying the compensation principles to appropriately reflect individual circumstances as well as changing healthcare and pharmaceutical industry conditions and priorities, and

·Involve a limited use of perquisites and supplemental benefits which will only be provided if a compelling business rationale exists.

Our Compensation Committee is composed exclusively of independent directors and meets regularly both with and without management. The Compensation Committee annually approves Named Executive Officer base salaries, establishes annual incentive compensation pay for performance objectives based on both goals for the company and individual employees, makes actual awards of annual incentive compensation based on attainment of these goals and other factors the Compensation Committee deems appropriate and considers awards of long-term equity compensation.

(FLOW CHART) 

Role of the CEO

The Compensation Committee also seeks input from the CEO, particularly related to the establishment and measurement of corporate and individual objectives and recommendations related to overall employee compensation matters. The CEO provides the Board with a self-evaluation of his performance, but the CEO does not participate in discussions or make recommendations with respect to his own compensation.

Our CEO reviews the performance of, and proposes salary increases for, all managers who report to him, including the other Named Executive Officers. Any increases are generally based upon the individual’s performance during the previous year and any changes in responsibilities for the upcoming year. The Compensation Committee reviews the reasonableness of any proposed compensation for the Named Executive Officers. In conducting its review and making its determinations, the Compensation Committee reviews a history of base salary, cash incentive bonus targets and payouts, and equity awards, prepared by the Company’s Human Resources Department. During the year, our CEO may change the base salary of the managers who report to him, with the exception of our Chief Financial Officer (“CFO”), Chief Operating Officer (“COO”) and General Counsel, without approval of our Compensation Committee. He may do so in order to address significant changes in the individual’s responsibilities, to be competitive in the market or for other business reasons. Proposed compensation changes for the CFO, COO and General Counsel are submitted by our CEO to the Compensation Committee for review and approval.

Our Human Resources Department (“HR”) evaluates total compensation levels and elements of compensation and fashions competitive pay packages on a company-wide basis. HR also works with the Compensation Committee and the enclosed proxy card,CEO in planning for recruitment and retention of employees. Based on HR’s research and the CEO’s recommendations, we fix these salaries at rates that we believe are generally competitive, but we do not attempt to pay at the high end of our competition.

AKORN, INC. 2016 Special Meeting Proxy Statement18

Role of the Compensation Consultants

The Compensation Committee has maintained a structured approach to compensation for our Named Executive Officers, and, since 2012, has retained Willis Towers Watson as its independent compensation consultant to provide the Compensation Committee with support, advice and recommendations on our compensation program for our executive officers.

The Compensation Committee has analyzed whether the work of our compensation consultant Willis Towers Watson has raised any conflict of interest, taking into consideration the following factors: (i) the provision of other services to the Company by Willis Towers Watson; (ii) the amount of fees from the Company paid to Willis Towers Watson as a percentage of Willis Towers Watson’s total revenue; (iii) the policies and procedures of Willis Towers Watson that are designed to prevent conflicts of interest; (iv) any business or personal relationship of Willis Towers Watson or the individual compensation advisors employed by Willis Towers Watson with our CEO; (v) any business or personal relationship of the individual compensation advisors with any member of the Compensation Committee; and (vi) any stock of the Company owned by Willis Towers Watson or the individual compensation advisors employed by Willis Towers Watson. The Compensation Committee has determined, based on its analysis of the above factors, that the work of Willis Towers Watson and the individual compensation advisors employed by Willis Towers Watson as compensation consultants to the company has not created any conflict of interest.

In addition, in 2016 in connection with our restatement process, the Compensation Committee engaged legal counsel to provide advice regarding the recovery of bonuses paid to our executive officers for 2014.

Role of Peer Group

In 2015, 2014 and 2013, our compensation consultant worked with the Compensation Committee in comparing our executive compensation with pertinent market data. The data was taken from filings made with the SEC by a selected peer group, which peer group we updated and refined in 2015. The following companies comprised our selected peer group in 2015:

2015 Peer Group
Alkermes Plc.Pharmacyclics Inc.
Biomarin Pharmaceutical Inc.Prestige Brands Holdings, Inc.
Endo International Plc.Quintiles Transnational Inc.
Impax Laboratories Inc.Salix Pharmaceuticals Ltd.
Incyte CorporationThe Medicines Company
Jazz Pharmaceuticals CompanyUnited Therapeutics Corporation
Mallinckrodt Plc.

Specifically, the Compensation Committee requested the consultant to report base and annual salary incentive percentages for executives in similar sized companies based on revenue and market capitalization and/or similar industries. The Compensation Committee reviewed the data in order to obtain a general understanding of current compensation practices and trends for specific positions held rather than focusing on the Named Executive Officers. This analysis was reviewed and updated in 2015, 2014 and 2013 in order to confirm the appropriate data, measures and comparisons.

With respect to establishing the CEO and CFO compensation, we gather, analyze and evaluate the compensation mix provided by our peer group, as well as consider the other factors set forth in the Compensation Committee’s charter. We do not target or benchmark our Named Executive Officers’ compensation at a certain level or percentage based on other companies’ compensation arrangements.

Role of the Shareholders

The Compensation Committee considers shareholder input when setting compensation for the Company’s Named Executive Officers.

At the annual shareholder meeting held in 2014, the Company’s advisory vote on executive compensation was approved by the following vote:

ForAgainstAbstainBroker
Non-Votes
85,598,356204,544359,1346,673,489

This represents a 99% level of approval. Although the effect of the advisory vote on executive compensation is non-binding, the Board and the Compensation Committee considered these results and determined that, given the significant level of shareholder support, no major re-examination of our executive compensation program was necessary at this time. The Compensation Committee will continue to consider the outcome of the future advisory votes, as well as shareholder feedback that we receive from our shareholder outreach program, when making compensation decisions for our Named Executive Officers and our compensation programs generally. Akorn values the opinions of its shareholders and is committed to considering their opinions in making compensation decisions. See “Shareholder Outreach Program.”

AKORN, INC. 2016 Special Meeting Proxy Statement19

(GRAPHIC)Elements of our Compensation Program

For 2015, the principal components of compensation for our Named Executive Officers were sentbase salary, performance based annual cash incentive and long-term equity incentive. In addition, we offer health and welfare benefits and certain limited perquisites and separation benefits.

ElementTypeAt Risk
Base salaryCashNo, fixed
Performance-based annual incentive(1)CashYes, at risk based on Company and individual performance
Long-term incentives(2)EquityYes, at risk because time-based vesting occurs over a period of years
(1)We occasionally also provide non-recurring discretionary cash bonuses to reflect superior individual performance, new responsibilities or to compensate new hires for amounts forfeited from their previous employer.

(2)Historically, we have awarded options and/or RSUs.

Base Salary

The salaries for our Named Executive Officers are established to yoube competitive with market practices in order to allow us to attract and retain senior executive talent. Salary decisions are also influenced by internal equity taking into consideration the relationship between salaries among the executives and each executive’s role and responsibilities and the impact on Company performance. Other factors considered by the Compensation Committee include an executive’s experience, specific skills, tenure and individual performance. In setting base salaries for the CEO, CFO, COO and General Counsel, we also consider external equity based on analysis of peer group data. The Compensation Committee typically reviews the base salaries of our Named Executive Officers annually in the first quarter with any increases effective as of January 1 of that year.

Performance-Based Annual Incentive Plan

Each year, the Compensation Committee adopts guidelines pursuant to which it calculates the annual performance-based cash incentive awards available to our Named Executive Officers. We have instituted management-by-objectives (MBO) to assess performance as a basis for determining awards for all of our Named Executive Officers paid out under our 2014 Option Plan. Our MBO based incentive program has continued to be a major component of our compensation strategy. It affords us the opportunity and framework for establishing both corporate and individual performance objectives. Individual MBOs extend beyond financial performance and include actions required for the continued future growth of the company. Each Named Executive Officer’s MBOs align with each of the corporate MBOs. The Compensation Committee believes that our annual incentive program provides our Named Executive Officers with a team incentive to both enhance our financial performance and perform at the highest level. No payments are made under the incentive plan unless a threshold Company objective, such as Adjusted EBITDA, is attained. See “2015 Performance-Based Annual Incentive Awards.”

In addition to cash bonus payments made under our annual cash incentive plan, the Compensation Committee may provide discretionary bonuses to reward an executive’s superior performance in overcoming unforeseen circumstances and exceptional achievements.

Long-Term Equity Incentive Plan

Under our 2014 Option Plan, the Compensation Committee has the flexibility to make equity awards based on the common stock of the Company, including time- and performance-based awards of stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, performance shares, and other equity based awards. Our Board developed a long-term equity incentive plan as part of our goal to structure our compensation in a manner where the largest increase in total direct compensation for our Named Executive Officers comes from appreciation in a long-term equity incentive award made under our 2014 Option Plan (“Long-Term Incentive Award”). Under the plan, the Long-Term Incentive Awards to executive officers would be awarded such that 75% of the grant-date fair value of each executive’s equity grant would be provided in the form of options and 25% in RSUs. We believe that Long-Term Incentive Awards should provide a large majority of compensation opportunity for our Named Executive Officers. The Company does not have any long-term cash incentives nor does it maintain a pension plan or a supplemental executive retirement plan. Our current Form of Non-Qualified Stock Option Award Agreement, Form of Incentive Stock Option Award Agreement and Form of Restricted Stock Unit Award Agreement were filed as exhibits to the Company’s Form 10-K filed with the SEC on May 10, 2016. The Company may from time to time grant other types of equity awards using other forms of award agreements.

Stock Options

Historically we have primarily awarded stock options as the long-term incentive awards. We grant NQSOs to our Named Executive Officers as a means of rewarding past performance and encouraging continued efforts to achieve personal and Company objectives in the current and future years. Our options are awarded at the closing price of our stock on the date of grant. Options awarded to our executive officers vest at 25% of the award per year on each of the first four anniversaries of the date of grant and expire five or seven years from the date of grant, as determined by the Compensation Committee and set forth in the applicable award agreement.

AKORN, INC. 2016 Special Meeting Proxy Statement20

Restricted Stock Units

Beginning in 2014, based in part upon the recommendation of the compensation consultant, the Compensation Committee determined that the long-term incentive awards to executive officers would be awarded such that 75% of the grant-date fair value of each executive’s equity grant would be provided in the form of options and 25% in RSUs. Each RSU represents the right to receive one share of our common stock on a stated date (the “vesting date”) unless the award is terminated earlier in accordance with terms and conditions established by the administrator of our 2014 Option Plan. The RSUs generally vest in equal installments, 25% of the award per year on each of the first four anniversaries of the date of grant. Unless the Compensation Committee determines otherwise, RSUs that do not vest will be forfeited. Holders of RSUs have no voting, dividend or other rights as a shareholder until such units are vested.

Timing of Equity Grants and Equity Grant Practices

At the Board meeting held immediately after our annual meeting of shareholders, the Compensation Committee typically will recommend equity compensation, if any, to be awarded to our Named Executive Officers and all other Company employees. All awards are made based on the closing price of our stock on the date of grant. In addition, awards may be made to new employees upon their joining the Company, and to employees who are promoted during the year. The timing of such awards depends on those specific circumstances and is not tied to any other particular company event, anticipated events or announcements. Under our long-term equity incentive plan, in 2015 each executive officer was eligible to receive an award with a value up to a certain percentage of the executive’s annual salary as follows: Mr. Rai 400%; Mr. Portwood 250%, Mr. Bonaccorsi 250%, Mr. Kutinsky 300%, Mr. Lichter 100%, Mr. Pollard 100%, Mr. Kafer 100% and Mr. Dick 250%.

In addition to awards made under our incentive plans, the Compensation Committee may provide discretionary bonuses to reward an executive’s superior performance in overcoming unforeseen circumstances and exceptional achievements.

(GRAPHIC)Analysis of What We Paid

2015 Base Salaries

In 2015, the Compensation Committee reviewed the base salaries of our Named Executive Officers and increases to base salaries were implemented with the weighted average base salary of our Named Executive Officers increasing approximately 11% in comparison to 2014. The Compensation Committee again reviewed the base salaries of our Named Executive Officers in 2016 and increases to base salaries were implemented with the weighted average base salary of our Named Executive Officers increasing approximately only 2% in comparison to 2015.

 2016 Base Salary
($)
2015 Base Salary
($)(1)
2014 Base Salary
($)
 What We Took Into Consideration in Setting 2015 Salaries
Raj Rai824,000800,000750,000 Mr. Rai’s performance in 2014 in completing the acquisitions of Hi-Tech Pharmacal and VersaPharm, as well as veterinary products from Lloyd, Inc.
Duane A. Portwood450,000450,000(1)N/A Offering a competitive salary in connection with Mr. Portwood’s appointment as Chief Financial Officer of our Company in October 2015
Joseph Bonaccorsi437,750425,000350,000 Mr. Bonaccorsi’s performance in 2014 in handling special legal projects, managing increased growth in our legal department and outside counsels and contributing to increased compliance measures
Bruce Kutinsky484,100470,000425,000 Mr. Kutinsky’s performance in 2014 in obtaining 14 unique product approvals, launching 5 products, and integrating more than 62 products acquired through acquisitions
Steven Lichter309,000300,000(1)N/A Offering a competitive salary in connection with Mr. Lichter’s appointment as Executive Vice President, Pharmaceutical Operations in April 2015
Randall E. Pollard275,000275,000(1)(2)N/A Offering a competitive salary in connection with Mr. Pollard’s appointment as Vice President and Corporate Controller in April 2015
Jonathan Kafer309,000300,000(1)N/A Offering a competitive salary in connection with Mr. Kafer’s appointment as Executive Vice President, Sales and Marketing in April 2015
Timothy Dick(3)385,000385,000 It was decided that Mr. Dick’s salary was competitive with the market.

(1)The base salaries actually paid to Messrs. Portwood, Lichter, Pollard and Kafer were pro-rated to their respective start dates of October 30, February 16, April 20, and April 20, 2015.

(2)In connection with his promotion to Interim Chief Financial Officer, Mr. Pollard’s salary was increased to $275,000 as of August 3, 2015 from $235,000.

(3)Mr. Dick resigned as Chief Financial Officer as of August 3, 2015.

AKORN, INC. 2016 Special Meeting Proxy Statement21

2015 Performance-Based Annual Incentive Awards

We structured specific annual incentive awards for 2015 based upon MBOs for our CEO, CFO, COO and General Counsel, as well as the Company’s achievement of its overall goals. After the Board reviewed the strategic plan and budget for the year, the Compensation Committee set annual incentive compensation targets designed to induce achievement of that plan and budget.

For 2015, we set the CEO’s bonus target at 100% of base salary, the CFO’s bonus at 50% of base salary, the COO’s bonuses at 50% of base salary and the General Counsel’s bonus at 50% of base salary. These were the same bonus targets set for the CEO, CFO and COO for 2014, and an increase for the General Counsel who had a bonus target of 40% of base salary for 2014. Messrs. Lichter, Pollard and Kafer had 2015 target bonus opportunities of 40% of base salary. In 2015, the Named Executive Officers each had additional opportunity for “stretch” bonus of between 20% to up to 60% of their base salary (as set forth below) if certain additional objectives were achieved.

In general, the Compensation Committee considered the experience, responsibilities, title and historical performance of each particular Named Executive Officer when determining the target and stretch bonus opportunities and approved specific performance objectives based on the CEO’s recommendation and the Compensation Committee’s review.

 2015 Target
Base Incentive
Bonus
Opportunity
as % of Base
Salary*
 2015 Target Base Incentive Bonus Opportunity
as $
  2015 Stretch Incentive
Bonus Opportunity
as % of Base Salary
 2015 Stretch Incentive Bonus Opportunity
as $
  2015 Total Incentive
Bonus
Opportunity
  Total Incentive Bonus Earned for 2015(1)
Raj Rai100% $800,000  50% $ 400,000 $1,200,000 $724,399
Duane A. Portwood(2)  (2)  (2)  (2)  (2)  (2)
Joseph Bonaccorsi50%  212,500  25%  106,250  318,750  218,510
Bruce Kutinsky50%  235,000  25%  117,500  352,500  122,200
Steven Lichter40%  103,846(3)  20%  51,923(3)  155,769(3)  90,865
Randall E. Pollard40%  110,000(3)  20%  55,000(3)  165,000(3)  110,000
Jonathan Kafer(4)40%  83,077(3)  60%   124,616(3)  207,693(3)  83,077
Timothy Dick50%  192,500  25%  96,250  288,750  (5)

(*)For purposes of our performance-based incentive plan, bonus eligible Base Salary is defined as the officer’s base pay earnings as shown on the officer’s W-2 for the applicable year.

(1)Upon the recommendation of management, the Compensation Committee unanimously decided to delay the payment of all bonuses earned by our Named Executive Officers for 2015 until the Company filed the audited financial statements for 2014 and 2015, which the Company filed in its Form 10-K that it filed with the SEC on May 10, 2016.

(2)Mr. Portwood joined Akorn on October 30, 2015, and so did not receive bonus targets for 2015, however, the Company agreed to pay a bonus of $56,250 to partially compensate for the bonus opportunity he gave up at his prior employer when joining Akorn. See “Summary Compensation Table.”

(3)The bonus opportunities for Messrs. Lichter and Kafer are pro-rated to each executive’s start date of February 16 and April 20, 2015, respectively. Pursuant to his offer letter, Mr. Pollard was entitled to the bonus opportunity for the full year.

(4)Pursuant to his offer letter, Mr. Kafer was entitled to receive a bonus payment in the amount of 50%, 75% or 100% of his base salary if certain objectives were achieved, if the objectives were exceeded by 5% or if specified additional objectives were achieved. Mr. Kafer’s maximum bonus opportunity for 2015 was $207,693.

(5)Mr. Dick resigned from the Company as of August 3, 2015 and so did not receive a bonus for 2015.

For the year 2015, the Compensation Committee determined the above bonus amounts were earned by each Named Executive Officer based on the Company’s achievement of its performance targets and each Named Executive Officer’s achievement of personal MBOs. However, upon the recommendation of management, the Compensation Committee unanimously decided to delay the payment of all bonuses earned by our Named Executive Officers for 2015 until the Company filed its audited financial statements for 2014 and 2015, which the Company filed in its Form 10-K that it filed with the SEC on May 10, 2016. For purposes of determining the target bonus amount earned by each Named Executive Officer, the Company objectives were weighted 50% as a group, and the individual MBOs were weighted 50% as a group. In addition, the Compensation Committee reviewed the Company’s performance and each individual executive’s performance against their respective objectives that were set in 2015 and then assigned the Company and each Named Executive Officer a performance rating from 0-100. An executive officer must have achieved at least 50% of his MBOs in order to receive a bonus under the incentive bonus plan. The Named Executive Officers were also eligible to receive a “stretch” bonus if certain objectives were achieved under the “stretch” portion of the incentive bonus plan.

AKORN, INC. 2016 Special Meeting Proxy Statement22

(GRAPHIC) 

Under the 2015 incentive bonus plan, if the Company did not achieve its Adjusted EBITDA target for the year, no bonuses would be paid even if other objectives were achieved.

2015 Performance-Based Annual Incentive Award for our Chief Executive Officer

For 2015, the Company achieved the following financial metrics: Sales of $985 million, Adjusted EBITDA of $460 million and Adjusted EPS of $2.02.

In addition to reviewing the Company’s financial metrics, the Compensation Committee evaluated the Company’s performance against key strategic initiatives designed to promote the Company’s long-term success, as well as significant events during 2015. We continue to make progress on our plan to prepare Akorn India Private Limited (AIPL) for FDA certification. We submitted 18 ANDAs and 1 NDA to the FDA, and we launched 12 new products. We also have concentrated our efforts to enhance our culture and develop organizational talent.

The Compensation Committee determined that Mr. Rai should be awarded an incentive bonus based on the following achievements in 2015. Mr. Rai led the Company to deliver $985 million in sales and $151 million (GAAP) net earnings. Additionally, Mr. Rai provided the leadership and direction during the unstable restatement environment that enabled the company to have these business successes. He significantly strengthened the talent of the organization through the hiring of key executives across all functions. He personally negotiated with lenders and regulatory agencies to ensure the Company maintained its ability to operate effectively. Mr. Rai ensured that all of the Company’s operations maintained regulatory compliance so that we could continue to manufacture, distribute and sell our products.

2015 Performance-Based Annual Incentive Award for our Other Named Executive Officers

Similar to prior years, for fiscal year 2015, Mr. Rai recommended and the Compensation Committee approved corporate goals and personal MBOs required for incentive payout to other Named Executive Officers. The goals for the other Named Executive Officers were significantly aligned with the Company’s overall stated goals and objectives, and were tailored to each Named Executive Officer’s role and responsibilities within the Company. The plan required achievement of the Adjusted EBITDA target before any individual payouts could be earned as well as achievement of at least 50% of the executive’s individual MBOs. The amounts of actual individual payouts to the other Named Executives Officers varied based on achievement of their personal MBOs which were in the range of 0% to 100% of individual goal achievement.

Mr. Dick resigned from the Company as of August 3, 2015 and so did not receive a bonus for 2015.

The Compensation Committee determined that Mr. Kutinsky should be awarded an incentive bonus based on the following achievements. Mr. Kutinsky provided leadership across our Pharmaceutical Operations and Sales and Marketing organizations during 2015. He greatly increased the effectiveness of our Sales, Marketing and Operations organizations through the addition new talent, especially at the senior levels, and the establishment of new business processes. The teams launched new products that contributed $36.0 million of revenue (growth of $31.0 million over the year ended December 31, 2014) to the company, negotiated contracts with major customers to increase our revenue opportunity, and responded to over 150 inquiries from regulatory agencies to ensure they had the information to review our ANDA, ANADA and NDA filings.

The Compensation Committee determined that Mr. Bonaccorsi should be awarded an incentive bonus based on the following achievements. In 2015, Mr. Bonaccorsi managed diverse litigation and regulatory challenges that not only required the deployment of the Company’s legal team, but more so the breadth of outside counsel required to meet the demands of regulators, board committees and litigation. In addition, he and his team provided outstanding legal services to the Company on a wide range of legal and regulatory matters.

The Compensation Committee determined that Mr. Pollard should be awarded an incentive bonus based on the following achievements. Mr. Pollard joined the Company on April 20, 2015 and much of his year was focused on addressing the issue of the financial restatement and establishing processes, fixing weaknesses, partnering with our auditors and investigators while at the same time dramatically increasing the size and caliber of our Finance organization. Mr. Pollard also served as the interim CFO for three months following the resignation of Mr. Dick. Mr. Pollard’s leadership in managing the Company’s debt was important to maintaining efficiency in our operations.

The Compensation Committee determined that Mr. Lichter should be awarded an incentive bonus based on the following achievements in 2015. Mr. Lichter ensured all manufacturing facilities maintained their regulatory compliance to operate. Additionally, he led the reduction of our weekly backorders by almost 60% from Q1 to year-end. Much of his effort and his success was focused on the creation of the Pharmaceutical Operations function within the Company and the associated organizational structure and the recruiting of talent and implementation of business processes such as S&OP, technical transfers and cost management programs.

AKORN, INC. 2016 Special Meeting Proxy Statement23

Mr. Kafer’s bonus for 2015 was directly linked to the sales performance of the Company and targets established by the Compensation Committee and the Board of Directors. In 2015, the Company achieved $985 million in sales, and while not a factor in the determination of Mr. Kafer’s bonus amount, the Compensation Committee noted Mr. Kafer’s successful implementation of business processes for new product launches and the evaluation of commercial viability of products, and the streamlining of the commercial organization.

2015 Long-Term Incentive Grants

Due to the restatement process, no equity awards were granted in 2015 under our long-term incentive plan. However, the following grants were made to our Named Executive Officers in connection with their joining the Company in 2015: Mr. Lichter was awarded 200,000 options on February 23, 2015, Mr. Pollard was awarded 50,000 options May 1, 2015, Mr. Kafer was awarded 125,000 options on May 1, 2015 and Mr. Portwood was awarded 300,000 options on October 30, 2015. In addition, Mr. Pollard was awarded 10,000 options on October 30, 2015 in recognition for his service as Interim Chief Financial Officer. The stock options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date.

The long-term incentive awards that were intended to be made in 2015 were delayed until 2016 and were granted 100% in options.

During 2015, the Board made the following grants of stock options to our Named Executive Officers:

 Number of Options Granted in 2015(1) 

Grant Date Fair Value $

Raj Rai 
Duane A. Portwood300,000 $3,186,270
Joseph Bonaccorsi 
Bruce Kutinsky 
Steven Lichter200,000 $3,641,160
Randall E. Pollard60,000 $941,269
Jonathan Kafer125,000 $2,087,650
Timothy A. Dick 
Total685,000 $9,856,349
(1)Long-term incentive awards were scheduled to be granted in May 2015 to our executive officers with 75% of the grant-date fair value of each executive’s equity grant to be provided in the form of options and 25% in RSUs. However, due to the restatement process, the grants were delayed until early this year and were awarded 100% in options as follows: on March 24, 2016, Mr. Rai was awarded 191,387 options; Mr. Kutinsky was awarded 26,058 options and Mr. Bonaccorsi was awarded 65,453 options.

In addition to the incentive awards described above, the Compensation Committee made discretionary cash bonuses to Named Executive Officers for their extraordinary contributions in 2015. See the “Summary Compensation Table” for the amounts of those awards.

(GRAPHIC)2016 Performance Objectives

For the 2016 performance-based annual incentive plan, the following Company financial goals were set at Sales of $1.08 billion, Adjusted EBITDA of $499 million and Adjusted EPS of $2.15, as well as individual MBOs for each executive officer.

(GRAPHIC)Other Elements of Compensation

Below are additional elements of compensation that we provide to our executive officers. For information regarding employment agreements and our executive severance plan, see “Potential Payments Upon Termination.”

Company-Wide Benefits

The Company does not have a pension plan and does not have a supplemental executive retirement plan. Executive officers and all full-time employees are eligible to participate in the Company’s benefit programs, which include health insurance (which is partially funded by the employee), 401(k), disability and life insurance (separate programs for executives and all other employees), flexible spending accounts, an employee stock purchase plan, an employee assistance program, an education assistance program, travel assistance, paid time off and holidays. Part-time employees are eligible to participate in a limited benefits program which includes a 401(k) plan, an employee stock purchase plan, and limited holiday and paid time off. Since January 1, 2011, the Company has been matching employee 401(k) contributions at a rate of 50% of the first 6% contributed by the employee.

Perquisites

In 2009, the Company largely eliminated perquisites for its executive officers. However, in 2015, the Company made several additions to its team of executive officers, and in doing so paid moving, temporary housing and related relocation costs to some of its Named Executive Officers. See “Summary Compensation Table” and “All Other Compensation Table.”

AKORN, INC. 2016 Special Meeting Proxy Statement24

ESPP

Historically, the Company has had an employee stock purchase plan that has permitted eligible employees to acquire shares of our common stock at a 15% discount from market price, through payroll deductions not exceeding 15% of base wages. Purchases under the plan were subject to an annual maximum purchase of $25,000 in market value of our common stock. Due to our restatement process, however, we were required to suspend purchases under and terminate our prior employee stock purchase plan. The Company has called the 2016 special meeting of shareholders to approve the Akorn, Inc. 2016 Employee Stock Purchase Plan.

Executive Share Retention and Ownership Guidelines

In order to promote equity ownership and further align the interests of management with the Company’s shareholders, the Company adopted stock ownership guidelines for the Company’s executive officers. The executive officers are expected to achieve the ownership level associated with their position within five years of their respective appointments.

RoleGuideline
Chief Executive Officer5 times base salary
All Other Executive Officers3 times base salary

Until the specified ownership levels are met, an executive officer will be required to retain 50% of all shares acquired upon option exercises and the vesting of RSUs (in both cases, less shares withheld to pay taxes or cost of exercise). The value of a share shall be measured as the greater of the then current market price or the closing price of a share of the Company’s common stock on the acquisition date. For purposes of the stock ownership guidelines, stock ownership includes:

·shares purchased on the open market,

·shares owned jointly with, or separately, by the officer’s spouse and dependent children,

·shares held in trust for the officer or immediate family member,

·shares held through any Company-sponsored plan, including specifically the Employee Stock Purchase Plan,

·shares obtained through the exercise of stock options, and

·50% of unvested restricted shares of stock.

As of December 31, 2015, Messrs. Rai, Bonaccorsi, Kutinsky and Dick had all met the minimum ownership guidelines, and Messrs. Portwood, Lichter, Pollard and Kafer have until five years from their respective appointments to attain the required ownership levels.

Hedging Policy

Under the Company’s hedging policy, executive officers are discouraged from engaging in the purchase of puts, calls or other hedging transactions involving Company stock.

Clawback Policy

In February 2016, the Company adopted a compensation clawback policy (“Clawback Policy”) that applies to all executive officers and incentive-based compensation (including discretionary bonuses) awarded to such officers. Under the policy, the Company may require the forfeiture and repayment of incentive-based compensation if (1) the Company is required to prepare an accounting restatement due to material noncompliance with financial reporting requirements under the federal securities laws, (2) an executive officer received incentive-based compensation based on materially inaccurate financial statements or materially inaccurately determined performance metrics, (3) an action or omission by an executive officer results in material financial or reputational harm to the Company, or (4) an executive officer violated a non-compete or non-solicit provision or engaged in a felony or professional conduct injurious to the Company, its customers, employees, suppliers, or shareholders. In any such event, the Compensation Committee may require that an executive officer forfeit or repay all or any portion of any outstanding unpaid incentive-based compensation that was awarded to the officers and any incentive-based compensation that was paid to the officers during the 36 months prior. If a restatement occurs or an award is based on materially inaccurate financial statements or performance metrics, the Compensation Committee will consider all facts and circumstances that it determines relevant, including whether anyone responsible engaged in misconduct and issues of accountability. Any amount repaid by an executive officer shall not exceed the amount of incentive-based compensation awarded by the Company in excess of what would have been awarded to such employee under the circumstances reflected by the accounting restatement since the effective date of the policy. Pursuant to the provisions of the Clawback Policy, the Company shall amend the policy as necessary to satisfy the requirements of the Dodd Frank Wall Street Reform and Consumer Protection Act and the NASDAQ. In order to ensure the enforceability of the Clawback Policy, the Company is inserting appropriate language regarding the policy into applicable award agreements and other documents.

In addition to the Clawback Policy, the Company’s CEO and CFO are subject to statutory clawback requirements under the Sarbanes Oxley Act of 2002, which generally requires public company chief executive officers and chief financial officers to disgorge bonuses, other incentive- or equity-based compensation and profits on sales of company stock that they receive within the 12-month period following the public release of financial information if there is a restatement because of material noncompliance, due to misconduct, with financial reporting requirements under the federal securities laws.

Recovery of Bonuses in Connection with the Restatement

In light of our restatement, and as referenced in the Form 10-K/A filed in April 2015, in May 2016 the Compensation Committee re-evaluated the base, “stretch” and discretionary bonuses paid to the individuals listed as “named executive officers” for fiscal year 2014 (the “2014 NEOs”). Under our performance-based annual incentive plan in which the 2014 NEOs participated, if we do not achieve our Adjusted EBITDA target for a year, no awards are to be paid under the plan, even if other objectives were achieved. As a result of our restatement, it was determined that the Adjusted EBITDA that we actually achieved for 2014 did not meet the target threshold for that year. As a result, the Compensation Committee determined, and the Board approved, that the Company would seek repayment of 100%

AKORN, INC. 2016 Special Meeting Proxy Statement25

of the after-tax bonuses (base, “stretch” and discretionary) that were paid to each of the 2014 NEOs who are still employed by the Company for their service in 2014. Although the Company’s Clawback Policy generally applies to incentive payments prospectively since its adoption in February 2016, the steps taken by the Compensation Committee with respect to the 2014 bonuses are consistent with such policy. The Compensation Committee indicated that the recovery of bonuses is not tied to any determination of fault on the part of the 2014 NEOs and results solely from the financial restatement. The 2014 NEOs are cooperating with the Company, and the Company and the 2014 NEOs will be implementing repayment terms.

Tax Considerations

Section 162(m) of the Internal Revenue Code generally prohibits publicly held companies from deducting more than $1.0 million per year in compensation paid to each of certain of the Company’s highest paid executive officers, unless, in general, the compensation is paid pursuant to a plan which is performance-related, non-discretionary and has been approved by our shareholders, such as our 2014 Option Plan. It has been and continues to be our intent that all non-equity incentive payments be deductible unless maintaining such deductibility would undermine our ability to meet our primary compensation objectives or is otherwise not in our best interest. In general, historically the Compensation Committee has structured awards to the executive officers under the Company’s non-equity incentive program to qualify for this exemption. However, in 2015, due to the restatement process and hiring of new executive officers, the Company set its performance objects later in the year than is typical and thus was unable to structure its non-equity incentive program to meet the strict compliance requirements of Section 162(m) for the 2015 performance period. As a result, the CEO’s total compensation exceeded the Section 162(m) deductibility limit by approximately $1,400,000, which represented a cost to the Company of approximately $526,000 as a result of the lost tax deduction. The Compensation Committee believes that this amount, including the cost of the lost tax deduction was justifiable in order to be able to hire and retain key strategic executives through the restatement process and set meaningful objectives. However, going forward, it is our intent that we will continue to strive to structure compensation (excluding certain equity incentives) paid to the Named Executive Officers so that it is deductible under Section 162(m) of the Internal Revenue Code to the extent practical, but we may award non-deductible compensation in certain circumstances as we deem appropriate.

We also regularly analyze the tax effects of various forms of compensation and the potential for excise taxes to be imposed on the executive officers which might have the effect of frustrating the purposes of such compensation.

Accounting Treatment Considerations

We are especially attuned to the impact of ASC 718 -Stock Compensation, with respect to the granting and vesting of equity compensation awards. Prior to the granting of such awards, we analyze the short and longer-term effects of any particular award on our budget for the year of grant and anticipated financial impact in future years. This information is taken into account in determining the type and vesting parameters for equity-based compensation awards.

AKORN, INC. 2016 Special Meeting Proxy Statement26

Executive Compensation Tables

(GRA) 2015 Summary Compensation Table

The following table sets forth information concerning compensation paid to or earned by our Named Executive Officers for the years ended December 31, 2015, 2014 and 2013.

Name and principal position Year Salary
($)
 Bonus*
($)
 Stock
Awards
($)(1)
 Option
Awards
($)(2)
 Non-Equity
Incentive Plan
Compensation*
($)(3)
 All Other
Compensation
($)(4)
 Total*
($)
Raj Rai
Chief Executive Officer
 2015 800,000 391,400   724,399 3,211 1,919,010
 2014 750,000 375,000(*) 4,412,253 1,948,882 1,125,000(*) 3,721 8,614,856
 2013  250,000  443,725 500,000 500,000 1,693,725
Duane A. Portwood
Executive Vice President and
Chief Financial Officer
 2015 70,962(5) 56,250(6)  3,186,270  104 3,313,586
 2014       
 2013       
Joseph Bonaccorsi
Senior Vice President,
General Counsel and Secretary
 2015 425,000 100,000   218,510 8,810 752,320
 2014 350,000  3,913,930 389,703 168,000(*) 10,769 4,832,402
 2013 286,340   82,348 114,400 9,290 492,378
Bruce Kutinsky
Chief Operating Officer
 2015 470,000    122,200 8,511 600,711
 2014 425,000  184,140 552,102 255,000(*) 4,668 1,420,910
 2013 313,685   144,279 122,070 6,453 586,487
Steven Lichter
Executive Vice President,
Pharmaceutical Operations
 2015 259,616(5) 94,854(7)  3,641,160 90,866 8,925 4,095,421
 2014       
 2013       
Randall E. Pollard
Former Interim CFO. Current Executive Vice President,
Corporate Controller and Chief Accounting Officer
 2015 178,846(8) 127,000(7)  941,269 132,000 30,284 1,409,399
 2014       
 2013       
Jonathan Kafer
Executive Vice President, Sales and Marketing
 2015 207,692(5) 39,100  2,087,650 83,077 20,786 2,438,305
 2014       
 2013       
Timothy A. Dick
Former Chief Financial Officer
 2015 232,480(9)     175,050 407,530
 2014 385,000  1,669,754 428,737  9,007 2,492,498
 2013 309,000   133,390 77,250 9,110 528,750

(*)In light of our restatement, the Compensation Committee re-evaluated the base, “stretch” and discretionary bonuses paid to our 2014 NEOs. Consistent with the terms of the Company’s new Clawback Policy, the Compensation Committee determined, and the Board approved, that the Company would seek repayment of 100% of the after-tax bonuses (base, “stretch” and discretionary) in respect of 2014 service that were paid to each of the 2014 NEOs who are still employed by the Company. See “Recovery of Bonuses in Connection with the Restatement.”

(1)This column shows the grant date fair value of RSUs granted during the applicable year. Due to the restatement process, no RSUs were awarded under our long-term incentive plan in 2015. Such long-term incentive awards were delayed until 2016 and were granted 100% in options. See “Long-Term Incentive Plan” and “2015 Long-Term Incentive Grants.”

(2)This column shows the grant-date fair value of stock options granted during the applicable year. These amounts were determined as of the options’ grant dates in accordance withASC 718 using the Black Scholes-Merton valuation model. The assumptions used were the same as those reflected in Note 11 – “Stock Options, Employee Stock Purchase Plan and Restricted Stock” in our Form 10-K filed with the SEC on May 10, 2016. Due to the restatement process, no stock options were awarded under our long-term incentive plan in 2015. However, in connection with joining the Company, Mr. Lichter was awarded 200,000 options on February 23, 2015, Mr. Pollard was awarded 50,000 options May 1, 2015, Mr. Kafer was awarded 125,000 options on May 1, 2015 and Mr. Portwood was awarded 300,000 options on October 30, 2015. In addition, Mr. Pollard was awarded 10,000 options on October 30, 2015 in recognition for his service as Interim Chief Financial Officer. The stock options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. The long-term incentive awards intended to be granted in 2015 were delayed until 2016 and were granted 100% in options. See “Long-Term Incentive Plan,” “2015 Long-Term Incentive Grants” and the notes to the “Grants of Plan-Based Awards” and “Outstanding Equity Awards” tables.

AKORN, INC. - 2016 Special Meeting Proxy Statement27

(3)The amounts shown in this column are performance-based annual incentive awards earned in the applicable year. Annual performance-based incentive awards are typically paid to the Named Executive Officers in the first quarter of the subsequent year in which they were earned. However, upon the recommendation of management, the Compensation Committee unanimously decided to delay payment of all bonuses earned by the Named Executive Officers for 2015 until the Company filed its Annual Report on Form 10-K for 2015. See “Performance-Based Annual Incentive” for additional information.

(4)The amounts reported in this column represent the dollar amount for each Named Executive Officer as set forth in more detail in the “All Other Compensation Table” below.

(5)The amounts shown represent the base salaries of Messrs. Portwood, Lichter and Kafer - $450,000, $300,000 and $300,000, respectively, pro-rated to their respective start dates of October 30, February 16 and April 20, 2015.

(6)Mr. Portwood joined Akorn on October 30, 2015, and so did not receive bonus targets for 2015; however, he received a guaranteed payment of $56,250 to partially compensate for the bonus opportunity he gave up at his prior employer when joining Akorn.

(7)Messrs. Lichter and Pollard were granted signing bonuses of $46,154 and $50,000, respectively. Messrs. Lichter and Pollard were also awarded discretionary bonuses in the amounts of $48,700 and $55,000, respectively. In addition, for his service as Interim Chief Financial Officer, Mr. Pollard was awarded a bonus in the amount of $22,000.

(8)In connection with his promotion to Interim Chief Financial Officer, Mr. Pollard’s salary was increased from his starting salary of $235,000 to $275,000 as of August 3, 2015.

(9)This amount represents Mr. Dick’s base salary of $385,000 pro-rated through his resignation date of August 3, 2015.

All Other Compensation Table

NameYear Fees for
Consulting
Services
($)
 401(k)
Match
($)
 Group
Term Life
Insurance
Premium
($)
 All
Other
($)
 Total
($)
Raj Rai2015  2,650 561  3,211
Duane A. Portwood2015   104  104
Joseph Bonaccorsi2015  7,950 860  8,810
Bruce Kutinsky2015  7,950 561  8,511
Steven Lichter2015  7,615 1,310  8,925
Randall E. Pollard2015   249 30,035(b) 30,284
Jonathan Kafer2015  4,846 573 15,367(b) 20,786
Timothy A. Dick2015 160,417(a) 7,950 395 6,288(c) 175,050

(a)These consulting fees were paid pursuant to a consulting arrangement entered into between the Company and Mr. Dick upon his resignation from the Company. See “Potential Payments Upon Termination.”

(b)The amount shown reflects moving, temporary housing and related relocation costs reimbursed to the executive.

(c)The amount shown represents the cost paid for continued health coverage after Mr. Dick’s resignation in 2015. See “Potential Payments Upon Termination.”

AKORN, INC. - 2016 Special Meeting Proxy Statement28

(GRA) 2015 Grants of Plan-Based Awards

The following table provides additional information about non-equity incentive compensation and stock option awards granted to our Named Executive Officers in 2015 under our 2014 Option Plan.

NameGrant
Date
Estimated Possible Payouts
Under Non-Equity Incentive
Plan Awards(1)
 Estimated Future Payouts
Under Equity Incentive
Plan Awards
 All Other Stock Awards: Number
of Shares
of Stocks
All Other
Option
Awards:
Number of
Securities
Underlying
Options(2)
Exercise
or Base
Price of
Option
Awards(3)
($/Sh)
Grant Date
 Fair Value
of Stock
and Option
Awards($)(4)

 
Thres-

hold
($)

Target
($)
Maximum
($)
 Thres-
hold
($)
Target
($)
Maximum
($)
 
Raj Rai                     
Non-Equity Incentive Compensation07/30/2015   800,000 1,200,000              
Duane A. Portwood                     
Stock Option10/30/2015               300,000 26.74 3,186,270
Joseph Bonaccorsi                     
Non-Equity Incentive Compensation07/30/2015   212,500 318,750              
Bruce Kutinsky                     
Non-Equity Incentive Compensation07/30/2015   235,000 352,500              
Steven Lichter                    
Non-Equity Incentive Compensation07/30/2015  103,846(5) 155,769(5)         200,000 48.05 3,641,160
Stock Option02/23/2015                    
Randall E. Pollard                    
Non-Equity Incentive Compensation07/30/2015  110,000(5) 165,000(5)              
Stock Option05/01/2015               50,000 43.00 835,060
Stock Option10/30/2015               10,000 26.74 106,209
Jonathan Kafer                     
Non-Equity Incentive Compensation07/30/2015   83,077(5) 207,693(5)              
Stock Option05/01/2015               125,000 43.00 2,087,650
Timothy A. Dick                     
Non-Equity Incentive Compensation(6)07/30/2015   192,500 288,750              

(1)For information on performance-based annual incentive awards granted in 2015, see “Performance-Based Annual Incentive” and “Summary Compensation Table - Non-Equity Incentive Plan Compensation.”

(2)The stock options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. Due to the restatement process, no equity awards were granted in 2015 under our long-term incentive plan. However, the following grants were made to Named Executive Officers in connection with their joining the Company in 2015: Mr. Lichter was awarded 200,000 options on February 23, 2015, Mr. Pollard was awarded 50,000 options May 1, 2015, Mr. Kafer was awarded 125,000 options on May 1, 2015 and Mr. Portwood was awarded 300,000 options on October 30, 2015. In addition, Mr. Pollard was awarded 10,000 options on October 30, 2015 in recognition for his service as Interim Chief Financial Officer. The long-term incentive awards that were intended to be granted in 2015 were granted earlier this year on March 24, 2016, as follows: Mr. Rai was awarded 191,387 options; Mr. Kutinsky was awarded 26,058 options and Mr. Bonaccorsi was awarded 65,453 options.

(3)The per-share exercise or base price of the options granted in the fiscal year is based on the closing price of our common stock on the grant date of each respective option.

(4)The grant date fair value of the option award granted during 2015 was based on the closing prices of our common stock on the grant date, and was calculated in accordance with ASC 718. The assumptions used for this grant were the same as those reflected in Note 11 – “Stock Options, Employee Stock Purchase Plan and Restricted Stock” in our Form 10-K filed with the SEC on May 10, 2016.

(5)The amounts shown for Messrs. Lichter and Kafer are pro-rated to their respective start dates of February 16 and April 20, 2015. Pursuant to his offer letter, Mr. Pollard was entitled to the bonus opportunity for the full year.

(6)Mr. Dick resigned from the Company as of August 3, 2015 and so did not receive a bonus for 2015.

AKORN, INC. - 2016 Special Meeting Proxy Statement29

(GRAPHIC)Outstanding Equity Awards at 2015 Year-End

The following table sets forth information with respect to outstanding equity awards held by our Named Executive Officers as of December 31, 2015. Market values have been determined based on the closing price of our common stock on December 31, 2015 of $37.31.

NameOPTION AWARDS(1) STOCK AWARDS
Number of
Securities
Underlying
Unexercised
Options
Exercisable
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
Equity
Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
Option
Exercise
Price
($)
Option
Expiration
Date
 Number of
Shares or
Units of
Stock That
Have Not
Vested
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)
Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights That
Have Not
Vested
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested
Raj Rai                
Option(1)32,600 32,600    15.36 5/3/2018      
Option(2)52,923 158,767    24.74 5/2/2019      
RSU(3)           19,703 735,128  
RSU(4)           73,944 2,758,879  
Duane A. Portwood                
Option(5) 300,000    26.74 10/30/2022      
Joseph Bonaccorsi                
Option(6)100,000     2.61 (6)      
Option75,000     6.62 (6)      
Option(1)6,050 6,050    15.36 5/3/2018      
Option(2)10,583 31,747    24.74 5/2/2019      
RSU(3)           3,940 147,020  
RSU(4)           74,370 2,774,775  
Bruce Kutinsky                
Option(6)250,000     5.43 (6)      
Option125,000     6.62 (6)      
Option(7)75,000 25,000    13.35 8/3/2017      
Option(1)10,600 10,600    15.36 5/3/2018      
Option(2)14,493 44,977    24.74 5/2/2019      
RSU(3)           5,582 208,274  
Steven Lichter                
Option(8) 200,000    48.05 2/23/2022      
Randall E. Pollard                
Option(9) 50,000    43.00 5/1/2022      
Option(5) 10,000    26.74 10/30/2022      
Jonathan Kafer                
Option(9) 125,000    43.00 5/1/2022      
Timothy A. Dick               
Option125,000     6.62 (6)      
Option(1)9,800     15.36 5/3/2018      
Option(2)11,643     24.74 5/2/2019      
RSU(3)           4,334 161,711  
RSU(4)           30,008 1,119,543  

See footnotes on next page

AKORN, INC. - 2016 Special Meeting Proxy Statement30

NOTES:

(1)The amounts shown represent the number of options granted to each executive officer May 3, 2013 that had not vested as of December 31, 2015. These options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. Mr. Dick’s remaining 9,800 options were forfeited as of his resignation August 3, 2015. Subsequent to December 31, 2015, the following options vested: Mr. Rai 3,025, Mr. Bonaccorsi 16,300 and Mr. Kutinsky 5,300.

(2)The amounts shown represent the number of options granted to each executive officer May 2, 2014 that had not vested as of December 31, 2015. These options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. Mr. Dick’s remaining 34,927 options were forfeited as of his resignation August 3, 2015. Subsequent to December 31, 2015, the following options vested: Mr. Rai 52,923, Mr. Bonaccorsi 10,583 and Mr. Kutinsky 14,993.

(3)The amounts shown represent the number of RSUs granted to each executive officer May 2, 2014 that had not vested as of December 31, 2015. These RSUs vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. RSUs that were scheduled to vest in 2015 are treated as vested for accounting purposes and purposes of determining diluted earnings per share. However, due to the Company’s restatement process, no shares could be issued with respect to any RSUs that vested in 2015 and the Company intends to issue such shares as soon as it is allowed. Subsequent to December 31, 2015, the following RSUs vested: Mr. Rai 6,568, Mr. Bonaccorsi 1,314 and Mr. Kutinsky 1,861. In accordance with his letter agreement, Mr. Dick’s remaining 4,334 RSUs vested on February 3, 2016.

(4)The amounts shown represent the number of RSUs granted to each executive officer September 5, 2014 that had not vested as of December 31, 2015. These RSUs vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. RSUs that were scheduled to vest in 2015 are treated as vested for accounting purposes and purposes of determining diluted earnings per share. However, due to the Company’s restatement process, no shares could be issued with respect to any RSUs that vested in 2015 and the Company intends to issue such shares as soon as it is allowed. In accordance with his letter agreement, Mr. Dick’s remaining 30,008 RSUs vested on February 3, 2016.

(5)The amounts shown represent the number of options granted on October 30, 2015 to Mr. Pollard in connection with his service as our Interim Chief Financial Officer and to Mr. Portwood in connection with his hire as our new Chief Financial Officer that had not vested as of December 31, 2015. These options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date.

(6)These options are fully vested and were scheduled to expire if not exercised. However, due to legal restrictions under the securities laws, during the restatement process the options could not be exercised before the end of 2015. Once the restrictions were lifted in 2016, the executives had 30 days to exercise such options before they expired.

(7)The amounts shown represent the number of options granted to each executive officer August 3, 2012 that had not vested as of December 31, 2015. These options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. The remaining options vest August 3, 2016.

(8)The amounts shown represent the number of options granted on February 23, 2015 to Mr. Lichter in connection with his hire that had not vested as of December 31, 2015. These options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. Subsequent to December 31, 2015 50,000 of Mr. Lichter’s options vested.

(9)The amounts shown represent the number of options granted on May 1, 2015 to Mr. Pollard and Mr. Kafer in connection with their hires. The options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. Subsequent to December 31, 2015, the following options vested: Mr. Pollard 12,500 and Mr. Kafer 31,250.

AKORN, INC. - 2016 Special Meeting Proxy Statement31

(GRAPHIC)2015 Option Exercises and Stock Vested Table

The following table provides a summary of the value realized by our Named Executive Officers from the exercise of option awards or the vesting of stock awards during the year ended December 31, 2015.

 OPTION AWARDS STOCK AWARDS
NameNumber of
Shares
Acquired
on Exercise
(#)
 Value
Realized
on
Exercise ($)(1)
 Number of
Shares
Acquired
on
Vesting
(#)(2)
 Number of
Shares Withheld
to Cover Tax
Liability(2)
 Value Realized
on Vesting
($)(2)
Raj Rai(3)1,700,000  64,090,976  31,216    1,261,183 
Duane A. Portwood         
Joe Bonaccorsi(4)100,000  4,661,094  26,104    1,045,060 
Bruce Kutinsky(5)     1,861    78,542 
Steven Lichter         
Randall E. Pollard         
Jonathan Kafer         
Timothy A. Dick(6)122,222  4,526,517  11,447    460,283 

(1)The stock option exercises included above were either same-day sales or were sales to cover the exercise price and taxes due upon exercise of the options. The value realized on exercise of these options equaled the difference between the average sales prices and the exercise prices for the underlying shares.
(2)As a result of the Company’s restatement process, no shares associated with vesting RSUs were issued in 2015 and accordingly, no shares could be withheld. For disclosure purposes, the Company has still reported the number of shares and value realized associated with the vesting of the RSUs.
(3)Of the 1,700,000 options exercised by Mr. Rai during the year ended December 31, 2015, 873,985 shares were sold to cover the exercise price and taxes due upon exercise of options and the remaining 826,015 shares were held by Mr. Rai. Of the $1.3 million of value realized on vesting of RSUs during the year ended December 31, 2015, $0.3 million of value was based on the vesting of 6,568 shares at the closing price of our common stock on the first trading day following the annual vesting on May 4, 2015 of $42.21 per share and $1.0 million of value was based on the vesting of 24,648 shares at the closing price of our common stock on the first trading day following the annual vesting on September 8, 2015 of $39.92 per share.
(4)Of the 100,000 options exercised by Mr. Bonaccorsi during the year ended December 31, 2015, 40,827 shares were sold to cover the exercise price and taxes due upon exercise of options and the remaining 59,173 shares were held by Mr. Bonaccorsi. Of the $1.0 million of value realized on vesting of RSUs during the year ended December 31, 2015, $0.1 million of value was based on the vesting of 1,314 shares at the closing price of our common stock on the first trading day following the annual vesting on May 4, 2015 of $42.21 per share and $1.0 million of value was based on the vesting of 24,790 shares at the closing price of our common stock on the first trading day following the annual vesting on September 8, 2015 of $39.92 per share.
(5)The value for Mr. Kutinsky was based on the closing price of our common stock on the first trading day following the annual vesting on May 4, 2015 of $42.21 per share.
(6)Of the 122,222 options exercised by Mr. Dick during the year ended December 31, 2015, 60,300 shares were sold to cover the exercise price and taxes due upon exercise of options and the remaining 61,922 shares were held by Mr. Dick. Of the $0.5 million of value realized on vesting of RSUs during the year ended December 31, 2015, $0.1 million of value was based on the vesting of 1,445 shares at the closing price of our common stock on the first trading day following the annual vesting on May 4, 2015 of $42.21 per share and $0.4 million of value was based on the vesting of 10,003 RSUs at the closing price of our common stock on the first trading day following the annual vesting on September 8, 2015 of $39.92 per share and $0.9 million of value was based on the accelerated vesting of the remaining 34,342 outstanding RSUs in connection with his resignation as discussed above, based on the price of our common stock on the first trading day following the vesting date of February 3, 2016 of $25.41 per share.

Potential Payments Upon Termination

Employment Agreements and Offer Letters

We have entered into employment agreements with our CEO, CFO, COO and General Counsel that, in addition to providing bonus opportunity, provide the officers with compensation if they are terminated without cause, they leave the Company with good reason or their employment terminates in certain circumstances in connection with a change of control. The agreements renew automatically for a one-year period unless written notice of termination is provided. We believe the terms of the employment agreements promote stability and continuity of senior management. Specifically, these common protections promote our ability to attract and retain management and assure us that our executive officers will continue to be dedicated and available to provide objective advice and counsel notwithstanding the possibility, threat or occurrence of a change in their circumstances or in the control of the Company. All of the employment agreements are listed in the Exhibit Index to our 2015 Annual Report on Form 10-K.

Each of our CEO, CFO, COO and General Counsel is entitled to receive benefits under the employment agreements if (1) we terminate the executive’s employment without cause, (2) the

AKORN, INC. 2016 Special Meeting Proxy Statement32

executive resigns for good reason or (3) if there is a change of control during the term of the agreement and within the 90 days prior to and 12 months following the change of control we terminate the executive’s employment without cause or he resigns for good reason. Under these scenarios, each of the executives is entitled to receive (1) any accrued but unpaid salary and pro-rata bonus, (2) reimbursement for any outstanding reasonable business expense, (3) vacation pay, (4) continued life and health insurance as described below and (5) a severance payment calculated as described below.

The term “cause” includes termination due to willful and continued failure to substantially perform assigned duties, the conviction of any felony or crime involving fraud, and breach of any material term of the employment agreement. The term “good reason” includes termination due to a material adverse change in status or responsibilities, relocation beyond fifty (50) miles from the executive’s job location or residence, a substantial reduction in base salary that is not comparable to that of other executives and is not part of a comprehensive reduction, and the failure of the Company to obtain an agreement satisfactory to the executive from any successor entities to assume the employment agreement.

If we terminate the executive without cause or the executive resigns for good reason, the severance payment will be equal to one times his then current base salary plus his total bonus opportunity most recently approved under the Company’s annual bonus incentive plan. In addition, the executive is eligible to receive payment of life and health insurance coverage for a period of 12 months following such executive’s termination of employment.

If there is a change of control during the term of the agreement and within the period from 90 days prior to and 12 months following the change in control we terminate the executive without cause or the executive resigns for good reason, the severance payment will be equal to three times in the case of the CEO and two times in the case of the CFO, COO or General Counsel, the sum of the greater of (a) the executive’s then current base salary and (b) his base salary immediately prior to the change of control, plus his total bonus opportunity most recently approved under the Company’s annual bonus incentive plan. In addition, the executive will be eligible to receive payment of life and health insurance coverage for a period of 36 months for the CEO and 24 months for each of the CFO, COO and General Counsel, following such executive’s termination of employment as well as vesting (as of the executive’s last day of employment) of any unvested options or RSUs previously granted to the executive.

Severance payments will be made in one lump sum within 30 days, or as soon as administratively practicable, following the termination date, subject to all applicable tax and other withholdings.

If the executive’s employment is terminated by the Company for cause, or by the executive without good reason, or due to the executive’s death or disability or retirement pursuant to the Company’s policies applicable to executive officers, the executive is not entitled to severance pay or continuation of payment of life and health insurance but will receive accrued, but unpaid salary, reimbursement for any outstanding reasonable business expense and pro-rata pay for unused vacation time.

The employment agreements contain non-competition and non-solicitation covenants that apply during the term and until the sooner to occur of 12 months following the executive’s termination date and 12 months following the change of control.

In the event that any payment or benefit received or to be received by the CEO, CFO, COO or General Counsel in connection with termination of his employment agreement would constitute a parachute payment within the meaning of Section 280G of the Internal Revenue Code or any similar or successor provision to 280G would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code, then such amounts would be reduced to the largest amount which would result in no portion of the amounts being subject to the excise tax. The agreements do not provide for any tax gross-up of severance pay.

In connection with his promotion to Chief Accounting Officer and Interim Chief Financial Officer, Mr. Pollard entered into a letter agreement dated August 25, 2015, which entitles Mr. Pollard to severance in an amount equal to twelve months of his then current base salary if his employment is terminated prior to August 3, 2016 without cause or due to a change in control that occurs within 60 days of August 3, 2016. Eligibility for this severance benefit is dependent upon execution of a termination and severance agreement at the time of termination of his employment.

A copy of each of the employment agreements and letter agreements we have with our Named Executive Officers has been filed with the SEC. Please see the exhibit list at Item 15.Exhibits, Financial Statement Schedules.

Executive and Key Management Change in Control Severance Plan

The severance and change in control arrangements for our CEO, CFO, COO and GC are set forth in their individual employment agreements, as set forth above. Severance and change in control arrangements for our other Named Executive Officers and key executives is set forth in the Executive Change in Control Severance Plan (the “Executive CIC Plan”) that has been instituted by our Compensation Committee. Participants in the Executive CIC Plan are selected by the Company’s Compensation Committee or Board of Directors. Under the Executive CIC Plan, if a Named Executive Officer, within the 90 days prior to and 12 months following a change of control of the Company, experiences an involuntary termination without cause or voluntarily terminates his employment for good reason, then he will be entitled to receive (i) a lump-sum cash severance payment equal to one year of his then current base salary, (ii) continued payment of health insurance coverage for a period of one year following termination of employment and (iii) vesting as of the executive’s last day of employment of any unvested options or RSUs previously granted to the executive. See “Payments in Connection with Various Termination Scenarios.”

The Executive CIC Plan provides the Company with assurance that it will have the continued dedication of, and the availability of objective advice and counsel from, key executives of the Company and its affiliates and to promote certainty and minimize potential disruption for key executives of the Company in the event the Company is faced with or undergoes a change in control. The Company updated its equity award agreements for its Named Executive Officers. Each of the Company’s equity award agreements for Named Executive Officers now provides for this “double trigger” vesting of equity awards in the event the

AKORN, INC. 2016 Special Meeting Proxy Statement33

Company undergoes a change in control transaction in which the awards are continued or assumed – that is, the award will vest if the recipient experiences an involuntary termination without cause or voluntarily terminates his employment for good reason within the 90 days prior to and 12 months following a change in control of the Company. Our current Form of Non-Qualified Stock Option Award Agreement, Form of Incentive Stock Option Award Agreement, and Form of Restricted Stock Unit Award Agreement were filed as exhibits to our Form 10-K that we filed with the SEC on May 10, 2016. Other equity awards may be granted under our 2014 Stock Option Plan using other forms of award agreements as may be determined from time to time in the form approved by the Compensation Committee.

The Executive CIC Plan does not provide for any tax gross-up of severance pay. In addition, payment of any cash severance under the Executive CIC Plan is contingent upon the participant’s execution of a separation agreement containing a release of claims in favor of the Company and its affiliates and covenants restricting the executive officer’s competition, solicitation of employees, disparagement of the Company and its affiliates and disclosure of confidential information.

Payments in Connection with Various Termination Scenarios

The following table indicates the cash amounts, accelerated vesting and other payments and benefits that each Named Executive Officer would have been entitled to receive upon termination under various circumstances pursuant to the terms of their respective employment agreements, the 2003 Plan and 2014 Option Plan, the award agreements made under the 2003 Plan and the 2014 Option Plan and the Company’s Executive CIC Plan. The table assumes that the executive’s termination of employment with the Company under the scenario shown occurred on December 31, 2015.

Executive / Termination Event(1)(2)Cash Severance Payment Acceleration of
Equity Awards(3)
 Life/Health
Insurance Benefits
 Total Termination
Benefits
Raj Rai            
without cause or with good reason,$ 2,000,000   $11,250(4) $2,011,250 
without cause or with good reason within 90 days prior to or 12 months following a change of control$6,000,000 $6,205,284 $33,750(5) $12,239,034 
Duane A. Portwood            
without cause or with good reason,$787,500   $ 11,250(4) $798,750 
without cause or with good reason within 90 days prior to or 12 months following a change of control$1,575,000 $3,171,000 $ 22,500(5) $4,768,500 
Joseph Bonaccorsi            
without cause or with good reason$680,000   $ 11,250(4) $691,250 
without cause or with good reason within 90 days prior to or 12 months following a change of control$1,360,000 $3,453,628 $22,500(5) $4,836,128 
Bruce Kutinsky            
without cause or with good reason,$ 822,500   $ 11,250(4) $833,750 
without cause or with good reason within 90 days prior to or 12 months following a change of control$1,645,000 $1,605,311 $22,500(5) $3,272,811 
Steven Lichter            
without cause or with good reason        
without cause or with good reason within 90 days prior to or 12 months following a change of control$300,000  (6) $11,250(4) $ 311,250 
Randall E. Pollard            
without cause(7)$275,000     $ 275,000 
without cause or with good reason within 90 days prior to or 12 months following a change of control$275,000 $105,700(6) $11,250(4) $ 391,950 
Jonathan Kafer            
without cause or with good reason        
without cause or with good reason within 90 days prior to or 12 months following a change of control$300,000  (6) $11,250(4) $311,250 
(1)The table does not give effect to any reduction in payments to any executive that might occur under his employment agreement in the event that the payment would become subject to additional taxes under Section 4999 of the Internal Revenue Code for receipt of excess parachute payments in the event of a termination or resignation following a change in control. In addition, the amounts shown in this table do not include accrued but unpaid salary, reimbursement for any outstanding reasonable business expense or vacation pay.
(2)If the executive’s employment is terminated by the Company for cause, or by the executive without good reason, or due to the executive’s death or disability or retirement pursuant to the Company’s policies, the executive will receive all accrued but unpaid salary, reimbursement for any outstanding reasonable business expense and vacation pay.
(3)The amount represents the intrinsic value of “in-the-money” unvested stock options and unvested RSUs based on $37.31 per share, which was the closing stock price of Akorn, Inc. common stock on December 31, 2015.
(4)The amount represents the estimated cost to continue health and life insurance coverage for 1 year.

AKORN, INC. 2016 Special Meeting Proxy Statement34

(5)The amount represents the estimated cost to continue health and life insurance coverage for Mr. Rai for 3 years, for Messrs. Portwood, Bonaccorsi and Kutinsky for 2 years.
(6)All of Messrs. Lichter’s and Kafer’s stock options were out of the money as of December 31, 2015. The amount shown for Mr. Pollard does not include 50,000 of his stock options which were out of the money as of December 31, 2015.
(7)Pursuant to his letter agreement dated August 25, 2015, Mr. Pollard is entitled to severance in an amount equal to twelve months of base salary if his employment is terminated prior to August 3, 2016 without cause.

Mr. Dick’s Resignation

On August 3, 2015, Mr. Dick tendered his resignation to pursue other opportunities. In connection with his departure, the Company entered into a letter agreement with Mr. Dick. Pursuant to the letter agreement, Mr. Dick agreed to serve as a consultant to the Company until February 3, 2016, all of Mr. Dick’s unvested stock options were immediately forfeited, his RSUs continued to vest through the consulting period, and the Company agreed to continue paying health coverage for one year. The table below shows the total amounts paid or to be paid to Mr. Dick in connection his resignation.

                 
  Cash
Severance
Payment
 Acceleration
of Equity
Awards(1)
 Life/Health
Insurance
Benefits(2)
 Consulting
Payments(3)
 Total
Termination
Benefits
 
Timothy A. Dick $ $872,624 $19,589 $256,667 $1,148,880 

(1)Represents the intrinsic value as of December 31, 2015 of unvested RSUs based on the closing stock price of Akorn, Inc. common stock on February 4, 2016 or $25.41.
(2)The amount represents the cost to continue health coverage for one year following Mr. Dick’s resignation - $6,288 in 2015 and $13,202 in 2016.
(3)The Company paid Mr. Dick $160,417 for consulting services he provided in 2015, and an additional $96,250 for consulting services provided in 2016.

Director Compensation

Director compensation is set by the Compensation Committee in coordination with management and submitted to the Board for approval. Each year, the Compensation Committee works with its independent compensation consultant to review current director compensation using published survey data of companies of similar size based on revenue and market capitalization and in the pharmaceutical industry, as well as director compensation of companies in our self-selected peer group, in order to guide the Compensation Committee towards establishing director compensation that falls in an appropriate range. In 2015, based upon the recommendations of the compensation consultant, the Compensation Committee revised our director compensation program to better align the program with median peer group practices to compensate for additional time commitment and risk associated with participation on Board committees.

Annual Compensation Element Amount
Chair Member
Annual Cash Retainer $125,000  $75,000
Annual Equity Award Grant Value $230,000  $230,000
Audit Committee - Cash Compensation $25,000  $12,500
Compensation Committee - Cash Compensation $20,000  $10,000
Nominating and Governance Committee - Cash Compensation $15,000  $7,500
Special Litigation Committee - Cash Compensation $20,000  $12,500
Special Committee - Cash Compensation(1) $15,000  $7,500
Stock Ownership Guidelines 5x annual equity
and cash retainer
  5x annual equity
and cash retainer
(1)From time to time, the Board may create one or more special committees. Generally, a chair of a special committee is paid $15,000 and a member $7,500 for his or her services, however, the compensation paid may vary and is approved on a case-by-case basis by the Compensation Committee.

AKORN, INC. 2016 Special Meeting Proxy Statement35

All retainers are paid quarterly in arrears. Annual equity awards are generally made immediately following the annual meeting of shareholders. In addition to the above fees, we reimburse our directors for reasonable and necessary expenses they incur in performing their duties as directors.

Annual equity awards are typically made to our directors at the Board meeting held immediately after our annual meeting of shareholders. In 2014, the annual equity awarded to our directors was 100% in options, vesting one year from the date of grant and expiring five years from the date of grant if not exercised. Beginning in 2015, the Compensation Committee determined that the annual equity awarded to our directors would be awarded 50% in options and 50% in RSUs. However, due to the Company’s restatement process, the Company paid each director cash in lieu of their annual equity award for 2015.

In connection with her appointment to the Board on May 1, 2015, Ms. Rappuhn was granted the option to purchase 20,000 shares of our common stock at the market price in effect on the date of grant. The option vested 100% upon the anniversary of the date of grant and expires five years from grant date if not exercised.

In connection with their service as our directors, we have provided to each of our independent directors supplemental indemnity assurances with respect to any claims associated with their serving as one of our directors, as a director of any of our subsidiaries, as a fiduciary of any of our employee benefit plans and in other positions held at our request.

(GRAPHIC)Director Stock Ownership Guidelines

The Compensation Committee believes that it is in the best interests of the Company and its shareholders to align the financial interests of the Company’s directors with those of the shareholders. Accordingly, the Compensation Committee established the following stock ownership guidelines for directors. Each director is expected to acquire and retain shares of the Company’s common stock having a value equal to at least five times the total value of the director’s annual stock and cash retainer. Directors shall have three years from the date of election or appointment to attain such ownership levels. The Nominating and Governance Committee in its discretion may extend the period of time for attainment of such ownership levels in appropriate circumstances. In the event a director’s annual retainer increases, he or she will have one year from the date of the increase to acquire any additional shares needed to meet the guidelines.

As of May 20, 2016, Messrs. Kapoor, Abramowitz, Johnson, Meyer, Tambi and Weinstein had all met the minimum ownership guidelines. Ms. Graves has not yet achieved the required level, largely because the Company paid the equity portion of the directors’ 2015 retainer fee in cash rather than equity. Ms. Rappuhn has until April 20, 2018 (three years from the date of her appointment) to attain the required ownership level. The following table sets forth compensation paid to our directors for the year 2015:

2015 DIRECTOR COMPENSATION TABLE

Name Fees Earned or
Paid in Cash
($)(1)
BonusOption
Awards
($)(2)
Total
($)
Dr. John N. Kapoor (Chairman) $355,000  $ $ $355,000 
Kenneth S. Abramowitz  314,375      314,375 
Dr. Adrienne Graves  336,938      336,938 
Ronald M. Johnson  335,625      335,625 
Steven Meyer  336,250  100,000(3)    436,250 
Terry Allison Rappuhn  293,750  100,000(3)  362,994  756,744 
Brian Tambi  305,000      305,000 
Alan Weinstein  340,000      340,000 

(1)The amounts shown in this column represent the retainer fees earned by each for serving as a director, including any retainer fees for serving as a chair or committee member. The amounts shown in this column also include $230,000 paid in cash to each director in lieu of their 2015 annual equity award. The amounts shown for Ms. Rappuhn and Mr. Weinstein each include $7,500, and for Mr. Johnson $15,000, for their service on a special committee in 2015.
(2)This column represents the aggregate grant date fair value of stock options granted during the year. Ms. Rappuhn was awarded 20,000 options on May 1, 2015, in connection with her appointment to the Board. The options were granted pursuant to our 2014 Option Plan and vest one year from the grant date. The grant date fair values are be determined in accordance withASC 718using the Black Scholes-Merton valuation model, and the assumptions used would be the same as those reflected in Note 11 –“Stock Options, Employee Stock Purchase Plan and Restricted Stock”in our Form 10-K filed with the SEC on May 10, 2016.
(3)Mr. Meyer and Ms. Rappuhn were each awarded a discretionary bonus of $100,000 for leading the Audit Committee’s independent investigation related to the Company’s restatement.

AKORN, INC. 2016 Special Meeting Proxy Statement36

Compensation Committee Interlocks and Insider Participation

Dr. Adrienne Graves, Chair, Alan Weinstein and Ronald M. Johnson, who currently comprise the Compensation Committee, are each independent, non-employee directors of the Company. No executive officer (current or former) of the Company served as a director or member of (i) the compensation committee of another entity in which one of the executive officers of such entity served on our Compensation Committee, (ii) the board of directors of another entity in which one of the executive officers of such entity served on our Compensation Committee, (iii) the compensation committee of any other entity in which one of the executive officers of such entity served as a member of our Board, or (iv) were directly or indirectly the beneficiary of any related transaction required to be disclosed under the applicable regulations of the Exchange Act, during the year ended December 31, 2015.

Equity Compensation Plans

(GRAPHIC)Equity Compensation Plans

Options granted under the 2003 Plan have exercise prices equivalent to the market value of our common stock on the date of grant and expire five years from that date. Options granted to our Directors typically vest one year from the date of grant and expire five years from the date of grant. All options granted from May 4, 2012 through November 6, 2013 vest annually over a four-year period. All existing option and restricted stock awards as of November 6, 2013, the date of expiration of the 2003 Option Plan, remain intact through their various expiration dates, but no further awards can be granted pursuant to the 2003 Option Plan.

On May 2, 2014, the Company obtained shareholder approval of the 2014 Option Plan, which was adopted by the Board of Directors on December 30, 2013. Under this plan, which replaced the expired 2003 Option Plan, 7,500,000 shares of common stock may be issued pursuant to options and other stock-based awards. The 7,500,000 shares set aside for issuance under the 2014 Option Plan is inclusive of the 6,816,500 shares authorized but unissued from the terminated 2003 Option Plan. Options granted under the 2014 Option Plan have exercise prices equivalent to the market value of our common stock on the date of grant. They vest over four years and expire five or seven years from the date of grant. As of October 26, 2016, there were 2,911,046 shares remaining available for issuance under the 2014 Option Plan. See Proposal 2 in this Proxy Statement for the proposed amendment and restatement of the 2014 Option Plan that is being put forth to shareholders for approval at the 2016 Special Meeting.

Historically, the Company has had an employee stock purchase plan that has permitted eligible employees to acquire shares of our common stock through payroll deductions in whole percentages from 1% to 15% of eligible wages, at a 15% discount from the market price of our common stock, subject to an annual maximum purchase of $25,000 in market value of common stock. However, due to our restatement process, we were required to suspend purchases under and terminate our prior employee stock purchase plan. The Company has called the 2016 special meeting of shareholders to approve the 2016 ESPP. See Proposal 1.

Summary Table

The following table sets forth certain information as of December 31, 2015, with respect to compensation plans under which shares of Akorn common stock were issuable as of that date. We do not have any equity compensation plans that have not been approved by our shareholders.

Plan CategoryNumber of securities to
be issued upon exercise
of outstanding options,
warrants
and rights
Weighted-average
exercise price of
outstanding options,
warrants and rights
 Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
the first column)
Equity Compensation plans approved by security holders: 5,014,379(1) $21.49 4,066,317 
(1)This amount reflects 2,444,151 outstanding options and 252,764 unvested restricted stock unit awards under the 2003 Plan, and 2,317,464 options under the 2014 Option Plan.

AKORN, INC. 2016 Special Meeting Proxy Statement37

III.Security Ownership of Certain Beneficial Owners and Management

As of October 28, 2016, the following persons were directors, nominees, Named Executive Officers or others with beneficial ownership of 5% or more of our common stock. The information set forth below has been determined in accordance with Rule 13d-3 under the Exchange Act based upon information furnished to us or to the SEC by the persons listed. Unless otherwise noted, the address of each of the following persons is 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045.

Beneficial Ownership of Holders of 5% or more of our Common Stock, Directors, and Named Executive Officers:

Beneficial Owner Shares
Beneficially
Owned(1)
 Percent
of
Class
Holders of 5% or more of our common stock (excluding Directors and Named Executive Officers):    
BlackRock, Inc. 7,230,228(2) 5.8%
Directors:    
John N. Kapoor, Ph.D. 31,461,625(3) 25.1%
Kenneth S. Abramowitz 42,504(4) *
Adrienne L. Graves, Ph.D. 34,820(5) *
Ronald M. Johnson 144,085(6) *
Steven J. Meyer 113,376](7) *
Terry Allison Rappuhn 24,567(8) *
Brian Tambi 69,395(9) *
Alan Weinstein 93,877(10) *
Named Executive Officers:    
Raj Rai 2,242,285(11) 1.8%
Duane A. Portwood 75,000(12) *
Joseph Bonaccorsi 415,817(13) *
Bruce Kutinsky, Pharm. D. 305,423(14) *
Steven Lichter 50,000(15) *
Randall E. Pollard 15,000(16) *
Jonathon Kafer 31,250(17) *
Timothy A. Dick 350,556(18) *
Directors and Executive Officers as a group (16 persons) 35,469,580 28.3%
(*)indicates Beneficial Ownership of less than 1%.
(1)Includes all shares beneficially owned, whether directly and indirectly, individually or together with associates, jointly or as community property with a spouse, as well as any shares as to which beneficial ownership may be acquired within 60 days of October 28, 2016 by the vesting of RSUs or the exercise of options, warrants or other convertible securities. Unless otherwise specified in the footnotes that follow, the indicated person or entity has sole voting power and sole investment power with respect to the shares.
(2)The stock ownership of BlackRock, Inc. is as of December 31, 2015 as reflected in the Schedule 13G/A filed with the SEC on January 25, 2016. The address of BlackRock, Inc. is 40 East 52nd Street, New York, New York 10022.
(3)Beneficial ownership for Mr. Kapoor includes (i) 4,907,524 shares of common stock owned by the Kapoor Trust, of which Dr. Kapoor is the sole trustee and beneficiary, (ii) 501,896 shares of common stock owned directly by Dr. Kapoor, and (iii) 13,654 shares of common stock issuable upon exercise of options. The total also includes (a) 15,050,000 shares of common stock owned by Akorn Holdings, L.P., a Delaware limited partnership, of which Dr. Kapoor is the indirect managing general partner, (b) 2,970,644 shares of common stock owned EJ Financial / Akorn Management L.P., of which Dr. Kapoor is the indirect managing general partner, (c) 3,590,445 shares of common stock owned by EJ Funds LP., of which Dr. Kapoor is the indirect managing general partner, and (d) 4,427,462 shares of common stock held through several trusts, the trustee of which is employed by a company controlled by Dr. Kapoor and the beneficiaries of which include Dr. Kapoor’s children and various other family members, all of which shares in (a) – (d) Dr. Kapoor disclaims beneficial ownership of to the extent of his actual pecuniary interest therein. Dr. Kapoor holds sole voting and dispositive power over 31,457,558 beneficially-owned shares and holds shared voting and dispositive power over 31,457,558 beneficially owned shares. Beneficial ownership of Mr. Kapoor excludes (i) 8,701 shares of common stock issuable upon the exercise of stock options scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019 and (ii) 3,495 RSUs scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019.
(4)Beneficial ownership for Mr. Abramowitz includes 13,654 shares of common stock issuable upon exercise of options and excludes; (i) 8,701 shares of common stock issuable upon the exercise of stock options scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019 and (ii) 3,495 RSUs scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019.
(5)Beneficial ownership for Dr. Graves includes 33,654 shares of common stock issuable upon exercise of options and excludes; (i) 8,701 shares of common stock issuable upon the exercise of stock options scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019 and (ii) 3,495 RSUs scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019.

AKORN, INC. 2016 Special Meeting Proxy Statement38

(6)Beneficial ownership for Mr. Johnson includes 13,654 shares of common stock issuable upon exercise of options and excludes; (i) 8,701 shares of common stock issuable upon the exercise of stock options scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019 and (ii) 3,495 RSUs scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019.
(7)Beneficial ownership for Mr. Meyer includes 13,654 shares of common stock issuable upon exercise of options and excludes; (i) 8,701 shares of common stock issuable upon the exercise of stock options scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019 and (ii) 3,495 RSUs scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019.
(8)Beneficial ownership for Ms. Rappuhn includes 22,901 shares of common stock issuable upon exercise of options and excludes; (i) 8,701 shares of common stock issuable upon the exercise of stock options scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019 and (ii) 3,495 RSUs scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019.
(9)Beneficial ownership for Mr. Tambi includes 13,654 shares of common stock issuable upon exercise of options and excludes; (i) 8,701 shares of common stock issuable upon the exercise of stock options scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019, (ii) 3,495 RSUs scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019 and (iii) 4,016 RSUs scheduled to vest in two equal installments on September 5, 2017 and September 5, 2018.
(10)Beneficial ownership for Mr. Weinstein includes 13,654 shares of common stock issuable upon exercise of options and excludes; (i) 8,701 shares of common stock issuable upon the exercise of stock options scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019 and (ii) 3,495 RSUs scheduled to vest in three equal installments on July 1, 2017, July 1, 2018 and July 1, 2019.
(11)Beneficial ownership for Mr. Rai includes 2 million shares owned by the Rajat Rai 2016 GRAT. The total also includes 154,746 shares of common stock issuable upon the exercise of options and excludes; (i) 13,136 RSUs scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018, (ii) 49,296 RSUs scheduled to vest in two equal installments on September 5, 2017 and September 5, 2018, (iii) 27,119 RSUs scheduled to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020 (iv) 16,300 shares of common stock issuable upon the exercise of stock options scheduled to vest on May 3, 2017, (v) 105,844 shares of common stock issuable upon the exercise of stock options scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018, (vi) 191,387 shares of common stock issuable upon the exercise of stock options scheduled to vest in four equal installments on March 28, 2017, March 28, 2018, March 28, 2019 and March 28, 2020 and (vii) 191,830 shares of common stock issuable upon the exercise of stock options scheduled to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020.
(12)Beneficial ownership for Mr. Portwood excludes; (i) 225,000 shares of common stock issuable upon the exercise of stock options scheduled to vest in three equal installments on October 30, 2017, October 30, 2018 and October 30, 2019 and (ii) 75,000 shares of common stock issuable upon the exercise of stock options scheduled to vest in four equal installments on August 9, 2017, August 9, 2018, August 9, 2019 and August 9, 2020.
(13)Beneficial ownership for Mr. Bonaccorsi includes 30,241 shares of common stock issuable upon the exercise of options and excludes; (i) 2,626 RSUs scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018, (ii) 49,580 RSUs scheduled to vest in two equal installments on September 5, 2017 and September 5, 2018, (iii) 9,004 RSUs scheduled to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020, (iv) 3,025 shares of common stock issuable upon the exercise of stock options scheduled to vest on May 3, 2017, (v) 21,165 shares of common stock issuable upon the exercise of stock options scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018, (vi) 65,453 shares of common stock issuable upon the exercise of stock options scheduled to vest in four equal installments on March 28, 2017, March 28, 2018, March 28, 2019 and March 28, 2020 and (vii) 63,693 shares of common stock issuable upon the exercise of stock options scheduled to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020.
(14)Beneficial ownership for Dr. Kutinsky includes 145,886 shares of common stock issuable upon the exercise of stock options and excludes; (i) 3,721 RSUs scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018, (ii) 11,949 RSUs scheduled to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020, (iii) 5,300 shares of common stock issuable upon the exercise of stock options scheduled to vest on May 3, 2017, (iv) 29,984 shares of common stock issuable upon the exercise of stock options scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018, (v) 26,058 shares of common stock issuable upon the exercise of stock options scheduled to vest in four equal installments on March 28, 2017, March 28, 2018, March 28, 2019 and March 28, 2020 and (vi) 84,525 shares of common stock issuable upon the exercise of stock options scheduled to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020.
(15)Beneficial ownership for Mr. Lichter includes 50,000 shares of common stock issuable upon the exercise of stock options and excludes; (i) 2,542 RSUs scheduled to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020, (ii) 150,000 shares of common stock issuable upon the exercise of stock options schedule to vest in three equal installments on February 23, 2017, February 23, 2018 and February 23, 2019, (iii) 84,000 shares of common stock issuable upon the exercise of stock options schedule to vest in four equal installments on February 19, 2017, February 19, 2018, February 19, 2019 and February 19, 2020 and (iv) 17,984 shares of common stock issuable upon the exercise of stock options schedule to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020.
(16)Beneficial ownership for Mr. Pollard includes 15,000 shares of common stock issuable upon the exercise of stock options and excludes; (i) 3,496 RSUs scheduled to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020 (ii) 37,500 shares of common stock issuable upon the exercise of stock options schedule to vest in three equal installments on May 1, 2017, May 1, 2018 and May 1, 2019, (iii) 7,500 shares of common stock issuable upon the exercise of stock options scheduled to vest in three equal installments on October 30, 2017, October 30, 2018 and October 30, 2019, (iv) 40,000 shares of common stock issuable upon the exercise of stock options schedule to vest in four equal installments on February 19, 2017, February 19, 2018, February 19, 2019 and February 19, 2020 and (v) 24,728 shares of common stock issuable upon the exercise of stock options schedule to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020.
(17)Beneficial ownership for Mr. Kafer includes 31,250 shares of common stock issuable upon the exercise of stock options and excludes; (i) 2,542 RSUs scheduled to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020, (ii) 93,750 shares of common stock issuable upon the exercise of stock options schedule to vest in three equal installments on May 1, 2017, May 1, 2018 and May 1, 2019, (iii) 43,400 shares of common stock issuable upon the exercise of stock options schedule to vest in four equal installments on February 19, 2017, February 19, 2018, February 19, 2019 and February 19, 2020 and (iv) 17,984 shares of common stock issuable upon the exercise of stock options schedule to vest in four equal installments on July 1, 2017, July 1, 2018, July 1, 2019 and July 1, 2020.
(18)Beneficial ownership for Mr. Dick was last confirmed as of April 29, 2016 and included (i) 146,443 shares of common stock issuable upon the exercise of stock options and (ii) 45,789 RSUs.

AKORN, INC. 2016 Special Meeting Proxy Statement39

IV.Questions and Answers

(GRAPHIC)Why have I received these materials? What is included in the proxy materials?

This proxy statement was provided to you because our Board is soliciting your proxy to vote at the annuala special meeting of shareholders to be held on [JUNE 10, 2004]. YouDecember 16, 2016. The proxy materials for our 2016 special meeting of shareholders include the Notice of 2016 Special Meeting, this proxy statement, our Form 10-K filed for fiscal year 2015, and the proxy card or voting instruction form you received with the paper copy of this Proxy Statement.

(GRAPHIC)Who may attend the 2016 Special Meeting? Are there procedures for attending?

Only shareholders as of October 28, 2016 or their legal proxy holders may attend the 2016 special meeting. Due to space constraints and other security considerations, we will not be able to accommodate the guests of either shareholders or their legal proxy holders.

To be admitted to the 2016 special meeting, you must present valid proof of ownership of the Company’s common stock as of October 28, 2016 or a valid legal proxy. All attendees must also provide a form of government-issued photo identification. If you arrive at the 2016 special meeting without the required items, we will admit you only if we are cordially invitedable to verify that you are a shareholder of the Company as of October 28, 2016.

Shareholders of record may gain admittance to the 2016 special meeting by providing proof of ownership of the Company’s common stock as of October 28, 2016. If your shares are held in the name of a bank, broker, trustee or other nominee and you plan to attend the annual2016 special meeting, you will need to bring proof of ownership as of October 28, 2016, such as a recent bank or brokerage account statement, and are requestedif you wish to vote in person, you must obtain a legal proxy issued in your name from your broker or other nominee. If you are not a shareholder but attending as proxy for a shareholder, you may attend the 2016 special meeting by presenting a valid legal proxy. Shareholders may appoint only one proxy holder to attend on the proposals described in this proxy statement. Akorn intendstheir behalf.

If you are representing an entity that is a shareholder, you must provide evidence of your authority to mail this proxy statement and accompanying proxy card on or about [ ], 2004 to all shareholders entitled to voterepresent that entity at the annual2016 special meeting. WHO IS ENTITLED TO VOTE AT THE ANNUAL MEETING? Shareholders holding shares in a joint account will be admitted to the 2016 special meeting if they provide proof of joint ownership.

(GRAPHIC)Who is entitled to vote at the 2016 Special Meeting?

Shareholders of record as of the close of business on [ ], 2004October 28, 2016 will be entitled to vote at the annualspecial meeting. On [ ], 2004,October 28, 2016, there were (i) [19,987,137]125,240,731 shares of common stock outstanding and entitled to vote, and (ii) 257,172 shares of Series A 6.0% Participating Convertible Preferred Stock ("Preferred Stock") outstanding and entitled to vote. Shareholder of Record: Shares Registered in Your Name

If on [ ], 2004,October 28, 2016 you were a "record"“record” shareholder of common stock (that is, if you held common stock or Preferred Stock in your own name in Akorn'sthe stock records maintained by our transfer agent, Computershare Investor Services, LLC ("Computershare"))Computershare), you may vote in person at the annualspecial meeting or by proxy. Whether or not you intend to attend the annualspecial meeting, we encourage you to complete and sign the accompanyingvote now, online, by phone, or proxy card and mail it to Akorn to ensure that your vote is counted. Beneficial owner: Shares Registered in the Name of a Broker or Bank

If on [ ], 2004,October 28, 2016, you were the beneficial owner of shares of common stock held in "street name"“street name” (that is, a shareholder who held common stock through a broker or other nominee) then these materials are being forwarded to you by the broker or other nominee. You may direct your broker or other nominee how to vote your shares of common stock. However, you will have to obtain a proxy form from the institution that holds your shares and follow the voting instructions on the form. If you wish to attend the annualspecial meeting and vote in person, you may attend the meeting but may not do sobe able to vote in person unless you first obtain a legal proxy issued in your name from your broker or other nominee. WHAT AM I VOTING ON?

A list of shareholders entitled to vote at the meeting will be open to the examination of any shareholder, for any purpose germane to the meeting, on and during ordinary business hours for 10 days prior to the date of the meeting at our principal offices located at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045.

(GRAPHIC)What am I voting on?

There are fourtwo matters scheduled for a vote: - Election of six directors; -

·Approval of the Akorn, Inc. 2016 Employee Stock Purchase Plan.

·Approval of the amendment and restatement of the Akorn, Inc. 2014 Stock Option Plan.

AKORN, INC. 2016 Special Meeting Proxy Statement40

(GRAPHIC)How do I cast my vote?

You may vote “FOR” or “AGAINST” or “ABSTAIN” from voting to approve the Akorn, Inc. 2016 Employee Stock Purchase Plan.

You may vote “FOR” or “AGAINST” or “ABSTAIN” from voting to approve the amendment and restatement of the Akorn, Inc. 20032014 Stock Option Plan; - Approval of an amendment to the Akorn, Inc. Articles of Incorporation to increase the authorized shares of common stock from 40,000,000 to 150,000,000; and - Ratification of the selection by the Audit Committee of the Board of Directors of BDO Seidman LLP as independent auditors of Akorn for its fiscal year ending December 31, 2004. HOW DO I VOTE? You may either vote "FOR" all the nominees to the Board of Directors or you may abstain from voting for any nominee you specify. Form each of the other matters to be voted on, you may vote "FOR" or "AGAINST" or abstain from voting. Shareholder of Record: Shares Registered in Your Name Plan.

If you are a shareholder of record, you vote over the Internet at www.proxyvote.com or vote by telephone at 1 (800) 690-6903. You may also vote by proxy card, voter instruction form or in person at the annual meeting, or you may vote by proxy using the enclosed proxy card. meeting.

Whether or not you plan to attend the annual meeting, we urge you to vote by proxynow to ensure your vote is counted. You may still attend the annualspecial meeting and vote in person if you have already voted by proxy. - To vote in person, come to the annual meeting and we will give you a ballot when you arrive. - To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided.

If you return your signed proxy card to us before the annual meeting, we will votehold your shares as you direct. Beneficial Owner: Shares Registered in the Name of Broker or Bank If you are a beneficial owner of shares registered instreet name, the name of your broker, bank, or other agent, you should have received a proxy card and voting instructions with these proxy materials from that organization rather than from Akorn. In order to vote, complete and mail the proxy card received from your broker or bank to ensure that your vote is counted. Alternatively, you may vote by telephone or over the Internet as instructed by your broker, bank or bank.such other applicable agent. To vote in person at the annualspecial meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker, bank, or bankother agent included with these proxy materials, or contact your broker, bank, or banksuch other agent to request a proxy form. HOW MANY VOTES DO I HAVE?

Each share of common stock is entitled to one vote with respect to each matter to be voted on at the annualspecial meeting. Each share of Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which a share of Preferred Stock can be converted on the record date. On [ ], 2004 each share of Preferred Stock was convertible into [ ] shares of common stock, and, therefore, each share of Preferred Stock is entitled to [ ] votes with respect to each matter to be voted on at the annual meeting. WHAT CONSTITUTES A QUORUM FOR PURPOSES OF THE ANNUAL MEETING?

(GRAPHIC)What constitutes a quorum for purposes of the special meeting?

A quorum of shareholders is necessary to hold a valid meeting. The presence at the annualspecial meeting in person or by proxy of the holders of a majority of the voting power of all outstanding shares of common stock and Preferred Stock entitled to vote, or 62,620,366 votes, shall constitute a quorum for the transaction of business.business at the meeting. Proxies marked as abstaining (including proxies containing broker non-votes) on any matter to be acted upon by shareholders will be treated as present at the meeting for purposes of determining a quorum but will not be counted as votes cast on such matters. If there is no quorum, a majority of the votes present at the meeting may adjourn the meeting to another date. 2 HOW DOES THE BOARD RECOMMEND THAT I VOTE MY SHARES? Unless you give other instructions on your proxy card, the persons named as proxy on the proxy card will vote in accordance with the recommendations of the Board.

(GRAPHIC)How does the Board recommend that I vote my shares?

The Board'sBoard’s recommendation is set forth together with the description of each item in this proxy statement. In summary, the Board recommends a vote: - FOR the proposal to elect the nominated Directors set forth on page 4; - FOR the proposal to approve the amendment of Akorn's Articles of Incorporation to increase the authorized shares of common stock from 40,000,000 to 150,000,000, as set forth on page 6; - FOR the adoption of the Akorn, Inc. 2003 Stock Option Plan, as set forth on page 8; and - FOR the ratification of the selection by the Audit Committee of BDO Seidman, LLP as independent auditors of Akorn for its fiscal year ending December 31, 2004, as set forth on page 11.

·FOR the approval of the Akorn, Inc. 2016 Employee Stock Purchase Plan (Proposal 1).

·FOR the approval of the amendment and restatement of the Akorn, Inc. 2014 Stock Option Plan (Proposal 2).

With respect to any other matter that properly comes before the annualspecial meeting, the proxies will vote as recommended by the Board or, if no recommendation is given, in their own discretion. AtAs of the date of this proxy statement, went to press, the Board had no knowledge of any business other than that described herein that would be presented for consideration at the annual2016 special meeting. WHAT IF I RETURN A PROXY CARD BUT DO NOT MAKE SPECIFIC CHOICES?

(GRAPHIC)What if I return a proxy card but do not make specific choices?

If you are the shareholder of record and return a signed and dated proxy card without marking any voting selections, your shares will be voted "For"“FOR” the election of all six nominees for director, "For" the adoptionapproval of the Akorn, Inc. 20032016 Employee Stock Purchase Plan and “FOR” the approval of the amendment and restatement of the Akorn, Inc. 2014 Stock Option Plan, "For" the amendment to Akorn's Certificate of Incorporation to increase the number of authorized shares of common stock from 40,000,000 to 150,000,000 shares, and "For" the selection of BDO Seidman LLP as independent auditors of Akorn for its fiscal year ending December 31, 2004.Plan. If any other matter is properly presented at the annualspecial meeting, your proxy (one of the individuals(the individual named on your proxy card) will vote your shares using his or her best judgment. HOW MANY VOTES ARE NEEDED TO APPROVE EACH PROPOSAL?

If you hold your shares in street name, and do not provide your nominee instruction with respect to any voting selections, your shares cannot be voted by your nominee for the approval of the Akorn, Inc. 2016 Employee Stock Purchase Plan nor for the approval of the amendment and restatement of the Akorn, Inc. 2014 Stock Option Plan. In such case, your vote will be considered a “broker non-vote.”

AKORN, INC. 2016 Special Meeting Proxy Statement41

(GRAPHIC)How many votes are needed to approve the proposals?

Proposal 1. The electionapproval of directorsthe 2016 Akorn, Inc. Employee Stock Purchase Plan requires the affirmativea “FOR” vote offrom a pluralitymajority of the votes cast at the annual meeting by shares represented in person or by proxycast. Abstention and entitled to vote for the election of directors. A plurality means the highest number of "For" votes. Therefore, the six nominees receiving the most proper "For" votes will be elected. Brokerbroker non-votes will have no effect on the outcome. The amendment of our Articles of Incorporation to increase the authorized shares of common stock from 40,000,000 to 150,000,000 shares must receive a "For" vote from the majority of the outstanding shares either in person or by proxy. If you "Abstain" from voting shares, it will have the same effect as an "Against" vote. Broker non-votes will have the same effect as "Against" votes.

Proposal 2. The approval of the amendment and restatement of the Akorn, Inc. 20032014 Stock Option Plan requires a "For"“FOR” vote from a majority of the shares represented in person or by proxyvotes cast. Abstention and entitled to vote on the matter for approval. If you "Abstain" from voting shares, it will have the same effect as an "Against" vote. Brokerbroker non-votes will have no effect on the outcome. The ratification

(GRAPHIC)Can I revoke or change my vote after I return my proxy card?

Yes.For shareholders of the selection by the Audit Committee of the Board of Directors of BDO Seidman, LLP as independent auditors of Akorn for its fiscal year ending December 31, 2004, requires a "For" vote from a majority of the shares represented in person or by proxy and entitled to vote on the matter for approval. If you "Abstain" from voting shares, it will have the same effect as an "Against" vote. Broker non-votes will have no effect on the outcome. 3 CAN I CHANGE MY VOTE AFTER I RETURN MY PROXY CARD? Yes. Afterrecord, any time after you have submitted a proxy card you may change your vote at any timeand before the proxy card is exercised, you may revoke or change your vote in one of three ways: -

·You may submit a written notice of revocation to Akorn’s Corporate Secretary at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045.

·You may submit a proxy bearing a later date.

·You may attend the special meeting and vote in person. Attendance at the meeting will not, by itself, revoke a proxy.

If you hold your shares in street name, you will need to Akorn's Secretary at 2500 Millbrook Drive, Buffalo Grove, Illinois 60089. - You may submit arevoke or resubmit your proxy bearing a later date. - You maythrough your nominee and in accordance with its procedures. In order to attend the annualspecial meeting and vote in person. Attendance atperson, you will need to obtain a proxy from your nominee, the meeting will not, by itself, revoke a proxy. WHO WILL BEAR THE EXPENSE OF SOLICITING PROXIES IN CONNECTION WITH THIS PROXY STATEMENT? shareholder of record.

(GRAPHIC)Who will bear the expense of soliciting proxies in connection with this proxy statement?

Akorn will bear the cost of soliciting proxies in the form enclosed. In addition to the solicitation by mail, proxies may be solicited personally or by telephone, facsimile, online posting or electronic transmission by our employees. Our employees will not receive any additional compensation for participating in proxy solicitation. We may reimburse brokers holding common stock in their names or in the names of their nominees for their expenses in sending proxy materials to the beneficial owners of such common stock. IS THERE ANY INFORMATION THAT I SHOULD KNOW ABOUT FUTURE ANNUAL MEETINGS? Shareholder Proposals Any shareholder who intends to present a proposal at the 2005 annual meeting of shareholders (the "2005 Annual Meeting") must deliver the proposal to Akorn's Corporate Secretary at 2500 Millbrook Drive, Buffalo Grove, Illinois 60089 not later

(GRAPHIC)What does it mean if I receive more than one proxy?

If you receive more than December 27, 2004, if the proposal is to be submitted for inclusion in ourone proxy, materials for that meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended. If a shareholder proposal is received after March 12, 2005, we may vote in our discretion as to that proposal all of the shares for which we have received proxies for the 2005 Annual Meeting of Shareholders. WHAT DOES IT MEAN IF I RECEIVE MORE THAN ONE PROXY? Itit means you have multiple accounts with brokers and/or our transfer agent. Please vote all of these shares. We recommend that you contact your broker and/or our transfer agent to consolidate as many accounts as possible under the same name and address. Our transfer agent is Computershare – Essential Registry Team, located at 2 North La Salle350 Indiana Street, Chicago, Illinois 60602,Suite 750, Golden, Colorado 80401 and may be reached at 1-800-[ - ]. PROPOSAL 1. ELECTION OF DIRECTORS On November 6, 2003, our Board held a meeting at our principal office to discuss, among other items, the composition of the Board. At the meeting, the Board amended our Bylaws to increase the number of our directors from five to six. The Board has nominated six candidates for election at the annual meeting and recommends that shareholders vote FOR the election of all six nominees. Each of the nominees listed below is currently a director of Akorn. Messrs. Przybyl, Waney and Treppel were elected to the Board in November 2003. If elected at the annual meeting, each of these nominees would serve until the 2005 annual meeting and until his or her successor is elected and has qualified, or until the director's death, resignation or removal. We encourage our directors and nominees for directors to attend our annual meetings of shareholders. Directors are elected by a plurality of the votes properly cast in person or by proxy. The six nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the six nominees named below. In the unanticipated 4 event that one or more of such nominees is unavailable as a candidate for director, the persons named in the accompanying proxy will vote for another candidate nominated by the Board. Each person nominated for election has agreed to serve if elected. Akorn has no reason to believe that any nominee will be unable to serve. The following table and narrative description sets forth, as of March 30, 2004, the age, principal occupation and employment, position with us, directorships in other public corporations, and year first elected as one of our directors, of each individual nominated for election as director at the annual meeting. Unless otherwise indicated, each nominee has been engaged in the principal occupation or occupations described below for more than the past five years. (303) 262-0678.

Director Name Age Since Present Position with Akorn - ---- --- -------- --------------------------- John N. Kapoor, Ph.D...................... 59 1991 Chairman
(GRAPHIC)What is householding of the Board Arthur S. Przybyl......................... 47 2003 President, Chief Executive Officer, Director Jerry N. Ellis*#sec....................... 66 2001 Director Ronald M. Johnson*sec..................... 58 2003 Director Jerry I. Treppel*#sec..................... 49 2003 Director Arjun C. Waney#sec........................ 63 2003 Director proxy materials?
- ------------------------ * Member of the Audit Committee. Mr. Ellis is Chair of the committee. # Member of the Compensation Committee. Mr. Waney is Chair of the committee. sec. Member of the Nominating and Corporate Governance Committee. Mr. Treppel is Chair of the committee. John N. Kapoor, Ph.D. Dr. Kapoor has served as our Chairman of the Board since May 1995 and from December 1991 to January 1993. Dr. Kapoor served as our Chief Executive Officer from March 2001 to December 2002. Dr. Kapoor also served as our acting Chairman of the Board from April 1993 to May 1995 and as our Chief Executive Officer from May 1996 to November 1998. Dr. Kapoor serves as Chairman of the Board of Option Care, Inc. (an infusion services and supplies company) and was Chief Executive Officer of Option Care, Inc. from August 1993 to April 1996. Dr. Kapoor is the president of E.J. Financial Enterprises, Inc. (a health care consulting and investment company) and has served as Chairman of the Board of NeoPharm, Inc. (a biopharmaceutical company) since July 1990. Dr. Kapoor is the Chairman of the board of First Horizon Pharmaceutical Corporation (a distributor of pharmaceuticals) and of Introgen Therapeutics, Inc. (a gene therapy company). Arthur S. Przybyl. Mr. Przybyl has served as our President and Chief Executive Officer since February 2003 and as one of our directors since his appointment by the Board in November of 2003. Previously, Mr. Przybyl served as President and Chief Operating Officer beginning September 2002. Mr. Przybyl joined Akorn in August 2002 as senior vice president of sales and marketing and served as interim Chief Executive Officer from January to February of 2003. Prior to joining Akorn, Mr. Przybyl served as president and chief executive officer for Hearing Innovations Inc., an innovative, start-up developer of medical devices for the profoundly deaf and tinnitus markets. Before that, he served as president and chief operating officer for Bioject, Inc., a NASDAQ company specializing in needle-free technology. Mr. Przybyl is also a director of Novadaq Technologies, Inc., a privately held research company. Jerry N. Ellis. Mr. Ellis has served as a Director of Akorn since 2001. Mr. Ellis is an Adjunct Professor in the Department of Accounting at The University of Iowa. Mr. Ellis was a consultant to Arthur Andersen, LLP ("Arthur Andersen") from 1994 to 2000 and a Partner at Arthur Andersen in the Dallas, Madrid and Chicago offices from 1973 to 1994. Mr. Ellis is a director of First Horizon Pharmaceutical Corporation (a distributor of pharmaceuticals). Mr. Ellis holds a BA in Economics and an MBA from the University of Iowa. Mr. Ellis is a Certified Public Accountant. 5 Ronald M. Johnson. Mr. Johnson was appointed as one of our directors by the Board on March 22, 2003. Mr. Johnson is currently Executive Vice President of Quintiles Consulting, a company which provides consulting services to pharmaceutical, medical device, biologic and biotechnology industries in their efforts to meet the regulatory requirements of the FDA. Prior to joining Quintiles in 1997, Mr. Johnson spent thirty years with the FDA holding various senior level positions primarily in the compliance and enforcement areas. Jerry I. Treppel. Mr. Treppel was appointed by the Board as a director on November 6, 2003. Mr. Treppel is the Managing Member of Wheaten Capital Management LLC, a capital management company focusing on investment in the health care sector. Over the past 15 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder, Peabody & Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. He also held administrative positions in the healthcare services industry early in his career. Mr. Treppel is a current member of the Board of Able Laboratories Inc., a generic drug company, and of Cangene, a Canadian biotechnology company. Mr. Treppel holds a BA in Biology from Rutgers College in New Brunswick, N.J., an MHA in Health Administration from Washington University in St. Louis, Mo., and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst (CFA) since 1988. Arjun C. Waney. Mr. Waney was appointed as one of our directors by the Board on November 6, 2003. Mr. Waney is Managing Director and the principal shareholder of Argent Fund Management Ltd., a UK-based fund management firm that manages First Winchester Investments Ltd., an offshore fund specializing in U.S. equities. Mr. Waney has over thirty years experience in the U.S. capital markets in connection with various investment funds. In 1965, he founded Import Cargo Inc. and Cost Less Imports Inc., multi-store retail operations in the U.S. and Europe, respectively, that were sold in succession to Pier 1 Imports Inc. In 1973, Mr. Waney founded Beeba's Creations Inc., now known as Nitches Inc., a U.S. apparel importer and wholesaler that went public in 1982. Mr. Waney is a significant shareholder of Akorn, and may be deemed to beneficially own more than 10% of the outstanding shares of Akorn's common stock. Under agreements between us and the John N. Kapoor Trust dated 9/20/89, an entity controlled by Dr. John N. Kapoor, our Chairman of the Board (the "Kapoor Trust"), the Kapoor Trust is entitled to designate two individuals to be nominated and recommended by our Board for election as a director. As of the date of this Proxy Statement, the Kapoor Trust has designated only Dr. Kapoor for this purpose, and is not expected to designate a second individual for nomination as a director prior to the annual meeting. THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" EACH OF THE NAMED NOMINEES IN PROPOSAL 1. PROPOSAL 2. APPROVAL OF AN AMENDMENT TO THE ARTICLES OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 40,000,000 TO 150,000,000. At the annual meeting, you will be asked to approve an amendment to the Articles of Incorporation to increase the number of authorized shares of common stock from 40,000,000 to 150,000,000. A copy of the proposed Articles of Amendment to the Articles of Incorporation is attached hereto as Appendix "A." The Board believes the authorization of the additional capital stock is beneficial for various reasons described below. As of [ ], 2004, [19,987,137] shares of common stock were issued and outstanding. Of the remaining [20,012,863] shares of common stock that are presently authorized but unissued, approximately [ ] shares are reserved, or are to be reserved, for issuance as follows: (i) [ ] shares for issuance under our stock option plans and (ii) [ ] shares for issuance under our employee stock purchase plan. As of [ ], 2004, we have granted options for [ ] shares of stock, and anticipate we will, from time to 6 time, grant additional options for the remaining balance of the shares of common stock reserved for issuance under our stock option plans. Additionally, under the Exchange Transaction described in "CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS" on page [ ], we have agreed to issue up to an aggregate of approximately [ ] shares, of which up to approximately [ ] are to be issued upon conversion of the Preferred Stock and up to approximately 9,809,000 are to be issued upon exercise of the Warrants, subject to anti-dilution adjustments. "Preferred Stock" and "Warrants" shall have the meaning set forth in "CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS". The Preferred Stock is convertible at any time into a number of shares of common stock equal to the quotient obtained by dividing (x) an amount equal to $100 per share, as may be adjusted from time to time as set forth in our Articles of Amendment to the Articles of Incorporation (the "Articles of Amendment"), plus any accrued but unpaid dividends by (y) $0.75, as such numbers may be adjusted from time to time pursuant to the terms of the Articles of Amendment. As of [ ], 2004, the Preferred Stock is convertible into approximately [ ] shares of common stock, or more if the conversion price is adjusted pursuant to anti-dilution provisions. In the event all of the Preferred Stock were converted into the maximum number of shares of common stock possible, and all of the Warrants we granted that are outstanding currently are exercised, a total of approximately [ ] shares of common stock will be issued in connection with the Exchange Transaction. CONSEQUENCES OF FAILURE TO RECEIVE SHAREHOLDER APPROVAL As noted above, we currently do not have sufficient shares of common stock authorized for the conversion of the Preferred Stock and the Warrants. If Shareholder Approval has not been received by October 7, 2004, the rate at which the Preferred Stock accrues dividends will increase from 6.0% to 10.0% per annum until Shareholder Approval has been received and sufficient shares of common stock are authorized and reserved. Further, if Shareholder Approval has not been received and sufficient shares of common stock reserved by October 31, 2011, we are required to redeem the Preferred Stock for an amount equal to $100 per share, as may be adjusted from time to time as set forth in the Articles of Amendment, plus all accrued but unpaid dividends on such shares. ADDITIONAL SHARES OF CAPITAL STOCK FOR FUTURE ISSUANCE Our Articles of Incorporation, presently authorize 45,000,000 shares of capital stock of which 40,000,000 shares consist of common stock and 5,000,000 shares consist of preferred stock. If the proposed amendment is approved, the additional authorized shares of common stock will be identical in all respects to the presently authorized shares of common stock. Adoption of the proposed amendment and issuance of the common stock would not affect the rights of the holders of our currently outstanding common stock, except for effects incidental to increasing the number of shares of our common stock outstanding, such as dilution of the earnings per share and voting rights of current holders of common stock. The Board believes that an increase in the number of authorized shares of common stock is desirable in order to provide us with shares which will be available for issuance from time to time, without further action or authorization by the shareholders, as needed for such proper corporate purposes as may be determined by the Board of Directors. Such corporate purposes might include, among other things, our ability to fulfill our current obligations under the Preferred Stock and Warrants presently outstanding and stock option plans presently outstanding and proposed in this Proxy Statement, the raising of capital funds through private or public offerings, the acquisition by 7 Akorn of other companies, declaration of stock splits or stock dividends, the issuance of stock under options granted or to be granted under various stock incentive plans or other benefit plans for our employees and non-employee directors and the issuance of stock under warrants granted or to be granted in the future. The additional shares of common stock that would become available for issuance if this proposal is adopted could also be used by us to oppose a hostile takeover attempt or to delay or prevent changes in control or management of Akorn. For example, without further shareholder approval, the Board could strategically sell shares of common stock in a private transaction to purchasers who would oppose a takeover or favor the current Board. Although this proposal to increase the authorized common stock has been prompted by business and financial considerations and not by the threat of any hostile takeover attempt (nor is the Board currently aware of any such attempts directed at Akorn), nevertheless, shareholders should be aware that approval of this proposal could facilitate future efforts by Akorn to deter or prevent changes in control of Akorn, including transactions in which the shareholders might otherwise receive a premium for their shares over then current market prices. If the amendment is adopted, it will become effective upon filing of an Articles of Amendment to the Articles of Incorporation of Akorn with the Secretary of State of the State of Louisiana. The affirmative vote of the holders of a majority of the outstanding shares of our common stock will be required to approve this amendment to Akorn's Amended and Restated Certificate of Incorporation. As a result, abstentions and broker non-votes will have the same effect as negative votes. AVAILABLE INFORMATION Copies of the documents executed in connection with the Exchange Transaction were filed as exhibits to our report on Form 8-K filed with the Securities and Exchange Commission on October 24, 2003. Copies of each of the foregoing documents may also be obtained, without charge, from the Office of our Secretary at 2500 Millbrook Drive, Buffalo Grove, Illinois 60089. OUR BOARD RECOMMENDS A VOTE "FOR" PROPOSAL NUMBER 2 TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK. PROPOSAL 3. ADOPTION OF AKORN, INC. 2003 STOCK OPTION PLAN PURPOSE OF PROPOSAL The Amended and Restated Akorn, Inc. 1988 Incentive Compensation Program ("1988 Plan") under which any of our officers or key employees were eligible to receive stock options as designated by our Board, and the Akorn, Inc. 1991 Stock Option (the "1991 Directors' Plan") under which options were issuable to our directors, expired on November 2, 2003, and December 7, 2001, respectively. On November 6, 2003, the Board adopted the Akorn, Inc. 2003 Stock Option Plan (the "2003 Stock Option Plan"). The Board believes that the 2003 Stock Option Plan will help us continue to attract and retain quality employees, officers, directors and consultants. Under the 2003 Stock Option Plan we may issue up to an aggregate total of 5,000,000 incentive or non-qualified options to purchase Akorn common stock. As of March 31, 2004, we have issued options under the 2003 Stock Option Plan to purchase a total of 1,224,500 shares of common stock. These options have been granted subject to the approval of the 2003 Stock Option Plan by our shareholders. A copy of the 2003 Stock Option Plan is attached hereto as Appendix B. ELIGIBLE PARTICIPANTS All of our directors, officers and employees, all of the directors, officers and employees of any parent or subsidiary that we may have, and certain of our or any such parent's or subsidiary's consultants shall be eligible to receive options under the Plan. We do not currently have any parent organization. We have one wholly owned subsidiary named Akorn (New Jersey), Inc. The selection of recipients of options shall be within the sole and 8 absolute discretion of the Board, or a committee of two or more members appointed by the Board (the "Committee") who are independent directors under Nasdaq Marketplace Rules and an outside director as defined in Treasury Regulation Section 1.162-27(e)(3). The Board or the Committee, as appropriate, shall have full authority and discretion to determine, and shall specify, whether the eligible individual will be granted options intended to qualify as incentive options ("Incentive Options") under Section 422 of the Internal Revenue Code of 1986, as amended (the "Code") or options which are not intended to qualify under Section 422 of the Code ("Non-Qualified Options"). Incentive Options shall only be granted to our employees, or the employees of our parent or subsidiary, and shall be subject to the special limitations set forth in the 2003 Stock Option Plan attributable to Incentive Options. No person shall be granted more than 500,000 options in any one-year period. For purposes of this Proposal 3, all further references to "Committee" shall indicate both the Board and Committee, whichever has been designated to govern the 2003 Stock Option Plan. SHARES AVAILABLE An aggregate of 5,000,000 shares of common stock are authorized for issuance under the 2003 Stock Option Plan. As of March 31, 2004, options to purchase a total of 1,224,500 shares of common stock have been issued under the 2003 Stock Option Plan of which none have been exercised. STOCK OPTIONS Stock options are granted pursuant to stock option agreements, the terms of which are set by the Committee. The exercise price of options shall be determined by the Committee, subject to the following rules: (i) the exercise price of any Incentive Option shall not be less than the fair market value of our common stock, as determined by the Committee, on the date of grant of such option, (ii) the exercise price of any option granted to any person who owns more than 10% of the total combined voting power of all classes of our stock, as determined for purposes of Section 422 of the Code, shall not be less than 110% of the fair market value of our common stock, as determined by the Committee, on the date of grant of such option, and (iii) the exercise price of any Non-Qualified Option shall not be less than 85% of the fair market value of our common stock, as determined by the Committee, on the date of grant of such option. In the event that the fair market value of the price of our common stock declines below the price at which the option is granted, the Committee shall have the discretion and authority to cancel, reduce, or otherwise modify the price of any unexercised option, including, but not limited to, a regrant of the option at a new price more commensurate with the fair market value of the stock. The Committee must receive the approval of the Board before any such action is taken. The closing price of our common stock on March 15, 2004 was $3.35 per share as quoted on the "Pink Sheets." ADJUSTMENTS UPON CHANGES IN CAPITALIZATION The number of shares of common stock covered by each outstanding option, and the exercise price thereof, shall be proportionately adjusted for any increase or decrease in the number of issued shares of our common stock resulting from a subdivision or consolidation of shares, including, but not limited to, a stock split, reverse stock split, recapitalization, continuation or reclassification, or the payment of a stock dividend (but only on the common stock) or any other increase or decrease in the number of such shares effected without receipt of consideration by us. Upon a sale or exchange of all or substantially all of our assets, a merger or consolidation in which we are not the surviving corporation, a merger, reorganization or consolidation in which we are the surviving corporation and our shareholders exchange their stock for securities or property, a liquidation of Akorn, or similar transaction as determined by the Committee (a "Capital Transaction"), the 2003 Stock Option Plan and each option issued under the 2003 Stock Option Plan, whether vested or unvested, shall terminate, unless such options are assumed by a successor corporation in a merger or consolidation, immediately prior to such Capital Transaction. If the outstanding options are not assumed by a successor corporation in a merger or consolidation, subject to terms 9 approved by the Committee, all optionees will have the right, during the 15 days prior to such Capital Transaction, to exercise all vested options. We shall, subject to any nondisclosure provisions, attempt to provide optionees at least 15 days notice of such option termination date. The Committee may (but shall not be obligated to) (i) accelerate the vesting of any option or (ii) apply the foregoing provisions, including but not limited to termination of the 2003 Stock Option Plan and options granted pursuant to the 2003 Stock Option Plan, in the event there is a sale of 51% or more of our stock in any two year period or a transaction similar to a Capital Transaction. PLAN ADMINISTRATION The Committee administers the 2003 Stock Option Plan. Subject to the terms of the 2003 Stock Option Plan, the Committee determines recipients, the numbers and types of stock awards to be granted, and the terms and conditions of the stock awards including the period of their exercisability and vesting. FEDERAL INCOME TAX CONSEQUENCES TO THE OPTIONEES. Non-Qualified Options. An optionee will not recognize any income for federal income tax purposes on the grant of a Non-Qualified Option. Upon the exercise of a Non-Qualified Option, an optionee generally will recognize compensation taxable as ordinary income, equal to the difference between the fair market value of our common stock on the date of exercise and the exercise price. This compensation is subject to withholding taxes. An optionee will recognize capital gain or loss on the sale or exchange of stock acquired pursuant to an exercise of a non-qualified stock option. Such gain or loss will be equal to the difference between the optionee's adjusted basis in the stock, which will include the exercise price and any ordinary income recognized on exercise of the option, and the fair market value of the stock on the date of sale or exchange. The gain may be subject to preferential tax treatment if the stock has been held for more than one year. Incentive Options. An optionee will not recognize any income for federal income tax purposes on the grant of a Incentive Option. Upon the exercise of an Incentive Option, tax is deferred until the underlying stock is sold. There is require tax withholding in connection with the exercise of an Incentive Option. When sold, the Incentive Option is taxed at the capital gains rate on the full amount of appreciation for the sales proceeds over the option cost, providing the employee has satisfied the holding period prescribed for Incentive Options -- the longer of two (2) years from the date of grant or one (1) year from the date of exercise. If the Incentive Option stock is sold within the holding period, non-qualified tax treatment is applied. Incentive Option exercises may also be subject to Alternative Minimum Taxes ("AMT") since the "spread" at exercise is considered a tax preference for AMT purposes. TO AKORN. We generally will be entitled to a business expense deduction at the time and in the amount that the optionee recognizes ordinary income in connection with the exercise of an option. 10 CURRENT STOCK OPTION GRANTS UNDER 2003 STOCK OPTION PLAN NEW PLAN BENEFITS Akorn, Inc. 2003 Stock Option Plan
Name and Position Dollar Value($) Number of Units - ----------------- --------------- --------------- Arthur S. Przybyl, President and CEO................. 1,500,000 750,000 Total: Executive Group............................... 1,500,000 750,000 Non-Executive, Director Group........................ 141,200 85,000 Non-Executive, Officer, Employee Group............... 750,465 389,500
EMPLOYEE STOCK PURCHASE PLAN The Akorn, Inc. Employee Stock Purchase Plan ("Employee Stock Purchase Plan") permits eligible employees to acquire shares of our common stock through payroll deductions not exceeding 15% of base wages, at a 15% discount from market price. A maximum of 1,000,000 shares of our common stock may be acquired under the terms of the Employee Stock Purchase Plan. New shares issued under the Employee Stock Purchase Plan approximated 127,000 in 2003, 99,000 in 2002, and 44,000 in 2001. Shares issued under the Employee Stock Purchase Plan cannot be sold until one year after the purchase date. THE BOARD BELIEVES THAT THE ADOPTION OF THE AKORN, INC. 2003 STOCK OPTION PLAN IS IN THE BEST INTEREST OF AKORN AND ITS SHAREHOLDERS AND RECOMMENDS THAT THE SHAREHOLDERS VOTE "FOR" APPROVAL OF THE PROPOSAL 3. PROPOSAL 4. RATIFICATION OF SELECTION OF AUDITORS The Board is seeking shareholder ratification of its selection of BDO Seidman, LLP ("BDO") to serve as our independent auditors for the fiscal year ending December 31, 2004. On April 24, 2003, our previous independent accountant, Deloitte & Touche LLP ("Deloitte") notified us that it would decline to stand for re-election as our independent accountant after completion of its audit of our consolidated financial statements as of and for the year ended December 31, 2002. Deloitte completed its audit and delivered its auditors' report, dated May 9, 2003, on May 20, 2003. Deloitte then advised us that the client-auditor relationship between Deloitte and us had ceased. Deloitte's reports on our consolidated financial statements for the years ended December 31, 2002 and 2001 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that Deloitte's report on our 2001 financial statements included an explanatory paragraph relating to the restatement of such financial statements discussed in Note S thereto, and its reports on our 2001 and 2002 consolidated financial statements included an explanatory paragraph relating to the uncertainty with respect to our ability to continue as a going concern. During the two fiscal years ended December 31, 2002 and 2001, and the subsequent interim period through the date of this report, there were no disagreements between us and Deloitte on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to Deloitte's satisfaction, would have caused Deloitte to make reference to the subject matter of the disagreement in connection with its reports on our financial statements. Except as set forth in the next paragraph, during the two most recent fiscal years and the subsequent interim period through the date of this report, there have been no reportable events as that term is defined in Item 304(a)(1)(v) of Regulation S-K. 11 Deloitte informed us that, in connection with its audit of our consolidated financial statements for the year ended December 31, 2002, it noted certain matters involving our internal control that Deloitte considers to be material weaknesses. A material weakness is a condition in which the design or operation of one or more of the internal control components does not reduce to a relatively low level the risk that misstatements caused by error or fraud in amounts that would be material in relation to the financial statements being audited may occur and not be detected within a timely period by employees in the normal course of performing their assigned functions. Deloitte concluded that the following matters constitute material weaknesses: (i) failure to analyze accounts receivable in a sufficient level of customer detail to enable management to adequately calculate an allowance for doubtful accounts; (ii) misstatements in fixed assets, including unrecorded disposals, balances for abandoned construction projects that had not been written off, the use of incorrect useful lives, failure to prepare and review fixed asset roll forward schedules and reconciliations on a timely basis and failure to take a physical inventory of fixed assets in several years; and (iii) when taken together, incomplete internal control documentation, inadequate communication of transactions and contract terms affecting financial results, untimely preparation and inadequate management review of analyses, inadequate documentation and analysis to support the assumptions used to calculate various account balances, and inadequate controls over manual journal entries. Deloitte further advised us that it believes that these material weaknesses constitute a reportable event as that term is defined in Item 304(a)(1)(v) of Regulation S-K. Our Audit Committee discussed these matters with Deloitte. We have reviewed the matters identified by Deloitte and have concluded that the misstatements identified by Deloitte are the result of errors and not fraud. Although we do not necessarily agree with Deloitte's judgment that there are material weaknesses in our internal controls, we decided to promptly conduct a full review of our internal controls and put in place procedures designed to address all relevant internal control issues, including those identified by Deloitte. We also began the process of selecting a new independent accountant. On October 22, 2003, upon recommendation of the Audit Committee and approval by our Board, we engaged BDO as our principal accountants to audit our financial statements for our fiscal year ended December 31, 2003, and to review our financial statements for the fiscal quarters ended March 31, June 30 and September 30, 2003. During the fiscal years ended December 31, 2002 and 2001 and any subsequent interim period preceding the engagement of BDO, neither us nor anyone on our behalf had consulted BDO regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial statements or (ii) any matter that was the subject of a disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K, or a reportable event, as described in Item 304(a)(1)(v) of Regulation S-K. We expect representatives of BDO to attend the annual meeting and will be available to respond to appropriate questions from shareholders regarding our audit for the year ended December 31, 2003. We do not expect representatives of Deloitte to attend the annual meeting. AUDIT FEES Aggregate fees, including out-of-pocket expenses, for professional services rendered by BDO in connection with (i) the audit of our consolidated financial statements as of and for the year ended December 31, 2003 and (ii) the reviews of the our unaudited condensed consolidated interim financial statements as of September 30, 2003, June 30, 2003, and March 31, 2003 were $233,500. Aggregate fees for these services as provided by Deloitte for the year ended December 31, 2002 were $326,000. 12 AUDIT-RELATED FEES Aggregate fees, including out-of-pocket expenses, for professional services rendered by BDO for audit-related services for the year ended December 31, 2003 were $10,200. Audit-related services included an audit of our employee benefit plan. Aggregate fees for these services as provided by Deloitte for the year ended December 31, 2002 were $75,000. TAX FEES Aggregate fees, including out-of-pocket expenses, for professional services rendered by Deloitte in connection with tax compliance and advice and preparation of employee expatriate tax returns for the year ended December 31, 2003 were $32,200. Aggregate fees for these services as provided by Deloitte for the year ended December 31, 2002 were $82,000. ALL OTHER FEES There were no additional fees to those described above during the years ended December 31, 2003. In December 31, 2002, fees for miscellaneous professional services as provided by Deloitte amounted to $50,000. These services included (i) review of our accounting software for potential validation issues, (ii) identification of application security requirements and (iii) consultation on implementation of sales and use software. AUDIT COMMITTEE PRE-APPROVAL POLICIES AND PROCEDURES The Audit Committee has considered whether the provision of services covered in the preceding paragraphs is compatible with maintaining BDO's independence. At their regularly scheduled and special meetings the Audit Committee of the Board considers and pre-approves any audit and non-audit services to be performed for us by our independent accountants. For 2003, those pre-approved audit, audit-related, tax and all other services represented 72%, 3%, 25% and 0% respectively of all services that year. THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" THE RATIFICATION OF BDO SEIDMAN, LLP AS AUDITORS OF AKORN FOR FISCAL YEAR 2004. II. CORPORATE GOVERNANCE AND RELATED MATTERS INDEPENDENCE OF THE BOARD OF DIRECTORS Although Akorn's common stock is traded on the Pink Sheets, Akorn attempts to comply with the listing standards of The NASDAQ Stock Market ("NASDAQ") where feasible. Akorn's Board has determined that a majority of the members of Akorn's Board qualify as "independent," as affirmatively determined by the Board using the NASDAQ listing standards. Consistent with these considerations, after review of all relevant transactions or relationships between each director, or any of his or her family members, and Akorn, its senior management and its independent auditors, the Board affirmatively has determined further that all of Akorn's directors are independent directors within the meaning of Marketplace Rule 4200 listing standards, except for Mr. Przybyl, our President and Chief Executive Officer and Dr. Kapoor, our former Chief Executive Officer. EXECUTIVE SESSIONS OF INDEPENDENT DIRECTORS Akorn's independent directors will meet regularly in executive sessions where only independent directors are present. Persons interested in communicating with the independent directors may address correspondence to a 13 particular director, or to the independent directors generally, in care of Corporate Secretary, Akorn, Inc. 2500 Millbrook Drive, Buffalo Grove, Illinois 60089. COMMITTEES OF THE BOARD The Board has three committees: an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee, with the members of each committee indicated below. - The Audit Committee is comprised of Mr. Ellis (Chairman), Mr. Johnson and Mr. Treppel. - The Compensation Committee, is comprised of Mr. Waney (Chairman), Mr. Ellis, and Mr. Treppel. - The Nominating and Corporate Governance Committee is comprised of Mr. Treppel (Chairman), Mr. Ellis, Mr. Johnson and Mr. Waney. The composition of Board committees is reviewed and determined each year at the initial meeting of the Board after the annual meeting of shareholders. During the year ended December 31, 2003, our Board held thirty-one (31) meetings. All of the directors attended at least 75% of the aggregate number of meetings of the Board and of the Board committees on which they serve. AUDIT COMMITTEE The Audit Committee of the Board of Directors oversees Akorn's corporate accounting and financial reporting process. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent auditors; determines and approves the engagement of the independent auditors; determines whether to retain or terminate the existing independent auditors or to appoint and engage new independent auditors; reviews and approves the retention of the independent auditors to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent auditors on Akorn's audit engagement team as required by law; confers with management and the independent auditors regarding the effectiveness of internal controls over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by Akorn regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; reviews the financial statements to be included in Akorn's Annual Report on Form 10-K and quarterly reports on Form 10-Q; and discusses with management and the independent auditors the results of the annual audit and the results of the reviews of Akorn's quarterly financial statements. The Audit Committee met ten (10) times during the 2003 fiscal year. The Audit Committee has adopted a written Audit Committee Charter that is attached as Appendix C to these proxy materials. As noted, although Akorn's common stock is not listed on the NASDAQ, it attempts to comply with the listing standards of NASDAQ where feasible. The Board has reviewed the NASDAQ listing standards definition of independence for Audit Committee members and has determined that all members of Akorn's Audit Committee are independent under Marketplace Rule 4200. The Board has determined that Mr. Ellis qualifies as an "audit committee financial expert," as defined in applicable SEC rules. The Board made a qualitative assessment of Mr. Ellis' level of knowledge and experience based on a number of factors, including his formal education, his experience as a Partner with Arthur Andersen LLP, and his experience as a director of First Horizon Pharmaceutical Corporation (a distributor of pharmaceuticals). The Board of Directors has determined that such simultaneous service does not impair Mr. Ellis' ability to effectively serve on Akorn's Audit Committee. COMPENSATION COMMITTEE The Compensation Committee, which met one (1) time during 2003, reviews and approves the overall compensation strategy and policies for Akorn. The Compensation Committee reviews and approves corporate 14 performance goals and objectives relevant to the compensation of Akorn's executive officers and other senior management; reviews and approves the compensation and other terms of employment of Akorn's Chief Executive Officer; reviews and approves the compensation and other terms of employment of the other executive officers; and administers Akorn's stock option and stock purchase plans. Each member of the Compensation Committee has been determined by the Board to be an independent member under Nasdaq Marketplace Rule 4200. NOMINATING AND CORPORATE GOVERNANCE COMMITTEE In November 2002, we established a special committee of the Board (the "Corporate Governance Committee") consisting of Mr. Ellis, as Chairman, and then Director Dan Bruhl. The Corporate Governance Committee was established to oversee our restructuring actions, including but not limited to our recapitalization. The Corporate Governance Committee met 43 times in 2003. As a result of the recapitalization resulting from the closing of the Exchange Transaction (see "CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS" below.), it was determined that it was no longer necessary for the Board to have a committee devoted to overseeing our restructuring. In November 2003, the Nominating and Corporate Governance Committee was established in place of the Corporate Governance Committee. The Nominating and Corporate Governance Committee is responsible for developing and implementing policies and processes regarding corporate governance matters, assessing Board membership needs and making recommendations regarding potential director candidates to the Board. A current copy of the Nominating and Corporate Governance Committee Charter, which has been adopted and approved by the Board, is available on our website at http://www.akorn.com. Each member of the Nominating and Corporate Governance Committee has been determined by the Board to be an independent member under Nasdaq Marketplace Rule 4200. The Nominating and Corporate Governance Committee did not meet during 2003. The Board believes that candidates for director should have certain minimum qualifications, including being able to read and understand basic financial statements, being over 21 years of age and having the highest personal integrity and ethics. The Board also considers such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of Akorn, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of Akorn's shareholders. However, the Board retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, the operating requirements of Akorn and the long-term interests of shareholders. In conducting this assessment, the Board considers skills, diversity, age, and such other factors as it deems appropriate given the current needs of the Board and Akorn, to maintain a balance of knowledge, experience and capability. In the case of incumbent directors whose terms of office are set to expire, the Board and the Nominating and Corporate Governance Committee review such directors' overall service to Akorn during their term, including the number of meetings attended, level of participation, quality of performance, and any other relationships and transactions that might impair such directors' independence. In the case of new director candidates, the Board also determines whether the nominee must be independent, which determination is based upon applicable SEC rules and regulations, with a view towards Nasdaq rules as well. In order to find a Board candidate, the Board uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Board conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Board meets to discuss and consider such candidates' qualifications and 15 then selects a nominee for recommendation to the Board by majority vote. To date, the Board has not paid a fee to any third party to assist in the process of identifying or evaluating director candidates. To date, the Board has not rejected a timely director nominee from a shareholder or shareholders. Although there is no formal procedure for shareholders to recommend nominees for the Board, the Nominating and Corporate Governance Committee will consider such recommendations if received one hundred twenty (120) days in advance of the annual meeting. Such recommendations should be addressed to the Nominating and Corporate Governance Committee at our address and provide all information relating to such person that the shareholder desires to nominate that is required to be disclosed in solicitation of proxies pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended. The Board members should possess such attributes and experience as are necessary to provide a broad range of personal characteristics including diversity, management skills, and pharmaceutical industry, financial, technological, business and international experience. Directors selected should be able to commit the requisite time for preparation and attendance at regularly scheduled Board and any committee meetings, as well as be able to participate in other matters necessary for good corporate governance. COMMUNICATIONS WITH THE BOARD Historically, Akorn has not adopted a formal process for shareholder communications with the Board. Nevertheless, every effort has been made to ensure that the views of shareholders are heard by the Board or individual directors, as applicable, and that appropriate responses are provided to shareholders in a timely manner. We believe our responsiveness to shareholder communications to the Board has been excellent. During the upcoming year, the Nominating and Corporate Governance Committee will give full consideration to the adoption of a formal process for shareholder communications with the Board and, if adopted, publish it promptly and post it to the Akorn website. DIRECTOR COMPENSATION Each director who is not one of our salaried officers receives a fee for his services as a director of $2,500 per regular meeting of the Board, $500 per telephone meeting and $500 per committee meeting, plus reimbursement of his expenses related to those services. The Akorn, Inc. 1991 Stock Option Plan for Directors (the "1991 Directors' Plan") expired in December 2001 and no awards were made to directors during 2002. If approved by the shareholders, all of our directors will participate in the Akorn, Inc. 2003 Stock Option Plan (the "2003 Stock Option Plan"). Under the 2003 Stock Option Plan, independent directors will be granted an option to acquire 10,000 shares of our common stock on January 1 of each calendar year in which such director serves. Any director appointed between annual meetings is entitled to receive a pro rata portion of an option to acquire 10,000 shares. Options granted under the 2003 Stock Option Plan vest immediately and expire five years from the date of grant. Upon joining the Board in 2001, Mr. Ellis was granted an option for 20,000 shares at fair market value at the time of the grant. For additional information regarding the 2003 Stock Option Plan, see "PROPOSAL 2: ADOPTION OF THE AKORN, INC. 2003 STOCK OPTION PLAN" above. REPORT OF THE AUDIT COMMITTEE The Audit Committee reviews Akorn's financial reporting process on behalf of the Board. Management has the primary responsibility for the financial statements and the reporting process, including the system of internal controls. In this context, the Audit Committee has met and held discussions with management and the independent auditors. Management represented to the Audit Committee that Akorn's consolidated financial statements were 16 prepared in accordance with generally accepted accounting principles, and the Audit Committee has reviewed and discussed the consolidated financial statements with management and the independent auditors. The Audit Committee discussed with the independent auditors matters required to be discussed by Statement on Auditing Standards No. 61 (Communication With Audit Committees). In addition, the Audit Committee has discussed with the independent auditors the auditors' independence from Akorn and its management, including the matters in the written disclosures required by the Independence Standards Board Standard No. 1 (Independence Discussions With Audit Committees). The Audit Committee has also considered whether the independent auditors' provision of non-audit services to Akorn is compatible with the auditors' independence. In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board, and the Board approved, that the audited consolidated financial statements be included in Akorn's Annual Report on Form 10-K for the year ended December 31, 2003, for filing with the SEC. SUBMITTED BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS JERRY TREPPEL RON JOHNSON JERRY N. ELLIS, CHAIR CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS Mr. John N. Kapoor, Ph.D., our current Chairman of the Board and Chief Executive Officer from March 2001 to December 2002, and a principal shareholder, is affiliated with E.J. Financial Enterprises, Inc., a health care consulting investment company ("E.J. Financial"). E.J. Financial is involved in the management of health care companies in various fields, and Dr. Kapoor is involved in various capacities with the management and operation of these companies. The John N. Kapoor Trust dtd 9/20/89 (the "Kapoor Trust"), the beneficiary and sole trustee of which is Dr. Kapoor, is a principal shareholder of each of these companies. As a result, Dr. Kapoor does not devote his full time to our business. Although such companies do not currently compete directly with us, certain companies with which E.J. Financial is involved are in the pharmaceutical business. Discoveries made by one or more of these companies could render our products less competitive or obsolete. In addition, one of these companies, NeoPharm, Inc. of which Dr. Kapoor is Chairman and a major shareholder, recently entered into a loan agreement with us. We also owe E.J. Financial $18,000 in consulting fees for each of 2002 and 2001, as well as expense reimbursements of $1,987.30 and $182,369.84 for 2002 and 2001, respectively. Further, The John N. Kapoor Trust has loaned us $5,000,000 resulting in Dr. Kapoor becoming one of our major creditors as well as a major shareholder. On March 21, 2001, in consideration of Dr. Kapoor assuming the positions of Akorn President and interim CEO, the Compensation Committee of the Board agreed to issue Dr. Kapoor 500,000 options under the Amended and Restated Akorn, Inc. 1988 Incentive Compensation Program in lieu of cash compensation. On July 12, 2001, we entered into a $5,000,000 subordinated debt transaction with the Kapoor Trust, the sole trustee and sole beneficiary of which is Dr. John N. Kapoor, our Chairman of the Board. The transaction is evidenced by a Convertible Bridge Loan and Warrant Agreement (the "Trust Agreement") in which the Kapoor Trust agreed to provide two separate tranches of funding in the amounts of $3,000,000 ("Tranche A" which was received on July 13, 2001) and $2,000,000 ("Tranche B" which was received on August 16, 2001). As part of the consideration provided to the Kapoor Trust for the subordinated debt, we issued the Trust two warrants which allow the Kapoor Trust to purchase 1,000,000 shares of common stock at a price of $2.85 per share and another 667,000 shares of common stock at a price of $2.25 per share. The exercise price for each warrant represented a 25% premium over the share price at the time of the Kapoor Trust's commitment to provide the subordinated debt. All unexercised warrants will expire on December 20, 2006. 17 Under the terms of the Trust Agreement, the subordinated debt bears interest at prime plus 3%, which is the same rate we pay on its senior debt. Interest cannot be paid to the Kapoor Trust until the repayment of the senior debt pursuant to the terms of a subordination agreement, which was entered into between the Kapoor Trust and our senior lenders. Should the subordination agreement be terminated, interest may be paid sooner. The convertible feature of the Trust Agreement, as amended, allows for conversion of the subordinated debt plus interest into our common stock at a price of $2.28 per share of common stock for Tranche A and $1.80 per share of common stock for Tranche B. In December 2001, we entered into a $3,250,000 five-year loan with NeoPharm, Inc. ("NeoPharm") to fund our efforts to complete our lyophilization facility located in Decatur, Illinois. Under the terms of the promissory note, dated December 20, 2001, evidencing the loan (the "Promissory Note") interest will accrue at the initial rate of 3.6% and will be reset quarterly based upon NeoPharm's average return on its cash and readily tradable long and short-term securities during the previous calendar quarter. The principal and accrued interest is due and payable on or before maturity on December 20, 2006. The note provides that we will use the proceeds of the loan solely to validate and complete the lyophilization facility located in Decatur, Illinois. In consideration for the loan, under a separate manufacturing agreement between us and NeoPharm, we, upon completion of the lyophilization facility, agree to provide NeoPharm with access to at least 15% of the capacity of our lyophilization facility each year. The Promissory Note is subordinated to our senior debt owed to Northern Trust but is senior to our subordinated debt owed to the Kapoor Trust. Dr. John N. Kapoor, our chairman, is also chairman of NeoPharm and holds a substantial stock position in that company as well as in us. Commensurate with the completion of the Promissory Note between us and NeoPharm, we entered into an agreement with the Kapoor Trust, which amended the Trust Agreement. The amendment extended the Trust Agreement to terminate concurrently with the Promissory Note on December 20, 2006. The amendment also made it possible for the Kapoor Trust to convert the interest accrued on the $3,000,000 tranche into our common stock. Previously, the Kapoor Trust could only convert the interest accrued on the $2,000,000 tranche. The change related to the convertibility of the interest accrued on the $3,000,000 tranche requires that shareholder approval be received by August 31, 2002, which date has been extended to September 30, 2004. As part of the Exchange Transaction, we issued the 2003 Subordinated Notes (defined below) to the Kapoor Trust, Arjun Waney and Argent Fund Management, Ltd. ("Argent"). Mr. Waney is one of our new directors and serves as Chairman and Managing Director and is a 51% owner of Argent. Both Mr. Waney and Argent are shareholders of Akorn. The 2003 Subordinated Notes mature on April 7, 2006 and bear interest at prime plus 1.75%, but interest payments are currently prohibited under the terms of certain subordination arrangements. Consequently, Mr. Waney is also a creditor of ours. In 2003, we paid approximately $115,000 for consulting fees to Quintiles, Inc., a firm at which Ron Johnson, one of our directors, is employed. We have an equity ownership interest in Novadaq Technologies, Inc. ("Novadaq") of 4,132,000 common shares, representing approximately 16.9% of the outstanding stock of Novadaq. Previously, we had entered into a marketing agreement with Novadaq, which was terminated in early 2002. We received, as part of the termination settlement, the aforementioned shares and entered into an agreement with Novadaq to be the exclusive future supplier of Indocyanine Green for use in Novadaq's diagnostic procedures. We also have the right to appoint one individual to the Board of Directors of Novadaq. Arthur S. Przybyl, our Chief Executive Officer, currently serves in this capacity. EXCHANGE TRANSACTION On October 7, 2003, a group of investors (the "Investors") purchased all of our then outstanding senior bank debt from the Northern Trust Company ("Northern Trust"), a balance of $37,731,000, at a discount and exchanged such debt with Akorn (the "Exchange Transaction") for (i) 257,172 shares of Series A 6.0% 18 Participating Convertible Preferred Stock of Akorn ("Preferred Stock"), (ii) subordinated promissory notes in the aggregate principal amount of approximately $2,767,000 (the "2003 Subordinated Notes"), (iii) warrants to purchase an aggregate of 8,572,400 shares of Akorn's common stock with an exercise price of $1.00 per share, and (iv) $5,473,862 in cash from the proceeds of the term loan under the New Credit Facility described in a following paragraph. The 2003 Subordinate Notes and cash were issued by Akorn to (a) the Kapoor Trust (b)Mr. Waney, and (c) Argent. Akorn also issued to the holders of the 2003 Subordinated Notes warrants to purchase an aggregate of 276,714 shares of common stock with an exercise price of $1.10 per share. A portion of the legal fees of the Investors was paid for by Akorn. Simultaneously with the consummation of the Exchange Transaction, we entered into a credit agreement with LaSalle Bank providing us with a $7,000,000 term loan and a revolving line of credit of up to $5,000,000 to provide for working capital needs (collectively, the "New Credit Facility") secured by substantially all of the assets of Akorn. Our obligations under the New Credit Facility have been guaranteed by the Kapoor Trust and Mr. Waney. In exchange for this guaranty, we issued additional warrants to purchase 880,000 and 80,000 shares of common stock to the Kapoor Trust and Mr. Waney, respectively, and have agreed to issue to each of them, on each anniversary of the date of the consummation of the Exchange Transaction, warrants to purchase an additional number of shares of common stock equal to 0.08 multiplied by the principal dollar amount of the our indebtedness then guaranteed by them under the New Credit Facility. The warrants issued in exchange for these guarantees have an exercise price of $1.10 per share. Collectively all of the warrants issued, and to be issued, in connection with the Exchange Transaction and the corresponding guarantees of the New Credit Facility shall hereafter be referred to as the "Warrants." The Preferred Stock accrues dividends at a rate of 6.0% per annum, which rate is fully cumulative, accrues daily and compounds quarterly, provided that in the event shareholder approval authorizing sufficient shares of common stock to be authorized and reserved for conversion of all of the Preferred Stock and Warrants issued in connection with the Exchange Transaction ("Shareholder Approval") has not been received by October 7, 2004, such rate is to increase to 10.0% until Shareholder Approval has been received and sufficient shares of common stock are authorized and reserved. Subject to certain limitations, on October 31, 2011, we are required to redeem all shares of Preferred Stock for an amount equal to $100 per share, as may be adjusted from time to time (the "Stated Value") as set forth in our Articles of Amendment to the Articles of Incorporation (the "Articles of Amendment"), plus all accrued but unpaid dividends on such shares. Shares of Preferred Stock have liquidation rights in preference over junior securities, including the common stock, and have certain antidilution protections. The Preferred Stock is convertible at any time into a number of shares of common stock equal to the quotient obtained by dividing (x) the Stated Value plus any accrued but unpaid dividends by (y) $0.75, as such numbers may be adjusted from time to time pursuant to the terms of the Articles of Amendment. Provided that if Shareholder Approval has been received and sufficient shares of common stock are authorized and reserved for conversion, all shares of Preferred Stock shall convert to shares of common stock on the earlier to occur of (i) October 8, 2006 and (ii) the date on which the closing price per share of common stock for at least 20 consecutive trading days immediately preceding such date exceeds $4.00 per share. We do not currently have sufficient shares of common stock authorized for issuance upon the conversion of the Preferred Stock and the Warrants. An amendment to the Articles of Incorporation is necessary to authorize sufficient shares of common stock for such conversion. 19 SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE During 2002 Arthur S. Przybyl and Bernard J. Pothast, both officers of Akorn, failed to file timely with the SEC one Form 4 to report changes in beneficial ownership, and during 2003, Jerry I. Treppel, a director of Akorn, failed to timely file with the SEC one Form 3 to report initial beneficial ownership, each as required by Section 16(a) of the Securities Exchange Act of 1934, as amended. All such transactions have been reported on amended statements or annual statements on Form 5. COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION Arjun C. Waney, Jerry I. Treppel and Jerry N. Ellis who currently comprise the Compensation Committee, are each independent, non-employee directors of Akorn. No executive officer of Akorn served as a director or member of (i) the compensation committee of another entity in which one of the executive officers of such entity served on the our Compensation Committee, (ii) the board of directors of another entity in which one of the executive officers of such entity served on our Compensation Committee, or (iii) the compensation committee of any other entity in which one of the executive officers of such entity served as a member of our Board, during the year ended December 31, 2003. As part of the Exchange Transaction, we issued the 2003 Subordinated Notes to the Kapoor Trust, Arjun Waney and Argent Fund Management, Ltd. ("Argent"). Mr. Waney is one of our new directors and both Mr. Waney and Argent are shareholders of Akorn. The 2003 Subordinated Notes mature on April 7, 2006 and bear interest at prime plus 1.75%, but interest payments are currently prohibited under the terms of certain subordination arrangements. Consequently, Mr. Waney is also a creditor of ours. 20 III. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT As of March 15, 2004, the following persons were directors, nominees, Named Executive Officers (as defined in "Executive Compensation" above), or others with beneficial ownership of five percent or more of our common stock. The information set forth below has been determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, based upon information furnished to us or to the SEC by the persons listed. Unless otherwise noted the address of each of the following persons is 2500 Millbrook Drive, Buffalo Grove, Illinois 60089.
Shares Beneficially Percent Beneficial Owner Owned of Class - ---------------- ------------------ -------- DIRECTORS AND NOMINEES John N. Kapoor, Ph.D. ...................................... 27,995,299(1) 64.14% Arjun C. Waney.............................................. 5,842,167(2)(8) 24.43% Jerry I. Treppel............................................ 833,334(3)(8) 4.00% Jerry N. Ellis.............................................. 22,000(4)(8) 0.11% Ronald M. Johnson........................................... --(8) 0.00% NAMED EXECUTIVE OFFICERS Arthur S. Przybyl........................................... 369,947(5) 1.82% Bernard J. Pothast.......................................... 106,250(6) 0.53% Directors and officers as a group (7 persons)............... 35,168,997 71.93% OTHER BENEFICIAL OWNERS Pequot Capital Management Inc. ............................. 13,733,334(7) 41.22%
- ------------------------ (1) Of such 27,995,299 shares, (i) 851,800 are owned directly by the John N. Kapoor Trust dtd 9/20/89 (the "Kapoor Trust") of which Dr. Kapoor is the sole trustee and beneficiary, (ii) 3,395,000 are owned by E.J. financial/Akorn Management, L.P. of which Dr. Kapoor is managing general partner, (iii) 25,000 are owned directly by Dr. Kapoor, (iv) 63,600 are owned by a trust, the trustee of which is Dr. Kapoor's wife and the beneficiaries of which are their children, (v) 385,000 are issuable pursuant to exercisable options granted by us directly to Dr. Kapoor, out of 510,000 options owned by Dr. Kapoor, (vi) 6,337,047 are issuable upon exercise of warrants issued to the Kapoor Trust, (vii) 2,426,900 are issuable upon the conversion of a convertible note held by the Kapoor Trust, (vii) 197,619 are issuable upon the conversion of interest related to the convertible note held by the Kapoor Trust, and (viii) 107,350 shares of Series A 6% Participating Convertible Preferred Stock convertible into 14,313,333 shares. (2) Of such 5,842,167 shares represented as beneficial to Mr. Waney, (i) 908,833 shares are held by Argent Fund Management, Ltd. ("Argent"), including 458,500 shares, 2,672 shares of Series A 6% Participating Convertible Preferred Stock currently convertible into 356,266 shares at $0.75 per share, 89,067 warrants currently exercisable to purchase shares at an exercise price of $1.00 per share and 5,000 warrants currently exercisable to purchase shares at an exercise price of $1.10 per share. (Mr. Waney serves as Chairman and Managing Director and owns 52% of Argent), (ii) 628,400 shares are held by First Winchester Investments Ltd., which operates as an equity fund for investors unrelated to Mr. Waney and whose investments are directed by Argent, (iii) 506,000 shares are held by Mr. Waney through Individual Retirement Accounts maintained in the United States, (iv) 3,798,933 shares are held jointly by Mr. Waney and Mrs. Waney, including 325,600 shares, 20,000 shares of Series A 6% Participating Convertible Preferred Stock currently 21 convertible into 2,666,666 Shares at $0.75 per share, 666,667 warrants currently exercisable to purchase shares at an exercise price of $1.00 per share and 140,000 warrants currently exercisable to purchase shares at an exercise price of $1.10 per share. Under the Rules of the SEC, Mr. Waney may be deemed to be the beneficial owner of the shares held by First Winchester Investments Ltd. (3) Of Mr. Treppel's 833,334 shares, (i) 333,333 represent 2,500 shares of Series A 6% Participating Convertible Preferred Stock currently convertible at $0.75 per share and (ii) 83,334 are warrants currently exercisable to purchase shares at an exercise price of $1.00 per share. There are an additional (i) 333,333 shares which represent 2,500 shares of Series A 6% Participating Convertible Preferred Stock currently convertible at $0.75 per share and (ii) 83,334 warrants currently exercisable to purchase shares at an exercise price of $1.00 per share which are held indirectly through Wheaton Capital Management LLC. (4) Of Mr. Ellis's shares, 2,000 represent direct ownership of shares. Mr. Ellis has been granted options to purchase 20,000 shares. (5) Of Mr. Przybyl's 369,947 shares, (i) 187,500 relate to granted options of 375,000, of which 187,500 are vested or exercisable, (ii) 7,447 shares, (iii) 140,000 shares underlying 1,050 shares of the Issuer's Series A 6% Participating Convertible Preferred Stock, and (iv) 35,000 shares underlying warrants, at a purchase price of $1.00 per share. (6) Mr. Pothast's shares include options to purchase 106,250 shares. These stock options represent presently exercisable options from three separate grants totaling 200,000 shares, each of which vest in four equal increments, one quarter on the grant date and one quarter for each of the next three successive anniversary dates. (7) Of such shares, Pequot Capital Management beneficially own 13,733,334 shares as follows: (i) 400,000 shares; (ii) 10,666,667 shares underlying 80,000 shares of the Issuer's Series A 6% Participating Convertible Preferred Stock; and (iii) 2,666,667 shares underlying warrants, at a purchase price of $1.00 per share. (8) Options to purchase stock of 750,000, 35,000, 30,000, 10,000 and 10,000 shares granted to Mr. Przybyl, Mr. Ellis, Mr. Johnson, Mr. Treppel and Mr. Waney, respectively are not included in the calculation of beneficial ownership. Such grants were made under the proposed 2003 Stock Option Plan and are subject to the approval of our shareholders. IV. EXECUTIVE COMPENSATION AND OTHER INFORMATION COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION General. The Compensation Committee of the Board, consisting of directors Arjun C. Waney, Jerry I. Treppel, Ronald M. Johnson and Jerry N. Ellis, none of whom are one of our employees, reviews, analyzes and makes recommendations to the full board related to compensation for our executive officers, evaluates the performance of the Chief Executive Officer and administers the grant of stock options under our Incentive Compensation Program. Compensation Objectives. The Compensation Committee believes that compensation for the executive officers should be determined in a manner which emphasizes increasing value for shareholders. Based upon this objective, the Compensation Committee's Incentive Compensation Program is designed to pay base salaries to executives at levels that enable us to attract, motivate and retain capable executives. In addition, the Compensation Committee may recommend annual cash bonuses as well as stock option grants as a component of compensation and/or as a reward for performance based upon: (i) individual performance, (ii) our operating and financial results and departmental goals, and (iii) other performance measures. Stock option grants, which are made at the fair market value of the common stock on the grant date, are intended to result in no reward if the stock price does 22 not appreciate, but may provide substantial rewards to executives as shareholders benefit from stock price appreciation. Consistent with this overall philosophy, the Compensation Committee's specific objectives are to: - align the financial interests of executive officers with those of shareholders by providing equity-based incentives. - allow for the awarding of variable cash bonus compensation payments that take into account the overall Company performance, individual contributions and other factors that increase shareholder value. - emphasize performance-based and equity-based compensation for executive officers which rewards performance that exceeds targeted goals, but, in particular, focuses more on overall Company performance, and individual contribution to the achievement of established departmental and company goals, and less on comparable market place compensation comparisons in determining the amount of equity-based compensation and annual cash bonuses. Components of Compensation. There are three major elements of executive officer compensation: (i) base salary, (ii) annual cash bonus awards, and (iii) equity-based incentive awards in the form of stock option grants. Executive officers also receive other standard benefits, including medical, disability and life insurance and, in certain instances, a car allowance. The Compensation Committee uses its subjective judgment in determining executive officer compensation levels and takes into account both qualitative and quantitative factors. Among the factors considered by the Compensation Committee are the recommendations of our CEO, with respect to the compensation of other key executive officers. While the Compensation Committee considers compensation practices and financial performance of companies in our industry and other comparable companies, the Compensation Committee does not target total executive compensation or any component thereof to any particular point within, or outside, the range of companies in our industry and other comparable companies' results. Specific compensation for individual officers will vary from these levels as a result of subjective factors considered by the Compensation Committee unrelated to compensation practices of comparable companies. Base Salary. Each Company executive receives a base salary. We target base pay at the level believed necessary to attract and retain capable executives. In determining salaries, the Compensation Committee also takes into account, among other factors, individual experience and performance and specific needs particular to us. In some cases, the amount of base salary may be determined by the provisions of an employment contract entered into with the individual that may provide for predetermined increases. Bonus. In addition to base salary, executive officers are eligible to receive an annual cash bonus. Bonuses are determined based upon the achievement of qualitative and quantitative individual, departmental and, especially, Company performance. Based on our recent performance, the Compensation Committee did not award any bonuses in either the calendar years 2001, 2002 or 2003. Stock Options. The Compensation Committee believes that it is important for executives to have an equity stake in us, and, toward this end, makes stock options grants to key executives from time to time. In making option awards, the Compensation Committee reviews our needs in obtaining or retaining a particular individual's services, the awards granted to other executives within us and the individual officers specific role and contribution to us. During fiscal 2002 and 2003 option grants were made to Mr. Przybyl and Mr. Pothast, and in 2004 to Mr. Przybyl, in order to retain their services and align their interests with shareholders. Additionally, in 2001 and 2002 options were awarded to Mr. Pera, President and our COO at that time, based on the terms of his employment agreement with us. Chief Executive Officer Compensation. Mr. Przybyl agreed to assume the duties of CEO in January 2003. Mr. Przybyl received a base salary for his service as CEO of $260,000, and, in light of our performance did not 23 receive a bonus in 2003, however in consideration for his assuming the CEO position, options to acquire 50,000 shares of common stock in the belief that this would more closely tie the reward for his efforts to our performance without impacting our cash flow. Tax Deduction for Compensation. It is the responsibility of the Committee to address the issues raised by tax laws under which certain non-performance based compensation in excess of $1 million per year paid to executives of public companies is non-deductible to us and to determine whether any actions with respect to this limit need to be taken by us. It is not anticipated that any of our executive officers will receive any compensation in excess of this limit. SUBMITTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ARJUN C. WANEY JERRY I. TREPPEL JERRY N. ELLIS 24 PERFORMANCE GRAPH The graph below compares the cumulative shareholder return on our common stock for the last five years through December 31, 2003 with the NASDAQ US Index and the NASDAQ Pharmaceutical Index. The graph assumes $100 was invested in December 1997 in our common stock and the two indices presented and that all dividends were reinvested. As of June 24, 2002, however, our common stock was delisted by Nasdaq. It was then quoted in the "Pink Sheets" until April 19, 2004. Since then it has been listed on the OTC Bulletin Board. (PERFORMANCE GRAPH)
TOTAL RETURN CHART 12/31/98 12/31/99 12/31/00 12/31/01 12/31/02 12/31/03 - --------------------------------------------------------------------------------------------------------- NASDAQ US 100 186 112 89 61 92 NASDAQ PHARM 100 189 235 200 129 190 AKRN (AKORN) 100 100 135 82 26 41
EMPLOYMENT AGREEMENTS In September 2001, Bernard J. Pothast received and accepted an employment offer letter for the position of our Vice President Finance and Chief Financial Officer. His letter provides for an annual salary of $135,000 (to be increased to $150,000 following our first full quarter of positive operating income), a discretionary bonus of up to 30% of his base salary, a grant of options to purchase 75,000 shares of our common stock, severance for six months of his base salary if he is terminated without cause, and other customary benefits for our employees. In January 2003, Arthur S. Przybyl received and accepted an employment offer letter for the position of our Interim Chief Executive Officer. He became our full Chief Executive Officer in February 2003. His letter provides for an annual salary of $260,000, a discretionary bonus of up to 50% of his base salary, a grant of options to purchase 50,000 shares of our common stock, severance for one year at his base salary if he is terminated without cause, and other customary benefits for our employees. We currently have no other employment agreements in place. In connection with his serving as our Chief Executive Officer, we have provided to Mr. Przybyl supplemental indemnity assurances with respect to any claims associated with his execution, filing and submission Chief Executive Officer Certifications of SEC reports for periods preceding his direct supervision of financial and accounting matters. 25 SUMMARY COMPENSATION TABLE The following table summarizes the compensation paid by us for services rendered during the years ended December 31, 2003, 2002 and 2001 to our current chief executive officer and to each person who, during 2002, served as our chief executive officer and to each other of our executive officers whose total annual salary and bonus for 2003 exceeded $100,000 (each a "Named Executive Officer").
Long-Term Compensation ------------ Annual Compensation Securities Name and Principal -------------------------------------------------- Other Annual Underlying All Other(1) Position Time Period Salary Bonus(2) Compensation Options/SARS Compensation - ------------------ ----------- ------ -------- ------------ ------------ ------------ John N. Kapoor(3).......... Year ended December 31, 2003 $ -- $ -- $ -- -- $ -- Chairman Year ended December 31, 2002 -- -- -- -- -- Year ended December 31, 2001 2,083 -- -- 500,000 -- Arthur S. Przybyl(4)....... Year ended December 31, 2003 259,089 -- 10,000 75,000 44,649 President and Year ended December 31, 2002 93,482 -- 3,308 300,000 -- Chief Executive Officer Year ended December 31, 2001 -- -- -- -- -- Bernard J. Pothast(5)...... Year ended December 31, 2003 170,154 -- 4,846 25,000 -- Sr. Vice President Year ended December 31, 2002 148,263 -- -- 100,000 -- Chief Financial Officer Year ended December 31, 2001 39,094 -- -- 75,000 -- Secretary and Treasurer
- ------------------------ (1) Represents contributions to our Savings and Retirement Plan, except as indicated in note (4). (2) There were no executive officer bonuses awarded for 2003, 2002 or 2001. (3) Dr. Kapoor currently serves as our Chairman and served as Chief Executive Officer from March 2001 to December 2002. In lieu of a salary for 2001, we issued Dr. Kapoor options to purchase 500,000 shares of our common stock. Dr. Kapoor was not paid a salary or granted options in 2003 or in 2002. (4) Mr. Przybyl became our Chief Executive Officer on February 17, 2003. Prior to that, Mr. Przybyl was our President and Chief Operating Officer. His "All Other Compensation" for 2003 is exclusively related to reimbursement for relocation expenses totaling $44,649 and "Other Annual Compensation" represents a $10,000 automobile allowance. (5) Mr. Pothast has been our Senior Vice President since June 2002 and our Chief Financial Officer, Secretary and Treasurer since September 2001. His "Other Annual Compensation" for 2003 represents an automobile allowance. EXECUTIVE OFFICERS
Year Became Name Position Age Officer - ---- -------- --- ------- Arthur S. Przybyl... President, Chief Executive Officer and Director 47 2002 Bernard J. Pothast........... Sr. Vice President, Chief Financial Officer, Secretary and Treasurer 42 2001
Arthur S. Przybyl. Mr. Przybyl has served as our President and Chief Executive Officer since February 2003 and as one of our directors since his appointment by the Board in November of 2003. Previously, Mr. Przybyl served as our interim Chief Executive Officer from January to February of 2003 and as our President and Chief Operating Officer beginning September 2002. Mr. Przybyl joined Akorn in August 2002 as senior vice president sales and marketing. Prior to joining us, Mr. Przybyl served as president and chief executive officer for Hearing Innovations Inc., an innovative, start-up developer of medical devices for the profoundly deaf and tinnitus markets. Before that, 26 he served as president and chief operating officer for Bioject, Inc., a NASDAQ company specializing in needle-free technology. Mr. Przybyl is also a director of Novadaq Technologies, Inc., a privately held research company. Bernard J. Pothast. Mr. Pothast has served as our Senior Vice President since June 2002 and as our Vice President, Chief Financial Officer, Secretary and Treasurer since September 2001. From 1998 to 2001, he was Director of Financial Planning and Analysis of Moore North America (a business form printing company). From 1995 to 1998, Mr. Pothast was Director of Business Planning and Corporate Finance of GATX Corporation (a transportation and logistics company). From 1990 to 1995, he was Manager of Financial Reporting and Analysis for The Perseco Company (a packaging and logistics company). Mr. Pothast began his career at the public accounting firm of Ernst & Young, LLP. OPTION GRANTS IN LAST FISCAL YEAR The following table sets forth certain information with respect to stock options granted to each of the Named Executive Officers in the fiscal year ended December 31, 2003, including the potential realizable value over the five-year term of the options, based on assumed rates of stock appreciation of 5% and 10% of the market price of the underlying security on the date of grant, compounded annually. These assumed rates of appreciation comply with the rules of the SEC and do not represents Akorn's estimate of future stock price. Actual gains, if any, on stock option exercises will be dependent on the future performance of Akorn's common stock.
Potential Realizable Value at Assumed Individual Grants Annual Rates of ----------------------------------------------------- Stock Price Number of Percent of Appreciation for Securities Total Options Exercise Option Term Underlying Granted to or Base -------------------- Options Employees in Price Expiration 5% 10% Name Granted(#) Fiscal Year ($/Sh) Date ($) ($) - ---- ---------- ------------- -------- ---------- --- --- Arthur S. Przybyl.......... 50,000(1) 10% 0.80 1/20/08 51,051 64,420 25,000(1) 5% 0.90 2/18/08 28,716 39,860 Bernard J. Pothast......... 25,000(1) 5% 0.90 2/18/08 28,716 39,860
- ------------------------ (1) Issued pursuant to the Amended and Restated 1988 Incentive Compensation Program. 27 AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FY-END OPTION VALUES The following table sets forth information with respect to the Named Executive Officers concerning the exercise of options during the last fiscal year and unexercised options held as of the end of the fiscal year.
Number of Value of Securities Underlying Unexercised in-the- Unexercised Options Money Options at at FY-End(#) FY-End($)(1) Value --------------------- ------------------- Shares Acquired Realized Exercisable/ Exercisable/ Name on Exercise(#) ($) Unexercisable Unexercisable - ---- --------------- -------- ------------- ------------- John N. Kapoor................. -- -- 385,000/125,000 --/-- Arthur S. Przybyl.............. -- -- 187,500/187,500 193,750/193,750 Bernard J. Pothast............. -- -- 106,250/93,750 56,250/56,251
- --------------- (1) Value of Unexercised in-the-Money options calculated using the December 31, 2003 closing price of $2.00. EQUITY COMPENSATION PLANS EQUITY COMPENSATION PLANS APPROVED BY SHAREHOLDERS The shareholders approved the Amended and Restated Akorn, Inc. 1988 Incentive Compensation Program ("1988 Plan"), under which our officers and key employees were eligible to receive stock options as designated by our Board, and the Akorn, Inc. 1991 Stock Option (the "1991 Directors' Plan"), under which options were issuable to our directors. The aforementioned 1988 Plan expired on November 2, 2003 and the 1991 Directors Plan expired December 7, 2001. EQUITY COMPENSATION PLANS NOT APPROVED BY SHAREHOLDERS With the expiration of the 1991 Directors' Plan, the Board has approved, subject to obtaining shareholders' approval at the annual meeting, the Akorn, Inc. 2003 Stock Option Plan (the "2003 Stock Option Plan"). Details of the 2003 Stock Option Plan are included in this Proxy Statement under the heading "PROPOSAL 3: ADOPTION OF THE AKORN, INC. 2003 Stock Option Plan" and are not included in the summary table below. Summary Table. The following table sets forth certain information as of December 31, 2003, with respect to compensation plans under which shares of Akorn common stock were issuable as of that date.
Number of securities remaining available for future Number of securities to Weighted-average issuance under equity be issued upon exercise exercise price of compensation plans of outstanding options, outstanding options, (excluding securities reflected Plan Category warrants and rights warrants and rights in the first column) - ------------- ----------------------- ----------------------- ------------------------------- Equity Compensation plans approved by security holders:............... 3,258,175 $2.3233 2,933,340 Equity Compensation plans not approved by security holders:...... 1,470,000 $1.1363 -- --------- ------- --------- Total.................... 4,728,175 -- 2,953,340 ========= ======= =========
28 INCORPORATION OF FINANCIAL INFORMATION Our audited consolidated financial statements and notes thereto, selected financial data, management's discussion and analysis of financial condition and results of operations, and quantitative and qualitative disclosures about market risk, for the fiscal year ended December 31, 2003, included in our 2003 annual report on Form 10-K, are hereby incorporated by reference and accompany this Proxy Statement. HOUSEHOLDING OF PROXY MATERIALS

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more shareholders sharing the same address by delivering a single proxy statement addressed to those shareholders. This process, which is commonly referred to as "householding,"“householding,” potentially means extra convenience for shareholders and cost savings for companies. This year, brokers

Brokers with account holders who are Akorn shareholders may be "householding"“householding” our proxy materials. A single proxy statement will be delivered to multiple shareholders sharing an address unless contrary instructions have been received from the affected shareholders. Once you have received notice from your broker that they will be "householding"“householding” communications to your address, "householding"“householding” will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in "householding"“householding” and would prefer to receive a separate proxy statement and annual report, please notify your broker and direct your written request to Akorn, Inc,Inc., Attention: Investor Relations, 2500 Millbrook Drive, Buffalo Grove,1925 West Field Court, Suite 300, Lake Forest, Illinois 60089.60045, or call (847) 279-6156. Shareholders who currently receive multiple copies of the proxy statement at their address and would like to request "householding"“householding” of their communications should contact their broker. OTHER MATTERS Management

AKORN, INC. 2016 Special Meeting Proxy Statement42

(GRAPHIC)How can I get a copy of the 2015 annual report or other proxy materials?

The Notice of Special Meeting, proxy statement and our Form 10-K for 2015 are available at proxyvote.com and at the Company’s website akorn.com.

We will provide, without charge, a copy of our Form 10-K, including financial statements and financial statement schedules, as filed with the SEC, upon request in writing from any person who was a holder of record or who represents in good faith that such person was a beneficial owner of common stock as of October 28, 2016.Requests should be made to Akorn, Inc., Attention: Investor Relations, 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045.

(GRAPHIC)What are thedeadlines for submitting shareholder proposals for the 2017 annual meeting?

Any proposal that a shareholder of our common stock wishes to submit for inclusion in the Akorn Proxy Statement for the 2017 annual meeting (“2017 Proxy Statement”) pursuant to Rule 14a-8 must be received by Akorn’s Corporate Secretary at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045 not later than November 24, 2016, or if such year’s annual meeting does not take place within 30 days from May 5, 2017, then the deadline is unawarea reasonable time before Akorn begins to print and send its proxy materials. Such proposals must comply with SEC regulations under Rule 14a-8 regarding the inclusion of shareholder proposals in company-sponsored proxy materials. In addition, notice of any matterproposal that a holder of our common stock wishes to propose for action by shareholdersconsideration at the 2017 annual meeting, other than those describedbut does not seek to include in the accompanying notice. The enclosed proxy, however, will confer discretionary authority2017 Proxy Statement pursuant to Rule 14a-8, must be delivered to the Company no later than November 24, 2016 if the proposing shareholder of our common stock wish for Akorn to describe the nature of the proposal in its 2017 Proxy Statement. Any shareholder proposals or notices submitted to Akorn in connection with respect to any other matter that may properly come before theour 2017 annual meeting should be addressed to: Akorn’s Corporate Secretary at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045. Any notice of a shareholder proposal submitted after November 24, 2016, or any adjournment thereof. It is the intention of the persons named in the enclosedif such year’s annual meeting does not take place within 30 days from May 5, 2017, a reasonable time before Akorn begins to print and send its proxy to vote in accordance with their best judgment on any such matter. materials, will be considered untimely.

By Order of the Board of Directors Ben J. Pothast

/S/Joseph Bonaccorsi

Joseph Bonaccorsi 

Secretary Buffalo Grove,

Lake Forest, Illinois

November[ ], 2004 29 APPENDIX●],2016

AKORN, INC. 2016 Special Meeting Proxy Statement43

Appendix A ARTICLES

See attached for Akorn, Inc. 2016 Employee Stock Purchase Plan

AKORN, INC.

2016 EMPLOYEE STOCK PURCHASE PLAN

(AKORN LOGO)

AKORN, INC.

2016 EMPLOYEE STOCK PURCHASE PLAN

TABLE OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF AKORN INC AtCONTENTS

  Page
   
1.Definitions1
   
2.Establishment of Plan2
   
3.Purpose2
   
4.Administration2
   
5.Eligibility2
   
6.Election to Participate2
   
7.Participation in One Offering Period2
   
8.Purchase Common Stock; Issuance of Shares2
   
9.Payroll Deductions3
   
10.Limitations on Shares to be Purchased4
   
11.Termination and Suspension of Participation4
   
12.Termination and Suspension of this Plan by the Company5
   
13.Corporate Transaction5
   
14.Nonassignability6
   
15.Reports6
   
16.No Rights to Continued Employment6
   
17.Equal Rights and Privileges6
   
18.Notices6
   
19.Term6
   
20.Designation of Beneficiary6
   
21.Compliance with Laws7
   
22.Applicable Law7
   
23.Amendment of this Plan7

1.          Definitions. For purposes of this Plan, the following terms have the following meanings unless the context requires otherwise:

Board” means the board of directors of the Company.

Business Day” means a meeting heldday, Monday through Friday, on June , 2004,which banks are generally open for business in the shareholdersUnited States.

Code” means the Internal Revenue Code of 1986, as amended.

Committee” means either the Board or a committee of the Board that is authorized by the Board to administer this Plan.

Common Stock” means the common stock of Akorn, Inc. (the "Corporation"

Company” means Akorn, Inc., and any successor thereto.

Current Compensation” means all W-2 cash compensation, including, but not limited to, base salary, wages, bonuses, commissions, overtime and shift premiums;provided,however, that for purposes of determining a Participant’s Current Compensation, any election by such Participant to reduce his or her regular cash remuneration under Sections 125 or 401(k) of the Code shall be treated as if such Participant did not make such election.

Election Change Form” means the Employee Stock Purchase Plan – Administration Form provided by the Human Resources Department pursuant to which a Participant elects to increase or decrease his or her rate of payroll deductions for the upcoming annual Offering Period. SeeExhibit A attached hereto.

Election to Participate Form” means the Employee Stock Purchase Plan – Administration Form provided by the Human Resources Department pursuant to which an employee authorizes payroll deductions from his or her Current Compensation under this Plan. SeeExhibit A attached hereto.

Eligible Employee” means any employee of the Company or a Participating Company other than (i) any employee who is not employed by the Company on the day before the first day of such Offering Period; (ii) any employee who is customarily employed for twenty (20) hours or less per week; (iii) any employee who is customarily employed for five (5) months or less in a calendar year; and (iv) any employee who owns stock or holds options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any Subsidiary, or as a Louisiana corporation having [19,987,137] outstandingresult of being granted an option under this Plan with respect to such Offering Period, would own stock or hold options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any Subsidiary.

Fair Market Value” means the closing sale price on a particular day or, in case no such sale takes place on such day, the average of the reported closing bid and asked prices, in either case as reported in the principal consolidated transaction reporting system with respect to securities listed on the principal national securities exchange on which the Common Stock is listed or admitted to trading or, if not quoted or listed or admitted to trading on any national securities exchange or quotation system, the last quoted sale price or, if not so quoted, the average of the high bid and low asked prices in the over-the-counter market, as reported by the Nasdaq or such other system then in use, or, if on any such date the Common Stock or such other securities are not quoted by any such organization, the average of the closing bid and asked prices as furnished by a professional market maker, selected by the Board, making a market in the Common Stock, in each case rounded to the next higher cent.

Human Resources Department” means the human resources department of the Company or a Participating Company.

Offering Date” means the first day of the Offering Period.

Offering Period” means (i) the annual period from January 1 through December 31 for each calendar year for which the Committee determines this Plan is in effect (except the initial year, 2017, for which the annual period will begin on January 9 and run through December 31); (ii) the period from July 1 through December 31 for each calendar year for which the Committee determines this Plan is in effect; or (iii) such other period or periods designated by the Committee in its sole discretion, provided that in no event shall any such period designated by the Committee be longer than twenty-seven (27) months.

Participant” means an Eligible Employee who has authorized payroll deductions in the manner set forth in this Plan.


Participating Company” means any Subsidiary the Committee has designated to participate in this Plan.

Plan” means this Akorn, Inc. 2016 Employee Stock Purchase Plan, as the same may be amended.

Purchase Date” means the last trading day of the applicable Offering Period.

Purchase Price” means the lower of (i) eighty-five percent (85%) of the Fair Market Value of a share of Common Stock on the Offering Date, or (ii) eighty-five percent (85%) of the Fair Market Value of a share of Common Stock on the Purchase Date.

Subsidiary” means an entity which is a “subsidiary corporation” of the Company within the meaning of Section 424(f) of the Code.

Withdrawal Notice Form” means the Employee Stock Purchase Plan – Administration Form provided by the Human Resources Department pursuant to which a Participant elects to cease making any further payroll deductions by withdrawing from this Plan. SeeExhibit A attached hereto.

2.          Establishment of Plan. The Company may sell an aggregate of 2,000,000 shares of commonCommon Stock under this Plan. In the event of a reclassification or stock split of the Common Stock, the foregoing number of shares shall be appropriately adjusted in accordance with Section 13 of this Plan.

3.          Purpose. The purposes of this Plan are to provide Eligible Employees with a convenient means of acquiring an equity interest in the Company through payroll deductions with no brokerage fees at a discounted rate and to provide an incentive for continued employment.

4.          Administration. This Plan shall be administered under the direction of the Committee. In administering this Plan, it will be necessary to follow various laws and regulations. It may be necessary from time to time to change or waive requirements of this Plan to conform to the law, to meet special circumstances not anticipated or covered in this Plan, or to carry on successful operations of this Plan. Therefore, it is necessary for the Company to reserve the right to make variations in the provisions of this Plan and, subject to the provisions of this Plan, all questions of interpretation or application of this Plan shall be determined by the Committee and its decisions shall be final and binding upon all Participants. The Company shall pay all expenses incurred in connection with the administration of this Plan.The Company may require each other Participating Company to reimburse the Company for any costs incurred in connection with the purchase of shares of Common Stock for Participants of that Participating Company.

5.          Eligibility. Any Eligible Employee may participate in this Plan.

6.          Election to Participate. Eligible Employees may make an election to participate in this Plan by completing and delivering an Election to Participate Form (seeExhibit A attached hereto) to the Human Resources Department, which authorizes payroll deductions from such employee’s Current Compensation. The Election to Participate Form must be completed and delivered to the Human Resources Department at least five (5) business days before the Offering Date to which it relates. A properly made election will take effect no later than the payday following the Offering Date to which it relates and continue until the earlier of any of the following: (i) the date this Plan is terminated or suspended, (ii) the date such Participant’s participation in this Plan is terminated or suspended under Section 11 or (iii) the date such Participant withdraws from this Plan.

7.          Participation in One Offering Period. A Participant may participate in only one Offering Period at a time. For example, if an Eligible Employee is participating in the Offering Period running from January 1 to December 31, that employee cannot also enroll in the Offering Period running from July 1 to December 31.

8.          Purchase Common Stock; Issuance of Shares.

8.1          Subject to Section 10, on each Purchase Date, so long as this Plan remains in effect and provided that a Participant’s participation in this Plan has not been terminated, suspended or withdrawn under Section 11, the Company shall automatically apply the funds then in the Participant’s payroll deduction account to


purchase that number of whole shares of Common Stock determined by dividing (a) such Participant’s payroll deduction account balance as of such Purchase Date by (b) the Purchase Price. In the event any cash is remaining in a Participant’s payroll deduction account following the purchase of such whole shares of Common Stock on a Purchase Date, or in the event that this Plan has been oversubscribed, all funds not used to purchase shares on the Purchase Date shall be returned to the Participant without interest. No Common Stock shall be purchased on a Purchase Date on behalf of any Participant whose participation in this Plan has been terminated, suspended or withdrawn prior to such Purchase Date.

8.2          As promptly as practicable after each Purchase Date, the Company shall electronically issue shares of Common Stock purchased as of the Purchase Date for a Participant into the brokerage accounts of such Participant. A Participant may not transfer (other than by gift or inheritance) any shares of Common Stock acquired by such Participant under this Plan for ninety (90) days following the date such shares are issued to such Participant, unless the Committee agrees in writing to such transfer. Any attempt to transfer any shares of Common Stock acquired under this Plan other than in accordance with this Plan shall be considered null and void and of no effect.

8.3          A Participant shall have no interest in any shares of Common Stock, including any voting rights, until the Company has purchased shares of Common Stock for such Participant under Section 8.1.

9.          Payroll Deductions.

9.1          Subject to Section 10, a Participant may elect payroll deductions from that Participant’s Current Compensation in whole percentages from one percent (1%) to fifteen percent (15%), or such lower limit as may be set by the Committee from time to time. Such payroll deductions shall commence on the first payday within the applicable Offering Period, provided an Eligible Employee has timely completed and delivered the enrollment form to the Human Resources Department in the manner set forth in Section 6 and shall continue until earlier of any of the following: (i) the date this Plan is terminated or suspended, (ii) the date such Participant’s participation in this Plan is terminated or suspended under Section 11, or (iii) the date such Participant withdraws from this Plan. No interest shall accrue or be paid by the Company or Participating Company on the payroll deductions of a Participant in this Plan.

9.2          Payroll deductions will be credited to each Participant’s payroll deduction account every pay period.

9.3          A Participant may not affect an increase or decrease in the rate of payroll deductions during an Offering Period, other than to submit a withdrawal from the Plan in accordance with Section 11.

9.4          A Participant may elect to increase or decrease his or her rate of payroll deductions for a subsequent Offering Period by completing and delivering, prior to the commencement of such Offering Period, an Election Change Form (seeExhibit A attached hereto) to the Human Resources Department which authorizes such changes to payroll deductions from the Participant’s Current Compensation in the manner set forth in Section 6. A Participant’s change to his or her payroll deduction will take effect no later than the payday following the Offering Date to which it relates. Participants may only change their deductions at the commencement of a new Offering Period and may not increase or decrease their deductions in the middle an Offering Period, except by completely withdrawing from this Plan. If a Participant is enrolled in an Offering Period in one year and takes no further action regarding his or her election related to the following year, the Participant will automatically be enrolled in the next annual Offering Period (January 1 to December 31) with the same level of payroll deduction as in the preceding year.

9.5          All funds withheld from a Participant’s Current Compensation in accordance with this Plan shall be credited to such Participant’s payroll deduction account. Unless required by law, a Participant may not make any separate payments or contributions into his or her payroll deduction account. All payroll deductions made for a Participant are credited to his or her payroll deduction account under this Plan and are deposited with the general funds of the Company or the Participating Company by which the Participant is employed. No interest accrues on any such payroll deductions. The Company may use all payroll deductions received or held by the Company for any corporate purpose, and the Company shall not be obligated to segregate such payroll deductions.


10.        Limitations on Shares to be Purchased.

10.1         No Participant shall be entitled to vote, amended Article V(A)purchase shares of its Restated ArticlesCommon Stock under this Plan with a Fair Market Value that exceeds $25,000, as determined as of Incorporationthe Offering Date (or such other limit as may be imposed by the Code), in any calendar year in which such Participant participates in this Plan. The Company shall automatically suspend the payroll deductions of any Participant as necessary to readenforce such limit provided that when the Company automatically resumes such payroll deductions, the Company must apply the payroll deduction percentage in effect immediately prior to such suspension.

10.2         Except as otherwise determined by the Committee prior to the Offering Date of any Offering Period, the aggregate number of shares that may be purchased by an individual Participant on the Purchase Date of an Offering Period shall not exceed fifteen thousand (15,000) shares.

10.3         If the number of shares of Common Stock to be purchased on a Purchase Date by all Participants exceeds the number of shares then available for issuance under this Plan, then the Company will make apro rata allocation of the remaining shares of Common Stock in as uniform manner as shall be reasonably practicable and as the Committee shall determine to be equitable. In such event, the Company shall give written notice of such reduction of the number of shares to be purchased to each Participant affected.

10.4         Any funds in a Participant’s payroll deduction account which are not used to purchase shares of Common Stock due to the limitations in this Section 10 shall be returned to such Participant as soon as practicable after the Purchase Date without interest.

11.        Termination and Suspension of Participation.

11.1         Withdrawal. A Participant may at any time cease making any further payroll deductions by withdrawing from this Plan by completing and delivering a Withdrawal Notice Form (seeExhibit A attached hereto) to the Human Resources Department provided that such Withdrawal Notice Form is received by the Human Resources Department at least five (5) Business Days before the next Purchase Date. Payroll deductions shall cease effective as of the next payroll period payday following the date the Human Resources Department receives such Withdrawal Notice Form. Upon withdrawal from this Plan, the balance of such Participant’s payroll deduction account shall be returned to such Participant as soon as practicable, without interest, and his or her participation in this Plan shall automatically and immediately terminate. In the event a Participant elects to withdraw from this Plan, he or she may not resume his or her participation in this Plan during the calendar year in which he or she withdrew, but he or she may elect to participate in any subsequent calendar year by filing a new Election to Participate Form as set forth below,in Section 6.

11.2         Termination of Employment. Termination of a Participant’s employment for any reason, including retirement or death, or the failure of a Participant to remain an Eligible Employee, immediately and automatically terminates his or her participation in this Plan. In such event, the payroll deductions credited to such Participant’s payroll deduction account shall be returned to him or her or, in the case of his or her death, to his or her designated beneficiary, in either case, without interest.

11.3         Leaves of Absence. A Participant who is placed on military, sick or other bona fide leave of absence and paid by votethe Company will continue participation in this Plan, unless such Participant elects to withdraw from this Plan in accordance with this Section 11. Notwithstanding the foregoing, if (i) any Participant is placed on military, sick or other bona fide leave of [ ] shares for, [ ] shares against, and [ ] shares abstained ([ ] shares being present atabsence, (ii) the meeting for purposesperiod of such vote)leave exceeds three (3) calendar months, and (iii) the participant’s right to reemployment with the Company is not provided by statute or contract, then such Participant’s participation in the Plan will immediately and automatically be terminated. In the event of such termination from this Plan, the payroll deductions credited to such Participant’s payroll deduction account shall be returned to him or her without interest. The employee may again be eligible to participate in this Plan with the next Offering Period after he or she returns to active employment. Employees returning from a leave of absence who had withdrawn from this Plan or whose participation in this Plan was terminated during the leave must complete and deliver an Election to Participate Form to the Human Resources Department in accordance with Section 6 to resume participation.


11.4         401(k) Hardship Withdrawal. ARTICLE V AUTHORIZED CAPITAL A. The CorporationIf a Participant makes a hardship withdrawal from any qualified retirement plan intended to satisfy section 401(k) of the Code, which is sponsored or participated in by the Company or any Subsidiary, such Participant’s payroll deductions under this Plan shall be automatically terminated from the date of such withdrawal, and the Company shall deliver to the Participant the then balance of such Participant’s payroll deduction account as soon as reasonably practicable without interest. A Participant may resume participation in this Plan on the first Offering Period that begins at least six months after the date of the hardship withdrawal, by authorizing payroll deductions in accordance with Section 9.

12.        Termination and Suspension of this Plan by the Company.

12.1         Right of the Company. This Plan is entirely voluntary on the part of the Company and any Participating Company and the continuance of this Plan shall not be construed as a contractual obligation of the Company or any Participating Company. Accordingly, the Company reserves the right to terminate or suspend this Plan at any time. Unless terminated earlier by the Company, this Plan shall terminate on the date all of the shares of Common Stock specified in Section 2 are purchased under this Plan unless additional shares of Common Stock are authorized and reserved for this Plan by the Board and stockholders of the Company.

12.2         Rights upon Termination or Suspension. If this Plan is terminated or suspended, the Committee may elect in its sole discretion to either (i) complete the purchase of shares of Common Stock on the next Purchase Date following the date of termination or date of suspension of this Plan or (ii) deliver to each Participant the then balance of such Participant’s payroll deduction account, if any, without interest, as soon as reasonably practicable following the date of termination or date of suspension of this Plan (or any combination of clauses (i) and (ii) as the Committee may elect in its sole discretion). In either case, no Participant shall have any right to acquire shares of Common Stock (other than under clause (i)) under this Plan. If this Plan is terminated, the participation of all Participants shall terminate immediately as of the date of termination of this Plan.

13.        Corporate Transaction.

13.1         Adjustment in Event of Corporate Transaction. The number of shares available for issuance under this Plan or during any Offering Period, the Purchase Price and the number of shares of Common Stock covered by each right to purchase shares of Common Stock under this Plan which have not yet been exercised shall be equitably adjusted by the Committee to reflect any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that affects the number or kind of shares of Common Stock outstanding. Such adjustment shall be made by the Committee, whose determination shall be final, binding and conclusive. The Committee shall have the authority to issue an aggregateadjust not only the number of 150,000,000securities, but also the class and kind of securities subject to this Plan and to make appropriate adjustments in the price of such securities if other than shares of common stock, no par value per share. These ArticlesCommon Stock of Amendment are dated June [ ], 2004. AKORN, INC. By: --------------------------------------- Arthur S. Przybyl Presidentthe Company, so long as any such action complies with applicable law.

13.2         Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the Offering Period then in progress shall be shortened by setting a new Purchase Date (the “New Purchase Date”), and CEO By: --------------------------------------- Ben J. Pothast Secretary A-1 APPENDIX B AKORN, INC. 2003 STOCK OPTION PLAN 1. Purpose. Thisshall terminate immediately prior to the consummation of such proposed dissolution or liquidation, unless provided otherwise by the Committee. The New Purchase Date shall be before the date of the Company’s proposed dissolution or liquidation. The Company shall notify each Participant, at least ten (10) business days prior to the New Purchase Date, that the Purchase Date for the Participant’s right to purchase shares of Common Stock Option Plan (the "Plan") is intendedhas been changed to servethe New Purchase Date and that the Participant’s right to purchase shares of Common Stock shall be exercised automatically on the New Purchase Date on such terms as an incentive to, and to encourage stock ownership by, certain eligible participants rendering services to Akorn, Inc., a Louisiana corporation, and certain affiliates asotherwise set forth below (the "Corporation"), soin this Plan.

13.3         Asset Sale or Other Transaction. In the event of a sale of all or substantially all of the assets of the Company, or the merger, consolidation or similar transaction involving the Company with or into


another corporation in which the Company is not the surviving, controlling corporation, each outstanding right to purchase shares of Common Stock shall be assumed or an equivalent right to purchase shares of Common Stock substituted by the successor corporation or a parent or subsidiary of the successor corporation. In the event that theythe successor corporation refuses to assume or substitute for the right to purchase shares of Common Stock, the Offering Period then in progress shall be shortened by setting a New Purchase Date. The New Purchase Date shall be at least fifteen (15) days prior to the date of the transaction described in this Section 13.3 is consummated. The Company shall notify each Participant, at least ten (10) business days prior to the New Purchase Date, that the Purchase Date for the Participant’s right to purchase shares of Common Stock has been changed to the New Purchase Date and that the Participant’s right to purchase shares of Common Stock shall be exercised automatically on the New Purchase Date on such terms as otherwise set forth in this Plan.

13.4         Authority. The existence of this Plan and any right to purchase shares of Common Stock granted hereunder shall not affect in any way the right and power of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in its capital structure or business structure, any merger or consolidation, any issuance of debt, preferred or prior preference stock ahead of or affecting the shares of Common Stock, additional shares of capital stock or other securities or subscription rights thereto, any dissolution or liquidation, any sale or transfer of all or part of its assets or business or any other corporate act or proceeding.

14.        Nonassignability. Any rights with regard to elect to purchase shares of Common Stock under this Plan or to receive shares of Common Stock under this Plan may acquirenot be assigned, transferred, pledged or increase their proprietary interestotherwise disposed of in any way (other than by will, the Corporationlaws of descent and distribution) by the Participant and shall not be subject to encourage themexecution, attachment or similar process. Any such attempt at assignment, transfer, pledge or other disposition, or levy of attachment or similar process shall be void and without effect. No amount in a Participant’s payroll deduction account may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution) by the Participant and any such attempt at assignment, transfer, pledge or other disposition shall be void and without effect.

15.        Reports.Individual records will be maintained for each Participant in this Plan. Promptly after the end of each calendar year, a report with information regarding the Participant’s participation for that year shall be made available to such Participant electronically or otherwise.

16.        No Rights to Continued Employment. Notwithstanding anything to the contrary herein, neither this Plan nor any Eligible Employee’s participation in this Plan shall confer any right on any employee of the Company or any Subsidiary to remain in the serviceemploy of the Corporation. 2. Administration. 2.1 Committee. TheCompany or any Subsidiary, or restrict the right of the Company or any Subsidiary to terminate such employee’s employment.

17.        Equal Rights and Privileges. All Eligible Employees shall have equal rights and privileges with respect to this Plan, within the meaning of Section 423 of the Code and the Treasury Regulations issued thereunder.

18.        Notices. All notices or other communications by a Participant to the Company or Participating Company under or in connection with this Plan shall be administereddeemed to have been duly given when received in the form specified by the Company or any Subsidiary, if any, at the location, or by the person, designated by the Company or any Subsidiary for the receipt thereof.

19.        Term. This Plan shall be effective upon approval by the stockholders of the Company and shall continue until the earlier of (a) termination of this Plan by the Committee in accordance with this Plan, or (b) issuance of all of the shares of Common Stock reserved for issuance under this Plan.

20.        Designation of Beneficiary.

20.1           At Participant’s time of hire with the Company, Participant will be asked to complete and deliver electronically a designation of a beneficiary with the Human Resources Department. By completion of that form, the Participant will be designating who is to receive any shares of Common Stock and cash, if any, from his or her payroll deduction account in the event of such Participant’s death after a Purchase Date but before delivery by the Company to him or her of such shares and cash, if any. Such designation of beneficiary form will also be used to


identify for the Human Resources Department who is to receive the balance of such Participant’s payroll deduction account in the event of such Participant’s death prior to a Purchase Date. A Participant may change the designation of any such beneficiary at any time by electronically completing and delivering online a new designation of a beneficiary with the Human Resources Department.

20.2           In the event of the death of a Participant and in the absence of a completed and signed designation of a beneficiary with the Human Resources Department who is then living at the time of such Participant’s death, the Company shall deliver any shares of Common Stock or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.

21.        Compliance with Laws. Shares of Common Stock shall not be issued with respect to this Plan unless the issuance and delivery of such shares pursuant to this Plan shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any stock exchange or automated quotation system upon which such shares may then be listed, and shall be further subject to the approval of counsel for the Company with respect to such compliance.

22.        Applicable Law. This Plan shall be governed by the substantive laws (excluding the conflict of laws rules) of the State of Illinois.

23.        Amendment of this Plan. This Plan may be amended by the Board but no amendment may have the effect of modifying a Participant’s election to participate with respect to funds previously withheld, without the consent of such Participant. In addition, the stockholders of the Company must approve any amendment to this Plan which (i) increases the number of shares of Common Stock which may be acquired through this Plan, (ii) changes the definition of Common Stock, (iii) materially increases the benefits accruing to Participants in this Plan, or (iv) materially modifies requirements for eligibility for participation in this Plan.

Approved [_________], 2016


Exhibit A

Employee Stock Purchase Plan - Administration Form

See attached form which is used as

Election to Participate Form,

Election Change Form,

and

Withdrawal Notice Form


Akorn, Inc.

Employee Stock Purchase Plan – Administration Form

Changes to the Employee Stock Purchase Plan payroll deduction may only be made at the beginning of the annual offering period. You may withdraw at any time.Please return to Human Resources or fax to Elaine Dillon, Benefits Manager at 847/353-4920.

1.Participant Information

Name:     FirstMiddle InitialLast

Street Address

CityStateZip Code

2.Enrollment

I would like to participate in the Akorn, Inc. employee Stock Purchase Plan. Please make a payroll deduction of % of my gross compensation from my pay check. I understand that my deduction cannot exceed 15% of my annual gross salary or $21,250.00 in total.(Note: deduction elections must be in whole percentages from 1% to 15%.)

 I wish to enroll in the offering period from [January 1][July 1] thru December 31.

DateSignature

3.Change Percentage(Changes to percentage amounts may only be made at the beginning of the next annual offering period, which begins January 1st.)

I am currently enrolled in the Employee Stock Purchase Plan. Please change my current payroll deduction to _____% effective January 1.

DateSignature

4.Withdrawal from Plan

I wish to withdraw from the Employee Stock Purchase Plan.

   I wish to cease participation in the upcoming year 2015.

I wish to withdrawal from the plan as soon as administratively possible and receive a full refund of my year to date contributions for 2014.

DateSignature


Appendix B

See attached for Amended and Restated Akorn, Inc. 2014 Stock Option Plan

AMENDED AND RESTATED

AKORN, INC.

2014 STOCK OPTION PLAN

(AKORN LOGO)

TABLE OF CONTENTS

       
      Page
ARTICLE 1  
PURPOSE OF THE PLAN 1
   
ARTICLE 2  
DEFINITIONS 1
 2.1 “409A Awards” 1
 2.2 “Administrator” 1
 2.3 “Affiliate” 1
 2.4 “Applicable Laws” 1
 2.5 “Award” 1
 2.6 “Award Agreement” 1
 2.7 “Awarded Stock” 1
 2.8 “Beneficial Owner” 1
 2.9 “Board” 1
 2.10 “Cause” 1
 2.11 “Change in Control” 2
 2.12 “Code” 2
 2.13 “Committee” 2
 2.14 “Common Stock” 2
 2.15 “Consultant” 2
 2.16 “Corporation” 2
 2.17 “Director” 2
 2.18 “Disability” 2
 2.19 “Effective Date” 2
 2.20 “Employee” 3
 2.21 “Exchange Act” 3
 2.22 “Exchange Program” 3
 2.23 “Fair Market Value” 3
 2.24 “Fiscal Year” 3
 2.25 “Incentive Stock Option” 3
 2.26 “Non-Qualified Stock Option” 3
 2.27 “Officer” 3
 2.28 “Option” 3
 2.29 “Other Stock Based Awards” 3
 2.30 “Outside Director” 3
 2.31 “Participant” 4
 2.32 “Performance Period” 4
 2.33 “Performance Share” 4
 2.34 “Performance Unit” 4
 2.35 “Period of Restriction” 4
 2.36 “Plan” 4
 2.37 “Restricted Stock” 4
 2.38 “Restricted Stock Unit” 4
 2.39 “Rule 16b-3” 4
 2.40 “Service Provider” 4
 2.41 “Share” 4
 2.42 “Stock Appreciation Right” or “SAR” 4
 2.43 “Substitute Awards” 4
 2.44 “Unrestricted Stock” 4

      
ARTICLE 3  
PLAN ADMINISTRATION5
 3.1 Procedure 5
 3.2 Powers of the Administrator 5
 3.3 Effect of Administrator’s Decision 6
      
ARTICLE 4  
STOCK SUBJECT TO THE PLAN 6
 4.1 Stock Subject to the Plan 6
 4.2 Lapsed Awards 7
 4.3 Adjustments for Changes in Capitalization and Similar Events 7
 4.4 Substitute Awards 7
      
ARTICLE 5  
PARTICIPATION 8
 5.1 Eligibility 8
 5.2 Termination of Participation 8
      
ARTICLE 6  
STOCK OPTIONS 8
 6.1 Option Grant 8
 6.2 Exercise Price 9
 6.3 Waiting Period and Exercise Dates 9
 6.4 Exercise of Option 9
 6.5 Form of Consideration 10
      
ARTICLE 7  
RESTRICTED STOCK 10
 7.1 Grant of Restricted Stock 10
 7.2 Restricted Stock Agreement 11
 7.3 Transferability 11
 7.4 Removal of Restrictions 11
 7.5 Voting Rights 11
 7.6 Dividends and Other Distributions 11
 7.7 Return of Restricted Stock to Corporation 11
      
ARTICLE 8  
UNRESTRICTED STOCK 11
   
ARTICLE 9  
STOCK APPRECIATION RIGHTS 11
 9.1 Grant of SARs 11
 9.2 Number of Shares 11
 9.3 Exercise Price and Other Terms 11
 9.4 SAR Agreement 11
 9.5 Expiration of SARs 12
 9.6 Payment of SAR Amount 12
 9.7 Buyout Provisions 12
      
ARTICLE 10  
PERFORMANCE UNITS AND PERFORMANCE SHARES 12
 10.1 Grant of Performance Units/Shares 12
 10.2 Value of Performance Units/Shares 12
 10.3 Performance Objectives and Other Terms 12
 10.4 Performance Measures 12
 10.5 Earning of Performance Units/Shares 12

ii 

 10.6 Form and Timing for Payment of Performance Units/Shares 13
 10.7 Cancellation of Performance Units/Shares 13
      
ARTICLE 11  
RESTRICTED STOCK UNITS 13
 11.1 Grant of Restricted Stock Units 13
 11.2 Restricted Stock Unit Agreement 13
 11.3 Settlement; Forfeiture 13
 11.4 Transferability 13
 11.5 Voting Rights 13
 11.6 Dividends and Other Distributions 13
      
ARTICLE 12  
OTHER STOCK BASED AWARDS 13
   
ARTICLE 13  
DISSOLUTION OR LIQUIDATION, OR CHANGE IN CONTROL 14
 13.1 Dissolution or Liquidation 14
 13.2 Change in Control 14
      
ARTICLE 14  
MISCELLANEOUS PROVISIONS 14
 14.1 No Uniform Rights to Awards 14
 14.2 Share Certificates 14
 14.3 No Rights as a Service Provider 14
 14.4 No Rights as Shareholder 14
 14.5 No Trust or Fund Created 15
 14.6 No Fractional Shares 15
 14.7 Requirement of Consent and Notification of Election Under Code § 83(b) or Similar Provision 15
 14.8 Requirement of Notification Upon Disqualifying Disposition Under Code § 421(b) 15
 14.9 Leaves of Absence 15
 14.10 Notices 15
 14.11 Non-Transferability of Awards 15
 14.12 Date of Grant 15
 14.13 Amendment and Termination of Plan 16
 14.14 Conditions Upon Issuance of Shares 16
 14.15 Severability 16
 14.16 Inability to Obtain Authority 16
 14.17 Shareholder Approval 16
 14.18 Governing Law 16
 14.19 Section 409A 16

iii 

AMENDED AND RESTATED

AKORN, INC. 2014 STOCK OPTION PLAN

ARTICLE 1

PURPOSE OF THE PLAN

The purpose of this Amended and Restated Akorn, Inc. 2014 Stock Option Plan is to promote the interests of Akorn, Inc. and its shareholders by: (i) attracting and retaining exceptional Directors, Employees and Consultants (including prospective Directors, Employees and Consultants) of the Corporation, and (ii) enabling such individuals to participate in the long-term growth and financial success of the Corporation.

Accordingly, the Plan provides for the granting of Incentive Stock Options, Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted Stock Awards, Restricted Stock Units, Stock Appreciation Rights, Performance Unit Awards, Performance Share Awards, and Other Stock Based Awards.

ARTICLE 2
DEFINITIONS

2.1          “409A Awardshas the meaning set forth in Section 14.19 of the Plan.

2.2          “Administratormeans the Board, the Committee, or any Officer or Employee of the Corporation to whom the Board or the Committee has delegated authority to administer the Plan.

2.3          “Affiliatemeans a “parent” or “subsidiary” corporation as defined in Code §§ 424(e) and (f), or that the Board has designated as participating in the Plan.

2.4          “Applicable Lawsmeans the requirements relating to the administration of equity-based awards or equity compensation plans under U.S. federal and state laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted, and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.

2.5          “Awardmeans, individually or collectively, a grant under the Plan of Incentive Stock Options, Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted Stock Awards, Restricted Stock Units, Stock Appreciation Rights, Performance Unit Awards, Performance Share Awards or Other Stock Based Awards.

2.6          “Award Agreementmeans the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan.

2.7          “Awarded Stockmeans the Shares subject to an Award.

2.8          “Beneficial Ownerhas the meaning set forth in Rule 13d-3 of the Exchange Act, provided that the exercise of voting rights by a nominee or proxy holder of the Board in connection with a meeting or proposed action by shareholders of the Corporation shall not be deemed to constitute such ownership and any ownership or voting power of the trustee under an employee benefit plan of the Corporation shall not be deemed to constitute such ownership.

2.9          “Boardmeans the Board of Directors of the Corporation.

2.10        “Causehas the meaning set forth in Section 5.2(a) of the Plan.

2.11        “Change in Controlmeans, unless otherwise defined under Code § 409A and reflected in the Award Agreement, the occurrence of any of the following events:

(a)          the consummation of a merger or consolidation of the Corporation (the "Boardwith any other entity which thereby becomes the Beneficial Owner of Directors"), or a committeemore than 50% of two or morethe outstanding “Voting Securities” (defined as securities the holders of which are entitled to vote for the election of Directors) of the surviving entity;

(b)          Directors who were members appointed byof the Board of Directors (the "Committee") who are independent directors under Nasdaq Marketplace Rules and an outside director as defined in Treasury Regulation Section 1.162-27(e)(3). The Committee shall select one of its members as Chairman and shall appointimmediately prior to a Secretary, who need not be a membermeeting of the Committee. The Committee shall hold meetingsshareholders of the Corporation which meeting involves a contest for the election of at such times and places as it may determine and minutes of such meetings shall be recorded. Acts byleast one directorship, do not constitute at least a majority of the Committee inDirectors following such meeting or election;

(c)          an acquisition, directly or indirectly, of more than 50% of the outstanding shares of any class of “Voting Securities” of the Corporation by any “Person”;

(d)          the shareholders of the Corporation approve a meeting at whichsale of all or substantially all of the assets of the Corporation or the liquidation of the Corporation; OR

(e)          there is a quorum is present and acts approved in writing bychange, during any period of two consecutive years or less of a majority of the membersBoard as constituted as of the Committee shall be valid actsbeginning of such period, unless the election of each Director who is not a Director at the beginning of such period was approved by a vote of at least two-thirds of the Committee. 2.2 Term. IfDirectors then in office who were Directors at the Board of Directors selects a Committee, the membersbeginning of the Committeeperiod.

Notwithstanding the foregoing, a Change in Control shall serve onnot be deemed to have occurred in the Committee forevent the periodCorporation forms a holding company as a result of time determined bywhich the Board of Directors and shall be subject to removal by the Board of Directors at any time. The Board of Directors may terminate the functionholders of the Committee at any time and resume all powers and authority previously delegatedCorporation’s “Voting Securities” immediately prior to the Committee. 2.3 Authority. The Committee shall have sole discretion and authority to grant options undertransaction, hold, in approximately the Plan to eligible participants rendering servicessame relative proportions as they held prior to the Corporation or any "parent" or "subsidiary"transaction, substantially all of the Corporation ("Parent or Subsidiary"), as defined in Section 424“Voting Securities” of a holding company owning all of the Corporation’s “Voting Securities” after the completion of the transaction.

2.12        “Codemeans the Internal Revenue Code of 1986, as amended, (the "Code")and the Treasury regulations promulgated thereunder. Any reference to a section of the Code herein will be a reference to any successor or amended section of the Code.

2.13        “Committeemeans a committee of Directors or other individuals satisfying Applicable Laws and appointed by the Board in accordance with Article 3 of the Plan. If the Committee is comprised of two Directors, both Directors shall be “non-employee directors” as that term is defined in Rule 16b-3.

2.14        “Common Stockmeans the Common Stock of the Corporation, or in the case of Awards not based on Shares, the cash equivalent thereof.

2.15        “Consultantmeans any person, including an advisor, engaged by the Corporation or an Affiliate to render services to such entity.

2.16        “Corporationmeans Akorn, Inc., at such times,a Louisiana corporation.

2.17        “Directormeans a member of the Board.

2.18        “Disabilitymeans, unless otherwise defined under suchCode § 409A and reflected in the Award Agreement, total and permanent disability as defined in Code § 22(e)(3), provided that in the case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform and non-discriminatory standards adopted by the Administrator from time to time.

2.19        “Effective Datemeans December 30, 2013.


2.20        “Employeemeans any person, including Officers and Directors, employed by the Corporation or an Affiliate. Neither service as a Director nor payment of a director’s fee by the Corporation will be sufficient to constitute “employment” by the Corporation.

2.21        “Exchange Actmeans the Securities Exchange Act of 1934, as amended.

2.22        “Exchange Programmeans a program under which (i) outstanding Awards are surrendered or cancelled in exchange for Awards of the same type (which may have lower exercise prices and different terms), Awards of a different type, and/or cash; or (ii) the exercise price of an outstanding Award is reduced. The terms and conditions of any Exchange Program will be determined by the Administrator.

2.23        “Fair Market Valuemeans, as of any date and unless the Administrator determines otherwise, the value of Common Stock determined as follows:

(a)          If the Common Stock is listed on any established stock exchange or a national market system, including, without limitation, the NASDAQ Global Select Market of the NASDAQ Stock Market, its Fair Market Value will be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or system for the day of determination, as reported in The Wall Street Journal or such amountsother source as the Administrator deems reliable;

(b)          If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a Share of Common Stock will be the mean between the high bid and low asked prices for the Common Stock for the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or

(c)          In the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator.

Notwithstanding the preceding, for federal, state, and local income tax reporting purposes and for such other purposes as the Administrator deems appropriate, the Fair Market Value shall be determined by the Administrator in accordance with uniform and nondiscriminatory standards adopted by it from time to time.

2.24        “Fiscal Yearmeans the fiscal year of the Corporation.

2.25        “Incentive Stock Optionmeans an Option intended to qualify as an incentive stock option within the meaning of Code § 422 and the Treasury regulations promulgated thereunder.

2.26        “Non-Qualified Stock Optionmeans an Option that by its terms does not qualify, or is not intended to qualify, as an Incentive Stock Option.

2.27        “Officermeans a person who is an officer of the Corporation within the meaning of § 16 of the Exchange Act and the rules and regulations promulgated thereunder.

2.28        “Optionmeans an Incentive Stock Option or a Non-Qualified Stock Option or both, as the context requires.

2.29        “Other Stock Based Awardsmeans any other awards not specifically described in the Plan that are valued in whole or in part by reference to, or are otherwise based on, Shares and are created by the Administrator pursuant to Article 12. Other Stock Based Awards may decide.include, without limitation, other Awards that represent an unfunded and unsecured promise to deliver Shares, cash, other securities or other property following a specified passage of time or period of service, the satisfaction of predetermined individual or Corporation performance goals and/or objectives or otherwise in accordance with the terms of the applicable Award Agreement.

2.30        “Outside Directormeans a Director who either: (i) is not a current Employee of the Corporation or an “affiliated corporation” (within the meaning of the Treasury regulations promulgated under Code § 162(m)), is


not a former employee of the Corporation or an “affiliated corporation” receiving compensation for prior services (other than benefits under a tax-qualified retirement plan), was not an officer of the Corporation or an “affiliated corporation” at any time, and is not currently receiving direct or indirect remuneration (within the meaning of the Treasury regulations promulgated under Code § 162(m)) from the Corporation or an “affiliated corporation” for services in any capacity other than as a Director; or (ii) is otherwise considered an “outside director” for purposes of Code § 162(m).

2.31        “Participantmeans the holder of an outstanding Award granted under the Plan.

2.32        “Performance Periodhas the meaning set forth in Section 10.3 of the Plan.

2.33        “Performance Sharemeans, pursuant to Article 10, an Award granted to a Service Provider under which, upon the satisfaction of predetermined individual or Corporation performance goals and/or objectives, shares of Common Stock are paid to the Participant.

2.34        “Performance Unitmeans, pursuant to Article 10, an Award granted to a Service Provider under which, upon the satisfaction of predetermined individual or Corporation performance goals and/or objectives, a cash payment shall be paid to the Participant based on the number of “units” awarded to the Participant. For purposesthis purpose, the term “unit” means bookkeeping units, each of which represents such monetary amount as shall be designated by the Administrator in each Award Agreement.

2.35        “Period of Restrictionmeans the period during which the transfer of Shares of Restricted Stock are subject to restrictions. Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.

2.36        “Planmeans the Akorn, Inc. 2014 Stock Option Plan, as amended from time to time.

2.37        “Restricted Stockmeans shares of Common Stock issued pursuant to a Restricted Stock Award under the Plan or issued pursuant to the early exercise of an Option.

2.38        “Restricted Stock Unitmeans an Award of an unfunded and unsecured promise to deliver Shares, cash, other securities or other property, subject to certain specified restrictions, granted under Article 11 of the Plan.

2.39        “Rule 16b-3means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when discretion is being exercised with respect to the Plan.

2.40        “Service Providermeans an Employee, Director or Consultant.

2.41        “Sharemeans a share of the Common Stock, as adjusted in accordance with Section 4.3 and Article 14 of the Plan.

2.42        “Stock Appreciation RightorSARmeans an Award that is designated as a SAR, and represents an unfunded and unsecured promise to deliver Shares, cash, other securities, other Awards or other property equal in value to the excess, if any, of the Fair Market Value per Share over the exercise price per Share of the SAR, subject to the terms of the applicable Award Agreement.

2.43        “Substitute Awardshas the meaning set forth in Section 4.4 of the Plan.

2.44        “Unrestricted Stockhas the meaning set forth in Article 8 of the Plan.


ARTICLE 3
PLAN ADMINISTRATION

3.1         Procedure.

(a)          Board’s Delegation.The Board may delegate administration of the Plan to a Committee or multiple Committees. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers possessed by the Board, subject, however, to such resolutions, not inconsistent with the provisions of this Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and vest in the Board the administration of the Plan. Different Committees with respect to different groups of Service Providers may administer the Plan.

(b)          Code § 162(m).To the extent that the Administrator determines it to be desirable and necessary to qualify Awards granted hereunder as “performance-based compensation” within the meaning of Code § 162(m), the Plan will be administered by a Committee of two or more Outside Directors.

(c)          Rule 16b-3.To the extent desirable to qualify transactions hereunder as exempt under Rule 16b-3, the transactions contemplated hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3.

(d)          Other Administration.Other than as provided above, the Plan will be administered by: (i) the Board, or (ii) a Committee, which committee will be constituted to satisfy Applicable Laws.

(e)          Delegation of Authority for Day-to-Day Administration.Except to the extent prohibited by Applicable Law, the Administrator may delegate to one or more individuals the day-to-day administration of the Plan and any Stock Option Agreement (as defined below),of the term "Corporation" shall includefunctions assigned to it in this Plan. Such delegation may be revoked at any Parent or Subsidiary, if applicable.time.

3.2         Powers of the Administrator. Subject to the express provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion:

(a)          To determine the Fair Market Value;

(b)          To select the Service Providers to whom Awards may be granted hereunder;

(c)          To determine the number of Shares to be covered by each Award granted hereunder;

(d)          To approve forms of agreement for use under the Plan;

(e)          To determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture or repurchase restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine in its sole discretion;

(f)          Subject to shareholder approval, to reduce the exercise price of any Award to the then current Fair Market Value if the Fair Market Value of the Common Stock covered by such Award shall have complete authoritydeclined since the date the Award was granted;

(g)          Subject to shareholder approval, to institute an Exchange Program;


(h)          To construe and interpret the terms of the Plan and Awards granted pursuant to the Plan, and to establish, amend and revoke rules and regulations for its administration;

(i)           To prescribe, amend and rescind the rules and regulations relating to the Plan, including rules and regulations relating to determinesub-plans established for the details and provisionspurpose of satisfying applicable foreign laws and/or qualifying for preferred tax treatment under applicable foreign tax laws;

(j)           To modify or amend each Award (subject to the amendment terms thereof), including the discretionary authority to extend the post-termination exercise period of Awards longer than is otherwise provided for in the Plan;

(k)          To allow Participants to satisfy withholding tax obligations by electing to have the Corporation withhold from the Shares or cash to be issued upon exercise or vesting of an Award that number of Shares or cash having a Fair Market Value equal to the minimum amount required to be withheld. The Fair Market Value of any Shares to be withheld will be determined on the date that the amount of tax to be withheld is to be determined. All elections by a Participant to have Shares or cash withheld for this purpose will be made in such form and under such conditions as the Administrator may deem necessary or advisable;

(l)            To authorize any person to execute on behalf of the Corporation any instrument required to affect the grant of an Award previously granted by the Administrator;

(m)          To allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that would otherwise be due to such Participant under an Award;

(n)           To determine whether Awards will be settled in Shares, cash or in any combination thereof;

(o)           To create Other Stock Option Agreement, to accelerate any options grantedBased Awards for issuance under the PlanPlan;

(p)           To establish a program whereby Service Providers designated by the Administrator can reduce compensation otherwise payable in cash in exchange for Awards under the Plan;

(q)          To impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any re-sales by a Participant or other subsequent transfers by the Participant of any Shares issued as a result of or under an Award, including, without limitation, (i) restrictions under an insider trading policy, and (ii) restrictions as to the use of a specified brokerage firm for such re-sales or other transfers; and

(r)          To make all other determinations deemed necessary or advisable for the administration ofadministering the Plan. 2.4 Type

3.3         Effect of Option.Administrator’s Decision. The Committee shall have full authority and discretion to determine, and shall specify, whether the eligible individual will be granted options intended to qualify as incentive options under Section 422 of the Code ("Incentive Options") or options which are not intended to qualify under Section 422 of the Code ("Non-Qualified Options"); provided, however, that Incentive Options shall only be granted to employees of the Corporation, or a Parent or Subsidiary thereof, andAdministrator’s decision shall be subjectbinding on Participants and any other holders of Awards.

ARTICLE 4
STOCK SUBJECT TO THE PLAN

4.1         Stock Subject to the special limitations set forth herein attributablePlan. Subject to Incentive Options. 2.5 Interpretation. The interpretationthe provisions of this Article 4 and construction by the Committee of any provisionsArticle 14 of the Plan, orthe maximum aggregate number of any optionShares that may be issued under the Plan is 7,500,000. Subject to the provisions of this Article 4 and Article 14 of the Plan, the following special limits apply to Shares available to Awards under the Plan: (i) the maximum number of Shares that may be delivered pursuant to Incentive Stock Options granted under the Plan shall be final and binding on all parties having an interest1,500,000; (ii) the maximum aggregate number of Shares that may be issuable or deliverable under Options or SARs granted in this Plan or any option granted hereunder. No member of the Committeecalendar year to any one Participant shall be liable for2,000,000 Shares; and (iii) with


respect to Awards intended to qualify as “performance-based compensation” within the meaning of Code § 162(m) (other than Options or SARs), the maximum aggregate number of Shares that may be issuable or deliverable under such Awards granted in any actioncalendar year to any one Participant shall be 2,000,000 Shares or, determination made in good faith with respect to Awards denominated in cash, $3,000,000 (measured as of the date of grant). In addition, subject to the provisions of this Article 4 and Article 14 of the Plan, the maximum aggregate number of Shares that may be issuable or deliverable under Awards granted in any option grantedcalendar year to any one Director shall be 200,000 Shares plus cash in an amount not to exceed $250,000. The Shares may be authorized and unissued, or reacquired Common Stock. Shares shall not be deemed to have been issued pursuant to the Plan with respect to any portion of an Award that is paid in cash. Upon payment in Shares pursuant to the exercise of an Award, the number of Shares available for issuance under the Plan shall be reduced only by the number of Shares actually issued in such payment. If a Participant pays the exercise price (or purchase price, if applicable) of an Award through the tender of Shares, or if Shares are tendered or withheld to satisfy any Corporation withholding tax obligations, the number of Shares so tendered or withheld shall again be available for issuance pursuant to future Awards under the Plan. B-1 3. Eligibility. 3.1 General. All directors, officers, employees of and consultants

4.2          Lapsed Awards. If any outstanding Award expires or is terminated or cancelled without having been exercised or settled in full, or if Shares acquired pursuant to an Award subject to forfeiture or repurchase are forfeited or repurchased by the Corporation, the Shares allocable to the Corporation,terminated portion of such Award or any Parentsuch forfeited or Subsidiary relative to the Corporation's, or any Parent's or Subsidiary's management, operation or developmentrepurchased Shares shall again be eligible to receive optionsavailable for grant under the Plan. The selection

4.3          Adjustments for Changes in Capitalization and Similar Events. In the event the Administrator determines that any dividend or other distribution (whether in the form of recipientscash, Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of options shall be within the sole and absolute discretionShares or other securities of the Committee. No person shall be granted an Incentive Option under this Plan unless such person is an employeeCorporation, issuance of warrants or other rights to purchase Shares or other securities of the Corporation, or other similar corporate transaction or event affects the Shares resulting in an adjustment, then the Administrator shall:

(a)          in such manner as it may deem equitable or desirable, adjust any or all of (i) the number of Shares or other securities of the Corporation (or number and kind of other securities or property) with respect to which Awards may be granted, including, without limitation, (1) the aggregate number of Shares that may be delivered pursuant to Awards granted under the Plan, as provided in Section 4.1 of the Plan, and (2) the maximum number of Shares or other securities of the Corporation (or number and kind of other securities or property) with respect to which Awards may be granted to any Participant in any fiscal year of the Corporation, and (ii) the terms of any outstanding Award, including, without limitation, (1) the number of Shares or other securities of the Corporation (or number and kind of other securities or property) subject to outstanding Awards or to which outstanding Awards relate, and (2) the exercise price with respect to any Award; or

(b)          if deemed appropriate or desirable, make provision for a Parentcash payment to the holder of an outstanding Award in consideration for the cancellation of such Award, including, in the case of an outstanding Option or Subsidiary onSAR, a cash payment to the holder of such Option or SAR in consideration for the cancellation of such Option or SAR in an amount equal to the excess, if any, of the Fair Market Value (as of a date specified by the Administrator) of grant. No personthe Shares subject to such Option or SAR over the aggregate exercise price of such Option or SAR (it being understood that, in such event, any Option or SAR having a per Share exercise price equal to, or in excess of, the Fair Market Value of a Share subject to such Option or SAR may be cancelled and terminated without any payment or consideration therefor).

(c)          Any such adjustments shall be granted an option under this Plan unless such person has executed, if requestedmade by the Committee,Administrator in its absolute discretion, and the grant representation letter set forth on Exhibit "A," as such Exhibit may be amended bydecision of the Committee from time to time. No personAdministrator shall be final, binding and conclusive.

Any Shares issuable as a result of any such adjustment shall be rounded to the next lower whole Share; no fractional Shares shall be issued. Any adjustment to the exercise price of an Award shall be rounded to the nearest penny.

4.4          Substitute Awards. The Administrator in its sole discretion shall have the right to substitute or assume Awards in connection with a share combination, share exchange, merger, consolidation, reorganization, or like corporate transaction which affects the number or nature of the Shares (“Substitute Awards”). The number of


Shares underlying any Substitute Awards shall be counted against the aggregate number of Shares available for Awards under the Plan; provided, however, that Substitute Awards issued in connection with the assumption of, or in substitution for, outstanding awards previously granted more than 500,000 options in any one year period. 3.2 Termination of Eligibility. 3.2.1 Ifby an optionee ceases to be employedentity that is acquired by the Corporation or its ParentAffiliate through a merger or Subsidiary,acquisition shall not be counted against the aggregate number of Shares available for Awards under the Plan; provided further, however, that Substitute Awards issued in connection with the assumption of, or in substitution for, outstanding stock options intended to qualify for special tax treatment under Code §§ 421 and 422 that were previously granted by an entity that is no longer an officer or member of the Board of Directors of the Corporation, or no longer performs services for the Corporation, or its Parent or Subsidiary, for any reason (other than for "cause," as hereinafter defined, or such optionee's death), any option granted hereunder to such optionee shall expire three (3) months after the occurrence giving rise to such termination of eligibility (or one (1) year in the event an optionee is "disabled," as defined in Section 22(e)(3) of the Code) or upon the date it expires by its terms, whichever is earlier. Any option that has not vested in the optionee as of the date of such termination shall immediately expire and shall be null and void. The Committee shall, in its sole and absolute discretion, decide, utilizing the provisions set forth in Treasury Regulations Section 1.421-7(h), whether an authorized leave of absence or absence for military or governmental service, or absence for any other reason, shall constitute termination of eligibility for purposes of this Section. 3.2.2 If an optionee ceases to be employedacquired by the Corporation or its Parentan Affiliate through a merger or Subsidiary,acquisition shall be counted against the aggregate number of Shares available for Incentive Stock Options under the Plan.

ARTICLE 5
PARTICIPATION

5.1          Eligibility. Any Director, Employee or Consultant (including any prospective Director, Employee or Consultant) of the Corporation and any Affiliate shall be eligible to be designated a Participant in the Plan for purposes of receiving Awards. However, Incentive Stock Options may be granted only to Employees.

5.2          Termination of Participation. If a Participant is no longer an officer or member of the Board of Directors of the Corporation, or no longer performs servicesa Service Provider due to a termination for the Corporation, or its Parent or Subsidiary, and such termination is as a result of "cause," as hereinafterCause (as defined below), then all optionsAwards granted hereunder to such optioneethe Participant shall expire onupon the earlier of: (i) the date of the occurrence giving rise to such termination, or (ii) the natural expiration of eligibility or upon the date it expires byAward according to its terms, whichever is earlier, and such optioneeunderlying terms. Thereafter, the Participant shall have no rights with respect to any unexercised options. Awards under the Plan.

(a)          Defining “Cause”.For purposes of thisthe Plan, "cause"Cause shall mean an optionee'sa Participant’s personal dishonesty, misconduct,dishonesty; misconduct; breach of fiduciary duty, incompetence,duty; incompetence; intentional failure to perform stated obligations,obligations; willful violation of any law, rule, regulation or final cease and desist order,order; or any material breach of any provision of this Plan, any Stock OptionAward Agreement, or any employment agreement. 3.3 Death

ARTICLE 6
STOCK OPTIONS

6.1          Option Grant. Subject to the provisions of Optioneethe Plan, the Administrator shall have sole and Transferplenary authority to determine the Service Providers to whom Options shall be granted, the number of Shares to be covered by each Option, whether for Employees the Option will be an Incentive Stock Option or a Non-Qualified Stock Option, and the conditions and limitations applicable to the vesting and exercise of the Option. In the event an optioneecase of Incentive Stock Options, the terms and conditions of such grants shall die, a vested optionbe subject to and comply with such rules as may be exercised (subjectprescribed by Code § 422 and any regulations related thereto, as may be amended from time to the condition that no option shall be exercisable after its expiration and only to the extent that the optionee's right to exercise such option had accrued at the time of the optionee's death) at any time within six months after the optionee's death by the executors or administrators of the optionee or by any person or persons who shall have acquired the option directly from the optionee by bequest or inheritance. Any option that has not vested in the optionee as of the date of death or termination of employment, whichever is earlier, shall immediately expire and shall be null and void. No option shall be transferable by the optionee other than by will or the laws of intestate succession. 3.4 Limitation on Incentive Options. No person shall betime. All Options granted any Incentive Option to the extent that the aggregate fair market value of the Stock (as defined below) to which such options are exercisable for the first time by the optionee during any calendar year (under all plans of the Corporation as determined under Section 422(d) of the Code) exceeds $100,000. B-2 4. Identification of Stock. The Stock, as defined herein, subject to the options shall be shares of the Corporation's authorized but unissued or acquired or reacquired common stock (the "Stock"). The aggregate number of shares subject to outstanding options shall not exceed 5,000,000 shares of Stock (subject to adjustment as provided in Section 6). If any option granted hereunder shall expire or terminate for any reason without having been exercised in full, the unpurchased shares subject thereto shall again be available for purposes of this Plan. 5. Terms and Conditions of Options. Any option granted pursuant to the Plan shall be evidenced byNon-Qualified Stock Options unless the applicable Award Agreement expressly states that the Option is intended to be an agreement ("Incentive Stock Option. If an Option is intended to be an Incentive Stock Option, Agreement") inand if for any reason such formOption (or any portion thereof) shall not qualify as the Committee shall from time to time determine, which agreement shall comply with and be subjectan Incentive Stock Option, then, to the following terms and conditions: 5.1 Numberextent of Shares. Each option shall state the number of shares of Stock to which it pertains. 5.2such non-qualification, such Option Exercise Price. Each option shall state the option exercise price, which(or portion thereof) shall be determined byregarded as a Non-Qualified Stock Option appropriately granted under the Committee;Plan, provided however, that (i)such Option (or portion thereof) otherwise complies with the exercise pricePlan’s requirements relating to Non-Qualified Stock Options.

(a)          Term of anyOption.The term of each Option will be stated in the Award Agreement. In the case of an Incentive Stock Option, shall notthe term will be less than the fair market value of the Stock, as determined by the Committee, on10 years from the date of grant or such shorter term as may be provided in the Award Agreement. Moreover, in the case of such option, (ii) the exercise price of any optionan Incentive Stock Option granted to any persona Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than 10% of the total combined voting power of all classes of the Corporation's stock as determined for purposes of Section 422 of the Code, shall not be less than 110%Corporation or any Affiliate, the term of the fair market value of theIncentive Stock as determined by the Committee, on the date of grant of such option, and (iii) the exercise price of any Non-Qualified Option shall notwill be less than 85% of the fair market value of the Stock, as determined by the Committee, on the date of grant of such option. In the event that the fair market value of the price of the common stock declines below the price at which the option is granted, the Committee shall have the discretion and authority to cancel, reduce, or otherwise modify the price of any unexercised option, including, but not limited to, a regrant of the option at a new price more commensurate with the fair market value of the stock. The Committee must receive the approval of the Board of Directors before any action is taken in accordance with this provision. 5.3 Term of Option. The term of an option granted hereunder shall be determined by the Committee at the time of grant, but shall not exceed tenfive years from the date of grant or such shorter term as may be provided in the grant.Award Agreement.

(b)          $100,000 Limitation for Incentive Stock Options.Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Non-Qualified Stock Option. However, notwithstanding such designation, to the extent the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Corporation and any Affiliate) exceeds $100,000, such Options will be treated


as Non-Qualified Stock Options. For purposes of this Section 6.1(b), Incentive Stock Options will be taken into account in the order in which they were granted. The termFair Market Value of anythe Shares will be determined as of the time the Option with respect to such Shares is granted. 

6.2          Exercise Price. Except as otherwise established by the Administrator at the time an Option is granted and set forth in the applicable Award Agreement, the exercise price of each Share covered by an Option shall be not less than 100% of the Fair Market Value of such Share (determined as of the date the Option is granted); provided, however, that in the case of an Incentive Stock Option granted to an employeeEmployee who, at the time of the grant of such Option, owns stock representing more than 10% of the total combined voting power of all classes of the Corporation's stock as determined for purposes of Section 422 of the Code,Corporation and any Affiliate, the per Share exercise price shall inbe no event exceed five years fromless than 110% of the Fair Market Value per Share on the date of the grant. All options shallOptions are intended to qualify as “qualified performance-based compensation” under Code § 162(m).

Notwithstanding the foregoing, Options may be subjectgranted with an exercise price of less than 100% of the Fair Market Value per Share on the date of grant if such Option is granted pursuant to early terminationan assumption or substitution for another option in a manner satisfying the provisions of Code § 424(a) (involving a corporate reorganization).

6.3          Waiting Period and Exercise Dates. At the time an Option is granted, the Administrator will fix the period within which the Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised.

6.4          Exercise of Option.

(a)          Procedure for Exercise; Rights as a Shareholder.Any Option granted hereunder will be exercisable according to the terms of the Plan and at such times and under such conditions as determined by the Administrator and set forth in this Plan. In no event shall any option be exercisable after the expiration of its term. 5.4 Method of Exercise.Award Agreement. An option shallOption may not be exercised by written notice tofor a fraction of a Share.

An Option will be deemed exercised when the Corporation byreceives: (i) written or electronic notice of exercise (in accordance with the optionee (or successor inAward Agreement) from the event of death)person entitled to exercise the Option, and execution by(ii) full payment for the optionee of an exercise representation letter in the form set forth on Exhibit "B," as such Exhibit may be amended by the Committee from time to time. Such written notice shall state the number of sharesShares with respect to which the optionOption is being exercisedexercised. Full payment may consist of any consideration and designate a time, during normal business hoursmethod of payment authorized by the Administrator and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Corporation, forParticipant or, if requested by the delivery thereof ("Exercise Date"), which time shall be at least 30 days after the giving of such notice unless an earlier date shall have been mutually agreed upon. At the time specifiedParticipant, in the written notice,name of the Corporation shall deliver toParticipant and his or her spouse. Until the optionee atShares are issued (as evidenced by the principal officeappropriate entry on the books of the Corporation or of a duly authorized transfer agent of the Corporation), no right to vote or receive dividends or any other rights as a shareholder will exist with respect to the Awarded Stock, notwithstanding the exercise of the Option. The Corporation will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Articles 4 and 14 of the Plan or the applicable Award Agreement.

Exercising an Option in any manner will decrease the number of Shares thereafter available for purchase under the Option, by the number of Shares as to which the Option is exercised.

(b)          Termination of Relationship as Service Provider. If a Participant ceases to be a Service Provider, other than upon the Participant’s death or Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for three (3) months following the Participant’s termination.

(c)          Disability of Participant.If a Participant ceases to be a Service Provider as a result of the Participant’s Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In theabsence of a specified time in the Award Agreement, the Option will remain exercisable for 12 months following the Participant’s termination.


(d)          Death of Participant.If a Participant dies while a Service Provider, the Option may be exercised following the Participant’s death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of death (but in no event may the option be exercised later than the expiration of the term of such Option as set forth in the Award Agreement), by the Participant’s designated beneficiary, provided such beneficiary has been designated prior to Participant’s death in a form acceptable to the Administrator. If no such beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant’s estate or by the person(s) to whom the Option is transferred pursuant to the Participant’s will or in accordance with the laws of descent and distribution. In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following Participant’s death.

(e)          Buyout Provisions.The Administrator may at any time offer to buy out for a payment in cash or Shares an Option previously granted based on such terms and conditions as the Administrator shall establish and communicate to the Participant at the time that such offer is made.

(f)          Reversion to Plan.Unless otherwise provided by the Administrator, if on the date of termination, Disability or death as provided in Sections 6.4(b), (c), and (d) of the Plan, Participant is not fully vested as to his or her Option, the Shares covered by the unvested portion of the Option will immediately revert to the Plan following the Participant’s termination, Disability or death. If the vested portion of the Option is not exercised within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.

6.5          Form of Consideration. The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration at the time of grant. To the extent permitted by Applicable Laws, consideration may consist entirely of:

(a)          cash;

(b)          check;

(c)          other Shares which meet the conditions established by the Administrator to avoid adverse accounting consequences (as determined by the Administrator);

(d)          consideration received by the Corporation under a cashless exercise program implemented by the Corporation in connection with the Plan;

(e)          a reduction in the amount of any Corporation liability to the Participant, including, without limitation, any liability attributable to the Participant’s participation in any Corporation-sponsored deferred compensation program or arrangement;

(f)          any combination of the foregoing methods of payment; or

(g)         such other appropriate placeconsideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws.

ARTICLE 7
RESTRICTED STOCK

7.1          Grant of Restricted Stock. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.


7.2          Restricted Stock Agreement. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator will determine in its sole discretion. Unless the Administrator determines otherwise, Shares of Restricted Stock will be held by the Corporation as escrow agent until the restrictions on such Shares have lapsed.

7.3          Transferability. Except as provided in this Article 7, Shares of Restricted Stock may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.

7.4          Removal of Restrictions. Except as otherwise provided in this Article 7, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction. The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed.

7.5          Voting Rights. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder shall not have voting rights with respect to those Shares, unless the Administrator determines otherwise.

7.6          Dividends and Other Distributions. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares unless otherwise provided in the Award Agreement. If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid.

7.7          Return of Restricted Stock to Corporation. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Corporation and again will become available for grant under the Plan.

ARTICLE 8
UNRESTRICTED STOCK

Pursuant to the terms of the applicable Award Agreement, a Service Provider may be awarded (or sold at a discount) shares of Common Stock that are not subject to a Period of Restriction, in consideration for past services rendered thereby to the Corporation and any Affiliate or for other valid consideration.

ARTICLE 9
STOCK APPRECIATION RIGHTS

9.1          Grant of SARs. Subject to the terms and conditions of the Plan, a SAR may be granted to Service Providers at any time and from time to time as will be determined by the Committee,Administrator, in its sole discretion.

9.2          Number of Shares. The Administrator will have sole discretion to determine the number of SARs granted to any Service Provider.

9.3          Exercise Price and Other Terms. The Administrator, subject to the provisions of the Plan, will have sole discretion to determine the terms and conditions of SARs granted under the Plan. Except as otherwise established by the Administrator at the time a certificate or certificates forSAR is granted and set forth in the applicable Award Agreement, the exercise price of each Share covered by a SAR shall be not less than 100% of the Fair Market Value of such shares.Share (determined as of the date the SAR is granted).

9.4          SAR Agreement. Each SAR grant will be evidenced by an Award Agreement that will specify the exercise price, the term of the SAR, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine.


9.5          Expiration of SARs. A SAR granted under the Plan will expire upon the date determined by the Administrator, in its sole discretion, and as set forth in the Award Agreement. Notwithstanding the foregoing, the rules of Sections 6.4(b), (c) and (d) will also apply to SARs.

9.6          Payment of SAR Amount. Upon exercise of a SAR, a Participant will be entitled to receive payment from the Corporation an amount determined by multiplying: (i) the difference between the Fair Market Value of a Share on the date of exercise over the exercise price; times (ii) the number of Shares with respect to which the SAR is exercised. At the discretion of the Administrator, the payment upon SAR exercise may postpone deliverybe in cash, in Shares of equivalent value, other securities, other Awards, other property or a combination of any certificateof the foregoing.

9.7          Buyout Provisions. The Administrator may at any time offer to buy out for a payment in cash or certificates after noticeShares a SAR previously granted based on such terms and conditions as the Administrator shall establish and communicate to the Participant at the time that such offer is made.

ARTICLE 10
PERFORMANCE UNITS AND PERFORMANCE SHARES

10.1        Grant of exercise for such reasonable period asPerformance Units/Shares. Subject to the terms and conditions of the Plan, Performance Units and Performance Shares may be requiredgranted to comply withService Providers at any applicable listing requirementstime and from time to time, as will be determined by the Administrator, in its sole discretion. The Administrator will have complete discretion in determining the number of any securities exchange. InPerformance Units and Performance Shares granted to each Participant.

10.2        Value of Performance Units/Shares. Each Performance Unit will have an initial value that is established by the event an option shall be exercisable by any person other than the optionee, the required notice under this Section shall be accompanied by appropriate proof of the right of such person to exercise the option. B-3 5.5 Medium and Time of Payment. The option exercise price shall be payable in fullAdministrator on or before the option Exercise Date in any onedate of the following alternative forms: 5.5.1 Full payment in cash or certified bank or cashier's check; 5.5.2 Subject to Section 5.5.7 hereof, a Promissory Note (as defined below); 5.5.3 Full payment in shares of Stock having a fair marketgrant. Each Performance Share will have an initial value on the Exercise Date in the amount equal to the option exerciseFair Market Value of a Share on the date of grant.

10.3        Performance Objectives and Other Terms. The Administrator will set performance objectives in its discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers. The time period during which the performance objectives must be met will be called the “Performance Period. Each Award of Performance Units/Shares will be evidenced by an Award Agreement that will specify the Performance Period, and such other terms and conditions as the Administrator, in its sole discretion, will determine. The Administrator may set performance objectives based upon the achievement of Corporation-wide, divisional, or individual goals, applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion.

10.4        Performance Measures. Performance Measures may be based on any one or more of the following: earnings (e.g., earnings before interest and taxes; earnings before interest, taxes, depreciation and amortization; or earnings per share); financial return ratios (e.g., return on investment; return on invested capital; return on equity; or return on assets); increase in revenue, operating or net cash flows; cash flow return on investment; total shareholder return; market share; net operating income, operating income or net income; debt load reduction; expense management; economic value added; Stock price; 5.5.4 Subjectand strategic business objectives, consisting of one or more objectives based on meeting specific cost targets, business expansion goals and goals relating to Section 5.5.7 hereof, throughacquisitions or divestitures. Performance Measures may be based on the performance of the Company as a special salewhole or of any one or more business units of the Company and remittance procedure pursuantmay be measured relative to a peer group or an index. Performance Measures may vary from Participant to Participant. Performance Periods may overlap and Participants may participate simultaneously with respect to Award for which the Committee has prescribed different Performance Periods.

10.5        Earning of Performance Units/Shares. After the applicable Performance Period has ended, the holder of Performance Units/Shares will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance Period, to be determined as a function of the extent to which the optionee shall concurrently provide irrevocable written instruction to (a)corresponding performance objectives have been achieved. After the grant of a Corporation-designated brokerage firm to effectPerformance Unit/Share, the immediate saleAdministrator, in its sole discretion, may reduce or waive any performance objectives for such Performance Unit/Share.


10.6        Form and Timing for Payment of Performance Units/Shares. Payment of earned Performance Units/Shares will be made as soon after the expiration of the purchased shares and remitapplicable Performance Period at the time determined by the Administrator. The Administrator, in its sole discretion, may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market Value equal to the Corporation, outvalue of the sale proceeds available onearned Performance Units/Shares at the settlement date pursuant to an irrevocable assignment by the optionee, sufficient funds to cover the aggregate exercise price payable for the purchased shares plus all applicable Federal, state and local income and employment taxes required to be withheld by the Corporation by reason of such exercise and (b) the Corporation to deliver the certificates for the purchased shares directly to such brokerage firm in order to complete the sale. 5.5.5 A combinationclose of the considerationapplicable Performance Period) or in a combination thereof.

10.7        Cancellation of Performance Units/Shares. On the date set forth in Sections 5.5.1, through 5.5.4 equal to the option exercise price;Award Agreement, all unearned or 5.5.6 Any other method of payment complying with the provisions of Section 422 of the Code with respect to Incentive Options, provided the terms of payment are established by the Committee at the time of grant and any other method of payment established by the Committee with respect to Non-Qualified Options. 5.5.7 Notwithstanding the foregoing, the methods of payment described in Section 5.5.2 and Section 5.5.4 shall notunvested Performance Units/Shares will be available to any optionee classified as "a director or executive officer (or equivalent thereof)" within the meaning of Section 402 of the Sarbanes-Oxley Act of 2002 ("Sarbanes-Oxley") at the time of the exercise, unless such optionee provides to the Corporation a written opinion of counsel satisfactory to the Corporation that the proposed medium of payment is not prohibited by Sarbanes-Oxley. 5.6 Fair Market Value. The fair market value of a share of Stock on any relevant date shall be determined in accordance with the following provisions: 5.6.1 If the Stock at the time is neither listed nor admitted to trading on any stock exchange nor traded in the over-the-counter market, then the fair market value shall be determined by the Committee after taking into account such factors as the Committee shall deem appropriate. 5.6.2 If the Stock is not at the time listed or admitted to trading on any stock exchange but is traded in the over-the-counter market, the fair market value shall be the mean between the highest bid and lowest asked prices (or, if such information is available, the closing selling price) of one share of Stock on the date in question in the over-the-counter market, as such prices are reported by the National Association of Securities Dealers through its NASDAQ system or any successor system. If there are no reported bid and asked prices (or closing selling price) for the Stock on the date in question, then the mean between the highest bid and lowest asked prices (or the closing selling price) on the last preceding date for which such quotations exist shall be determinative of fair market value. 5.6.3 If the Stock is at the time listed or admitted to trading on any stock exchange, then the fair market value shall be the closing selling price of one share of Stock on the date in question on the stock exchange determined by the Committee to be the primary market for the Stock, as such price is officially quoted in the composite tape of transactions on such exchange. If there is no sale of Stock on such exchange on the date in question, then the fair market value shall be the closing selling price on the exchange on the last preceding date for which such quotation exists. B-4 5.7 Promissory Note. Subject to the requirements of applicable state or Federal law or margin requirements, payment of all or part of the purchase price of the Stock may be made by delivery of a full recourse promissory note ("Promissory Note"). The Promissory Note shall be executed by the optionee, made payableforfeited to the Corporation, and bear interestagain will be available for grant under the Plan.

ARTICLE 11
RESTRICTED STOCK UNITS

11.1        Grant of Restricted Stock Units. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant Restricted Stock Units to Service Providers in such rateamounts as the CommitteeAdministrator, in its sole discretion, will determine. Without limiting the generality of the foregoing, Restricted Stock Units may be granted in the form of Performance Shares and Performance Units, as described in Article 10.

11.2        Restricted Stock Unit Agreement. Each Award of Restricted Stock Units will be evidenced by an Award Agreement that will specify the period during which the Restricted Stock Units are subject to restrictions (which restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator), the number of Shares granted, and such other terms and conditions as the Administrator will determine in its sole discretion.

11.3        Settlement; Forfeiture. Restricted Stock Units may be settled in Shares, cash, other securities or other property, as the Administrator shall determine. The Administrator, in its sole discretion may permit Restricted Stock Units to be settled or paid as a lump sum, in installments or on a deferred basis, in accordance with rules and procedures established by the Administrator and in conformance with Code § 409A. Restricted Stock Units shall be subject to forfeiture until no longer subject to restrictions and any other vesting criteria has been attained. In the event of any forfeiture, all rights of the Participant to such Restricted Stock Units, including to any dividend equivalents that may have been accumulated and withheld while the applicable restriction on the Restricted Stock Unit applied, shall terminate without further action or obligation on the part of the Company.

11.4        Transferability. Except as provided in this Article 11, neither the Restricted Stock Units nor any Shares thereunder (or any interest therein) may be sold, transferred, pledged, assigned or otherwise alienated or hypothecated for the applicable restriction period.

11.5        Voting Rights. Unless and until unrestricted Shares are issued and delivered in respect of the applicable Restricted Stock Units, Service Providers holding Restricted Stock Units shall not have voting rights with respect to those Shares, unless the Administrator determines otherwise.

11.6        Dividends and Other Distributions. Generally, Service Providers holding Restricted Stock Units shall not be entitled to receive dividend equivalents, unless provided in the Award Agreement or as otherwise determined by the Administrator. If so provided in the applicable Award Agreement, Restricted Stock Units may be credited with dividend equivalent payments (upon the payment by the Company of dividends on Shares) either in cash or in Shares having a Fair Market Value equal to the amount of such dividends, which accumulated dividend equivalents (and interest thereon, if applicable) shall be payable at the same time as the underlying Restricted Stock Units are settled following the release of restrictions on such Restricted Stock Units.

ARTICLE 12
OTHER STOCK BASED AWARDS

Other Stock Based Awards may be granted either alone, in addition to, or in tandem with, other Awards granted under the Plan and/or cash awards made outside of the Plan. The Administrator shall have authority to


determine the Service Providers to whom and the time or times at which Other Stock Based Awards shall be made, the amount of such Other Stock Based Awards, and all other conditions of the Other Stock Based Awards including, without limitation, any dividend and/or voting rights.

ARTICLE 13
DISSOLUTION OR LIQUIDATION, OR CHANGE IN CONTROL

13.1        Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Corporation, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction. The Administrator in its discretion may provide for a Participant to have the right to exercise his or her Award, to the extent applicable, until 10 days prior to such transaction as to all of the Awarded Stock covered thereby, including Shares as to which the Award would not otherwise be exercisable. In addition, the Administrator may provide that any Corporation repurchase option or forfeiture rights applicable to any Award shall lapse 100%, and that any Award vesting shall accelerate 100%, provided the proposed dissolution or liquidation takes place at the time and in the manner contemplated. To the extent it has not been previously exercised or vested, an Award will terminate immediately prior to the consummation of such proposed action.

13.2        Change in Control. If a Change in Control occurs and a Participant’s Awards are not continued, converted, assumed, or replaced by (i) the Corporation or an Affiliate of the Corporation, or (ii) a successor entity in such manner that the value of the awards is not diminished upon effecting the change, such Awards shall become fully exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse immediately prior to such Change in Control. Upon, or in anticipation of, a Change in Control, the Administrator may cause any and all Awards outstanding hereunder to terminate at a specific time in the future, including but not limited to the date of such Change in Control, and shall give each Participant the right to exercise such Awards during a period of time as the Administrator, in its sole and absolute discretion, shall determine, but in no case lessshorter than the minimum rate which will not cause under the Code (i) interestten (10) trading days.

ARTICLE 14
MISCELLANEOUS PROVISIONS

14.1        No Uniform Rights to be imputed, (ii) original issue discountAwards. The Corporation has no obligation to exist,uniformly treat Participants or (iii) any other similar results to occur. Unless otherwise determined by the Committee, interest on the Note shall be payable in quarterly installments on March 31, June 30, September 30 and December 31holders or beneficiaries of each year. A Promissory Note shall contain such otherAwards. The terms and conditions asof Awards and the Administrator’s determinations and interpretations with respect thereto need not be the same with respect to each Participant and may be determined by the Committee; provided, however, that the full principal amountmade selectively among Participants, whether or not such Participants are similarly situated.

14.2        Share Certificates. All certificates for Shares or other securities of the Promissory Note and all unpaid interest accrued thereon shall be due not later than five years from the date of exercise. The Corporation may obtain from the optionee a security interest in all shares of Stock issued to the optioneeor Affiliate delivered under the Plan forpursuant to any Award or the purpose of securing paymentexercise thereof shall be subject to such stop transfer orders and other restrictions as the Administrator may deem advisable under the Promissory NotePlan, the applicable Award Agreement or the rules, regulations and may retain possessionother requirements of the SEC, the NYSE or any other stock exchange or quotation system upon which such Shares or other securities are then listed or reported and any applicable Federal or state laws, and the Administrator may cause a legend or legends to be put on any such certificates representingto make appropriate reference to such shares in order to perfect its security interest. 5.8restrictions.

14.3        No Rights as a Shareholder. An optioneeService Provider. Neither the Plan nor any Award shall confer upon a Participant any right with respect to continuing his or successorher relationship as a Service Provider, nor shall they interfere in any way with the right of the Participant or the right of the Corporation or its Affiliate to terminate such relationship at any time, with or without cause.

14.4        No Rights as Shareholder. No Participant or holder or beneficiary of any Award shall have noany rights as a shareholder with respect to any Shares to be distributed under the Plan until he or she has become the holder of such Shares. In connection with each grant of Restricted Stock, underlying any option untilexcept as provided in the date ofapplicable Award Agreement, the issuanceParticipant shall not be entitled to such optioneethe rights of a certificate forshareholder in respect of such Stock. No adjustmentRestricted Shares during the Period of Restriction. Except as otherwise provided in Section 4.3 or the applicable Award Agreement, no adjustments shall be made for dividends (ordinaryor distributions on (whether ordinary or extraordinary, and whether in cash, Shares, other securities or other property) or distributions, or other rightsevents relating to, Shares subject to an Award for which the record date is prior to the date such Stock certificate isShares are delivered.


14.5        No Trust or Fund Created. Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Corporation or Affiliate, on one hand, and a Participant or any other person, on the other. To the extent that any person acquires a right to receive payments from the Corporation or Affiliate pursuant to an Award, such right shall be no greater than the right of any unsecured general creditor of the Corporation or Affiliate.

14.6        No Fractional Shares. No fractional Shares shall be issued except as provided in Section 6. 5.9 Modification, Extension and Renewal of Options. Subjector delivered pursuant to the termsPlan or any Award, and conditionsthe Administrator shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Shares or whether such fractional Shares or any rights thereto shall be cancelled, terminated or otherwise eliminated.

14.7        Requirement of Consent and Notification of Election Under Code § 83(b) or Similar Provision. No election under Code § 83(b) (to include in gross income in the year of transfer the amounts specified in Code § 83(b)) or under a similar provision of law may be made unless expressly permitted by the terms of the Plan,applicable Award Agreement or by action of the Committee may modify, extend or renew outstanding options grantedAdministrator in writing prior to the making of such election. If an Award recipient, in connection with the acquisition of Shares under the Plan or accept the surrender of outstanding options (to the extent not exercised) and authorize the granting of new options in substitution therefor. 5.10 Vesting and Restrictions. The Committee shall have complete authority and discretion to setotherwise, is expressly permitted under the terms conditions, restrictions, vesting schedules and other provisions of any option in the applicable Award Agreement or by such Administrator action to make such an election and the Participant makes the election, the Participant shall notify the Administrator of such election within 10 days of filing notice of the election with the IRS or other governmental authority, in addition to any filing and notification required pursuant to regulations issued under Code § 83(b) or other applicable provision.

14.8        Requirement of Notification Upon Disqualifying Disposition Under Code § 421(b). If any Participant shall make any disposition of Shares delivered pursuant to the exercise of an Incentive Stock Option Agreement and shall have complete authorityunder the circumstances described in Code § 421(b) (relating to require conditions and restrictions oncertain disqualifying dispositions) or any Stock issued pursuant to this Plan; provided, however, that except with respect to options granted to officers or directorssuccessor provision of the Code, such Participant shall notify the Corporation optionsof such disposition within 10 days of such disposition.

14.9        Leaves of Absence. Unless the Administrator provides otherwise, vesting of Awards granted pursuant to this Plan shallhereunder may be exercisable or "vest" at the ratesuspended during any unpaid leave of at least 20% per year over the 5-year period beginningabsence and will resume on the date the option is granted. Options grantedParticipant returns to officers and directors shall become exercisable or "vest," subject to subject towork on a regular schedule as determined by the condition of continued employment and/or continued service on the Board of Directors, as appropriate. The maximumCorporation; provided, however, that no vesting period for options granted to officers or directorscredit will be ten years fromawarded for the datetime vesting has been suspended during such leave of grant. 5.11 Other Provisions. The Stock Option Agreements shall contain such other provisions, including without limitation, restrictionsabsence. A Service Provider will not cease to be an Employee in the case of (i) any leave of absence approved by the Corporation or conditions upon the exercise of options, as the Committee shall deem advisable. 6. Adjustments upon Changes in Capitalization. 6.1 Subdivision or Consolidation. Subject to any required action by shareholders(ii) transfers between locations of the Corporation the number of shares of Stock covered by each outstanding option, and the exercise price thereof, shall be proportionately adjusted for any increase or decrease in the number of issued shares of Stock ofbetween the Corporation resulting from a subdivision or consolidationits Affiliate. For purposes of shares, including, but not limited to, a stock split, reverse stock split, recapitalization, continuationIncentive Stock Options, no such leave may exceed 3 months, unless reemployment upon expiration of such leave is guaranteed by statute or reclassification, or the paymentcontract. If reemployment upon expiration of a stock dividend (but only on the Stock) or any other increase or decrease in the numberleave of such shares effected without receipt of considerationabsence approved by the Corporation. Any fraction of a share subject to option that would otherwise result from an adjustment pursuant to this Section shall be rounded downward to the next full number of shares without other compensation or consideration to the holder of such option. 6.2 Capital Transactions. Upon a sale or exchange of all or substantially all of the assets of the Corporation, a merger or consolidation in which the Corporation is not so guaranteed, then 6 months from the surviving corporation,first day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a merger, reorganization or consolidation in whichNon-Qualified Stock Option.

14.10      Notices. Any written notice to the Corporation is the surviving corporation and shareholdersrequired by any provisions of the B-5 Corporation exchange their stock for securities or property, a liquidationPlan shall be addressed to the Secretary of the Corporation or similar transaction asand shall be effective when received.

14.11      Non-Transferability of Awards. Other than pursuant to a domestic relations order (within the meaning of Rule 16a-12 promulgated under the Exchange Act) and unless determined otherwise by the Committee ("Capital Transaction"), this Plan and each option issued under this Plan, whether vested or unvested, shall terminate, unless such options are assumed by a successor corporation in a merger or consolidation, immediately prior to such Capital Transaction; provided, however, that unless the outstanding options are assumed by a successor corporation in a merger or consolidation, subject to terms approved by the Committee, all optionees will have the right, during the 15 days prior to such Capital Transaction, to exercise all vested options. The Corporation shall, subject to any nondisclosure provisions, attempt to provide optionees at least 15 days notice of the option termination date. The Committee may (but shall not be obligated to) (i) accelerate the vesting of any option or (ii) apply the foregoing provisions, including but not limited to termination of this Plan and options granted pursuant to the Plan, in the event there is a sale of 51% or more of the stock of the Corporation in any two year period or a transaction similar to a Capital Transaction. 6.3 Adjustments. To the extent that the foregoing adjustments relate to stock or securities of the Corporation, such adjustments shall be made by the Committee, whose determination in that respect shall be final, binding and conclusive. 6.4 Ability to Adjust. The grant ofAdministrator, an option pursuant to the Plan shall not affect in any way the right or power of the Corporation to make adjustments, reclassifications, reorganizations or changes of its capital or business structure or to merge, consolidate, dissolve, liquidate, sell or transfer all or any part of its business or assets. 6.5 Notice of Adjustment. Whenever the Corporation shall take any action resulting in any adjustment provided for in this Section, the Corporation shall forthwith deliver notice of such action to each optionee, which notice shall set forth the number of shares subject to the option and the exercise price thereof resulting from such adjustment. 6.6 Limitation on Adjustments. Any adjustment, assumption or substitution of an Incentive Option shall comply with Section 425 of the Code, if applicable. 7. Nonassignability. Options granted under this PlanAward may not be sold, pledged, assigned, hypothecated, transferred, or transferreddisposed of in any manner other than by will or by the laws of intestate succession,descent or distribution, and may be exercised, during the lifetime of an optioneethe Participant, only by the Participant. If the Administrator makes an Award transferable, such optionee. Any transfer in violationAward will contain such additional terms and conditions as the Administrator deems appropriate.

14.12      Date of this Section shall voidGrant. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting such option, and any Stock Option Agreement entered intoAward, or such other later date as is determined by the optioneeAdministrator. Notice of the determination will be provided to each Participant within a reasonable time after the date of such grant.


14.13     Amendment and Termination of Plan.

(a)          Amendment and Termination.Subject to Sections 14.13(b) and (c) of the Corporation regarding such transferred option shall be void and have no further forcePlan, the Board may at any time amend, alter, suspend or effect. No option shall be pledged or hypothecated in any way, nor shall any option be subject to execution, attachment or similar process. 8. No Right of Employment. Neitherterminate the grant nor exercise of any option nor anything inPlan. Unless sooner terminated, this Plan shall impose uponterminate on December 30, 2023, the Corporation or any other corporation any obligation to employ or continue to employ any optionee. The right of the Corporation and any other corporation to terminate any employee shall not be diminished or affected because an option has been granted to such employee. 9. Term of Plan. This Plandate that is effective on10 years from the date the Plan iswas originally adopted by the Board or approved by the shareholders of Directorsthe Corporation, whichever was earlier.

(b)          Shareholder Approval.The Corporation will obtain shareholder approval of the Plan and options may be granted pursuantof any Plan amendment to the extent necessary and desirable to comply with Applicable Laws.

(c)          Effect of Amendment or Termination.No amendment, alteration, suspension or termination of the Plan from time to time within a period of ten (10) years from such date, orwill impair the daterights of any required shareholder approval required underParticipant, unless mutually agreed upon between the Plan, if earlier.Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Corporation. Termination of the Plan shallwill not affect any option theretofore granted. B-6 10. Amendment of the Plan. The Board of Directors ofAdministrator’s ability to exercise the Corporation may, subjectpowers granted to any required shareholder approval, suspend, discontinue or terminate the Plan, or revise or amend it in any respect whatsoeverhereunder with respect to any shares of Stock at that time not subjectAwards granted under the Plan prior to options. 11. Application of Funds. The proceeds received by the Corporation from the sale of Stock pursuant to options may be used for general corporate purposes. 12. Reservation of Shares. The Corporation, during the term of this Plan, shall at all times reserve and keep available such number of shares of Stock as shall be sufficient to satisfy the requirements of the Plan. 13. No Obligation to Exercise Option. The granting of an option shall not impose any obligation upon the optionee to exercise such option. 14. Approval of Board of Directors and Shareholders. The Plan shall not take effect until approved by the Board of Directors of the Corporation. This Plan shall be approved by a vote of the shareholders within 12 months from the date of approval by the Boardsuch termination.

14.14     Conditions Upon Issuance of Directors. In the event such shareholder vote isShares.

(a)          Legal Compliance.Shares will not obtained, all options granted hereunder, whether vested or unvested, shall be null and void. Further, any stock acquiredissued pursuant to the exercise of any options under this Agreement may not count for purposes of determining whether shareholder approval has been obtained. 15. Withholding Taxes. Notwithstanding anything else to the contrary in this Plan or any Stock Option Agreement,an Award unless the exercise of any option shallsuch Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be conditioned upon payment by such optionee in cash, or other provisions satisfactoryfurther subject to the Committee,approval of all local, state, federal or other withholding taxes applicable, incounsel for the Committee's judgment,Corporation with respect to such compliance.

(b)          Investment Representations. As a condition to the exercise or to later disposition of shares acquired upon exercisereceipt of an option. 16. Parachute Payments. Any outstanding option underAward, the PlanCorporation may not be acceleratedrequire the person exercising or receiving such Award to represent and warrant at the extent any such acceleration of such option would, when added to the present value of other payments in the nature of compensation which becomes due and payable to the optionee would result in the payment to such optionee of an excess parachute payment under Section 280G of the Code. The existencetime of any such excess parachute paymentexercise or receipt that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Corporation, such a representation is required.

14.15     Severability. Notwithstanding any contrary provision of the Plan or an Award to the contrary, if any one or more of the provisions (or any part thereof) of this Plan or the Awards shall be held invalid, illegal or unenforceable in any respect, such provision shall be modified so as to make it valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions (or any part thereof) of the Plan or Award, as applicable, shall not in any way be affected or impaired thereby.

14.16     Inability to Obtain Authority. The inability of the Corporation to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Corporation’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, will relieve the Corporation of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority will not have been obtained.

14.17     Shareholder Approval. The Plan shall be duly approved by the shareholders of the Corporation within 12 months after the date the Plan was adopted, or shall otherwise be rendered not effective.

14.18     Governing Law. The validity, construction and effect of the Plan and any rules and regulations relating to the Plan and any Award Agreement shall be determined in accordance with the sole and absolute discretionlaws of the Committee. 17. Securities Laws Compliance. Notwithstanding anything contained herein, the Corporation shall not be obligated to grant any option under this Plan or to sell, issue orState of Illinois, without giving effect any transfer of any Stock unless such grant, sale, issuance or transfer is at such time effectively (i) registered or exempt from registration under the Securities Act of 1933, as amended (the "Act"), and (ii) qualified or exempt from qualification under the California Corporate Securities Law of 1968 and any other applicable state securities laws. As a condition to exercise of any option, each optionee shall make such representations as may be deemed appropriate by counsel to the Corporation forconflict of laws provisions thereof.

14.19     Section 409A. It is the Corporation to use any available exemption from registration under the Act or qualification under any applicable state securities law. B-7 18. Restrictive Legends. The certificates representing the Stock issued upon exercise of options granted pursuant to this Plan will bear any legends required by applicable securities laws as determined by the Committee. 19. Notices. Any notice to be given under the terms of the Plan shall be addressed to the Corporation in care of its Secretary at its principal office, and any notice to be given to an optionee shall be addressed to such optionee at the address maintained by the Corporation for such person or at such other address as the optionee may specify in writing to the Corporation. As adopted by the Board of Directors on November 6, 2003. B-8 EXHIBIT A AKORN INC 2003 STOCK OPTION PLAN GRANT REPRESENTATION LETTER Neill E. Shanahan, Vice President, Human Resources Akorn, Inc. 2500 Millbrook Drive Buffalo Grove, IL 60089-4694 Re: 2003 Stock Option Plan Dear Mr. Shanahan: This letter is delivered to Akorn, Inc., a Louisiana corporation (the "Corporation"), in connection with the grant to (the "Optionee") of an option (the "Option") to purchase shares of common stockintention of the Corporation (the "Stock") pursuantthat no Award shall be “deferred compensation” subject to Code § 409A, unless and to the Akorn, Inc. 2003 Stock Option Plan originally dated , 2003 (the "Plan"). The Optionee understandsextent that the Corporation's receipt ofAdministrator specifically determines otherwise, and this letter executed by the Optionee is a condition to the Corporation's willingness to grant the Option to the Optionee. The Optionee acknowledges that the grant of the Option by the Corporation is in lieu of any and all other promises of the Corporation to the Optionee, whether written or oral, express or implied, regarding the grant of options or other rights to acquire Stock. Accordingly, in anticipation of the grant of the Option, the Optionee hereby relinquishes all rights to such other rights, if any, to acquire stock of the Corporation. In addition, the Optionee makes the following representations and warranties with the understanding that the Corporation will rely upon them. 1. The Optionee acknowledges receipt of a copy of the Plan and Agreement. The Optionee has carefully reviewed the Plan and Agreement. 2. The Optionee acknowledges receipt of a prospectus regarding the Plan, if requested, which includes the information required by Section (a)(1) of Rule 428 under the Securities Act of 1933. 3. The Optionee understands and acknowledges that the Option and the Stock are subject to the terms and conditions of the Plan. 4.all Awards shall be interpreted accordingly. The Optionee understandsterms and agrees that, at the time of exercise ofconditions governing any part of the Option for Stock, the Optionee may be required to provide the Corporation with additional representations, warranties and/or covenants similar to those contained in this letter. 5. The Optionee is a resident of the State of ________. 6. The Optionee will notify the Corporation immediately of any change in the above information which occurs before the Option is exercised in full by the Optionee. Signed Optionee------------------------------- Print Name----------------------------- Date----------------------------------- EXHIBIT B AKORN INC. 2003 STOCK OPTION PLAN NOTICE OF INTENT TO EXERCISE Steven Koulogeorge, Controller Akorn, Inc. 2500 Millbrook Drive Buffalo Grove, IL 60089-4694 Dear Mr. Koulogeorge, Please be advised that I seek to exercise options to purchase shares of Akorn Inc. stock, pursuant to the Options Grant number dated at the price of per share. This notice is delivered to Akorn, Inc., a Louisiana corporation, pursuant to the Akorn, Inc. 2003 Stock Option Plan, originally dated November 6, 2003. I understand that employees of the Company responsible for authorizing and processing this transaction will do so at their earliest convenience, but that there may be delays following receipt of this letter due to normal business activities andAwards that the Company cannot guarantee immediate authorization and processing. I hereby freely waive any and all claims for damages of any kind that may result from any delay in processing this transaction. Furthermore, I represent and agree as follows: 1. I acknowledge receipt of a copy of the Plan and Agreement and have carefully reviewed the Plan and Agreement. 2. I am a resident of the State of . 3. If I am an "affiliate" (as defined in Rule 144 under the Securities Act of 1933) of the Corporation at the time I desire to sell any Akorn stock, IAdministrator determines will be subject to certain restrictions under, and will comply with allCode § 409A, including, without limitation, any rules for elective or mandatory deferral of the requirementsdelivery of applicable federalcash or shares of Common Stock pursuant thereto and state securities laws. Signed Name Date -------------------- - ------------------------------------------------------------ Print Name - ------------------------------------------------------------ Address Phone ------------------- - ------------------------------------------------------------
APPENDIX C AKORN, INC. AUDIT COMMITTEE CHARTER I. Purpose The primary functionany rules regarding treatment of such Awards in the Audit Committee (the "Committee")event of Akorn, Inc. (the "Company") is to assist the Board of Directorsa Change in fulfilling its oversight responsibilities by reviewing: the financial reports and other financial information provided by the Company to designated regulatory bodies or the public; the Company's systems of internal controls regarding finance, accounting, legal compliance and ethics that management has established; and the Company's auditing, accounting and financial reporting processes. Management is responsible for (a) the preparation, presentation and integrity of the Company's financial statements; (b) accounting and financial reporting principles; and (c) the Company's internal controls and procedures designed to promote compliance with accounting standards and applicable laws and regulations. The Company's independent auditing firm is responsible for performing an independent audit of the consolidated financial statements in accordance with generally accepted auditing standards. Regardless of whether the Committee members are or have been professional accountants or auditors, their functions are not intended to duplicate or to certify the activities of management and the independent auditor, nor can the Committee certify that the independent auditor is "independent" under applicable rules. The Audit Committee serves a board level oversight role where it oversees the relationship with the independent auditor, asControl, shall be set forth in this charter,the applicable Award Agreement and provides advice, counselrules established by the Administrator, and general direction, as it deems appropriate,shall comply in all respects with Code § 409A. The following rules will apply to management and the auditors on the basisAwards intended to be subject to Code § 409A (“409A Awards”):


(a)          If a Participant is permitted to elect to defer an Award or any payment under an Award, such election will be permitted only at times in compliance with Code § 409A, including, without limitation, applicable transition rules thereunder.

(b)          The Corporation shall have no authority to accelerate distributions relating to Code § 409A Awards in excess of the information it receives, discussions withauthority permitted under Code § 409A.

(c)          Any distribution of a Code § 409A Award following a separation from service that would be subject to Code § 409A(a)(2)(A)(i) as a distribution following a separation from service of a “specified employee” as defined under Code § 409A(a)(2)(B)(i), shall occur no earlier than the auditor, and the experienceexpiration of the Committee's members in business, financial and accounting matters. II. Duties and Responsibilities The Committee: - Serves as an independent and objective party to monitorsix-month period following such Separation.

(d)          In the Company's financial reporting process and internal control system. - Reviews and approves all related-party transactions. - Reviews and appraisescase of any distribution of a Code § 409A Award, if the audit efforts of the Company's independent auditors, including the scope, fees and timing of the audit. - Providessuch distribution is not otherwise specified in this Plan or an open avenue of communication among the independent auditors, financial and senior management and the Board. - Reviews and discusses reports from the independent auditors on (a) all critical accounting policies and practices used by the Company, (b) alternative accounting treatments within GAAP related to material items that have been discussed with management, including the ramifications of the use of the alternative treatments and the treatment preferred by the independent auditor, and (c) other material written communications between the independent auditor and management. - Reviews with the independent auditor its judgments as to the quality, not just the acceptability, of the Company's accounting principles and such matters as are required to be discussed with the Committee under generally accepted auditing standards. - Discusses with management and the independent auditor quarterly earnings press releases, including the interim financial information included therein, reviews the year-end audited financial statements and C-1 "Management's Discussion and Analysis of Financial Condition and Results of Operations" and, if deemed appropriate, recommends to the Board that the audited financial statements be included in the Annual Report on Form 10-K. - Reviews and discusses with management and the independent auditor various topics and events that may have significant financial impact on the Company or that are the subject of discussions between management and the independent auditors. - Reviews and discusses with management the Company's major financial risk exposures and the steps management has taken to monitor and control such exposures. - Reviews and discusses with management and the independent auditor: (a) the adequacy and effectiveness of the Company's internal controls (including any significant deficiencies and significant changes in internal controls reported to the Committee by the independent auditor or management; (b) the Company's internal audit procedures; and (c) the adequacy and effectiveness of the Company's disclosures controls and procedures, and management reports thereon. - Establishes procedures for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls, or auditing matters, and the confidential, anonymous submission by employees of concerns regarding questionable accounting or auditing matters. - Is directly responsible for the appointment, replacement, compensation and oversight of the work of the Company's independent auditors (including resolutions of disagreements between management and the independent auditors regarding financial reporting). The independent auditor shall report directly to the Committee. - Publishes the report of the Committee required by the rules of the Securities and Exchange Commission to be included in the Company's annual proxy statement. - Reviews and approves, in advance, all permissible non-audit services to be performed by the Company's independent auditors, with exceptions provided for de minimus amounts under certain circumstances as described by law. - Reviews and discusses the written statement from the independent auditor concerning any relationship between the auditor and the Company or any other relationships that may adversely affect the independence of the auditor, and, based on such review, assesses the independence of the auditor. - Obtains and reviews annually a report by the independent auditor describing such independent auditor's internal quality-control procedures; any material issues raised by the most recent internal quality-control review or peer review or by any inquiry or investigation by governmental or professional authorities, within the preceding five years, respecting one or more independent audits carried out by the firm, and any steps taken to deal with any such issues. - Conducts an annual self-assessment, including a review of its charter, and recommends any changes to the full Board. - Has the authority to engage independent legal, accounting and other advisers, as it determines necessary to carry out its duties, with the Committee having sole authority to approve related fees and retention terms. - Has the power to conduct or authorize investigations into matters within the Committee's scope of responsibilities and retain independent counsel, accountants or others to assist it in the conduct of an investigation. C-2 III. Composition The Committee shall be comprised of three or more directors as determined by the Board, each of whom shall be directors who are independent of management, and free from any relationship that, in the opinion of the Board, would interfere with the exercise of his or her independent judgment as a member of the Committee. All members of the Committee shall be determined by the Board to meet the independence and financial literacy requirements of the NASDAQ Stock Market, Inc. ("NASDAQ") and applicable federal law, including Section 10A of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All members of the Committee shall be "financially literate" under the rules of the NASDAQ, meaning they have the ability to read and understand fundamental financial statements, including a company's balance sheet, income statement, and cash flow statement. At least one member of the Committee shall have past employment experience in finance or accounting, requisite professional certification in accounting, or any other comparable experience or background which results in the individual's financial sophistication, including being or having been a chief executive officer, chief financial officerAward Agreement or other senior officer with financial oversight responsibilities. The members ofgoverning document, the Committee shall be elected by the Board at the annual organizational meeting of the Board or until their successors shall be duly elected and qualified. Unless a Chair is elected by the Board, the members of the Committee may designate a Chair by vote of the Committee. Designation of any Committee members as an "audit committee financial expert"distribution shall be made on an annual basis bynot later than the full Board upon recommendationend of the Nominating and Corporate Governance Committee. IV. Meetings The Committee shall meet at least four times annually, or more frequently as circumstances dictate. As part of its job to foster open communications,calendar year during which the Committee shall meet at least annually with management and the independent auditors in separate executive sessions to discuss any matters that the Committee or either of these groups believe should be discussed. C-3 TEXT OF PROXY CARD PROXY This Proxy is Solicited on Behalfsettlement of the BoardCode § 409A Award is specified to occur.

(e)          In the case of Directorsan Award providing for distribution or settlement upon vesting or the lapse of AKORN, INC. The undersigneda risk of forfeiture, if the time of such distribution or settlement is not otherwise specified in this Plan or an Award agreement or other governing document, the distribution or settlement shall be made not later than March 15 of the year following the year in which the Award vested or the risk of forfeiture lapsed.

This Plan is hereby constitutesamended and appoints Arthur S. Przybyl and Ben J. Pothast or eitherrestated on this _____ day of them__________________, 2016.

AKORN, INC.
By:
Title:


AKORN, INC.
1925 WEST FIELD COURT, SUITE 300
LAKE FOREST, IL 60045





 (BAR CODE)

VOTE BY INTERNET - www.proxyvote.com

Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.

ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS

If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years.
VOTE BY PHONE - 1-800-690-6903

Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you call and then follow the instructions.

_______
_______
_______

VOTE BY MAIL
Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.




TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:            ☒   

KEEP THIS PORTION FOR YOUR RECORDS

DETACH AND RETURN THIS PORTION ONLY

THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.

The Board of Directors recommends you vote FOR proposals 1 and 2.ForAgainstAbstain
1.Proposal to approve the Akorn, Inc. 2016 Employee Stock Purchase Plan.
2.Proposal to approve the amendment and restatement of the Akorn, Inc. 2014 Stock Option Plan.
NOTE: Such other business as may properly come before the meeting or any adjournment thereof.
For address change/comments, mark here.
(see reverse for instructions)YesNo
Please indicate if you plan to attend this meeting
Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name, by authorized officer.

SHARES
CUSIP #
SEQUENCE #

JOB #
Signature [PLEASE SIGN WITHIN BOX]DateSignature (Joint Owners)Date

0000302249_1     R1.0.1.2902     0000000000

Important Notice Regarding the Availability of Proxy Materials for the undersigned, with full power of substitution, to represent the undersigned and to vote, as designated below, all of the shares of common stock of Akorn, Inc. (the "Company") that the undersignedSpecial Meeting: The Notice & Proxy Statement is entitled to vote held of record by the undersigned on [____], 2004,available at the annual meeting of shareholders of Akorn to be held on [JUNE 10, 2004] (the "Annual Meeting"), and at all adjournments thereof. THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE NOMINEES LISTED BELOW AND FOR EACH OF THE OTHER MATTERS PRESENTED TO THE MEETING AS DESCRIBED IN THE PROXY STATEMENT. 1. Election of Directors. FOR [ ] all nominees listed below (except as marked to the contrary below) WITHHOLD AUTHORITY [ ] to vote for all nominees listed below. INSTRUCTIONS: To withhold authority to vote for any individual nominee, strike a line through the nominee's name in the list below: John N. Kapoor, Ph.D. Arthur S. Przybyl Jerry N. Ellis Ronald M. Johnson Jerry I. Treppel Arjun C. Waney 2. Proposal to approve the amendment of Akorn's Articles of Incorporation to increase the authorized shares of common stock from 40,000,000 to 150,000,000. FOR [ ] AGAINST [ ] ABSTAIN [ ] 3. Proposal to approve the adoption of the Akorn, Inc. 2003 Stock Option Plan. FOR [ ] AGAINST [ ] ABSTAIN [ ] 4. Proposal to ratify the selection of BDO Seidman, LLP to serve as Akorn's independent auditors for the fiscal year ending December 31, 2004. FOR [ ] AGAINST [ ] ABSTAIN [ ] 5. In their discretion to vote upon such other business as may properly come before the Annual Meeting and any adjournments thereof. (Please See Reverse Side) This proxy when properly executed will be voted in the manner directed herein by the undersigned shareholder. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED FOR EACH OF THE NOMINEES AND FOR THE PROPOSALS LISTED ON THE REVERSE SIDE. THE INDIVIDUALS DESIGNATED ABOVE WILL VOTE IN THEIR DISCRETION ON ANY OTHER MATTER THAT MAY PROPERLY COME BEFORE THE MEETING. Date: ------------------------- ------------------------ Signature of Shareholder ------------------------ Signature if held jointly Please sign exactly as name appears on the certificate or certificates representing shares to be voted by this proxy, as shown on the label to the left. When signing as executor, administrator, attorney, trustee, or guardian please give full title as such. If a corporation, please sign full corporation name by president or other authorized officer. If a partnership, please sign in partnership name by authorized persons. PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.

www.proxyvote.com

AKORN, INC.
Special Meeting of Shareholders
December 16, 2016 10:00 AM

This proxy is solicited on behalf of the Board of Directors of Akorn, Inc.

The undersigned hereby constitutes and appoints Duane Portwood and Joseph Bonaccorsi as proxies for the undersigned, each with full power of substitution, to represent the undersigned. The proxy holders are instructed to vote as designated on the reverse side hereof, and according to the discretion of the proxy holder on any other matters that may properly come before the meeting, all of the shares of common stock of Akorn, Inc. held of record by the undersigned on October 28, 2016 that the undersigned is entitled to vote at the Special Meeting of Shareholders to be held on December 16, 2016 and at all adjournments thereof.

This proxy when properly executed and dated will be voted in the manner directed herein by the undersigned shareholder.

IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED FOR THE APPROVAL OF THE AKORN, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN AND FOR THE AMENDMENT AND RESTATEMENT OF THE AKORN, INC. 2014 STOCK OPTION PLAN AS DESCRIBED IN THE COMPANY’S PROXY STATEMENT FOR ITS SPECIAL MEETING OF SHAREHOLDERS. THE PROXY HOLDERS WILL VOTE IN THEIR DISCRETION ON ANY OTHER MATTER THAT MAY PROPERLY COME BEFORE THE MEETING.

     Address change/comments:
(If you noted any Address Changes and/or Comments above, please mark corresponding box on the reverse side.)
Continued and to be signed on reverse side

0000302249_2   R1.0.1.29